Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

  Exhibit 4.3    
    

FORM
OF SUBORDINATED INDENTURE 

GOLDEN
MINERALS COMPANY, 

ISSUER,

AND 

[                        ], 

TRUSTEE

INDENTURE

DATED
AS OF [                        ], 201[  ] 

SUBORDINATED
DEBT SECURITIES 

 
 

  CROSS-REFERENCE TABLE(1)    
    

 

 

			
	Section of Trust Indenture Act of 1939, as amended

 
	 	Section of

Indenture 
	310(a)(1)	 	7.09
	310(a)(2)	 	7.09
	310(a)(3)	 	Inapplicable
	310(a)(4)	 	Inapplicable
	310(b)	 	7.08
	 	 	7.10
	310(c)	 	Inapplicable
	311(a)	 	7.13
	311(b)	 	7.13
	311(c)	 	Inapplicable
	312(a)	 	5.01
	 	 	5.02(a)
	312(b)	 	5.02(c)
	312(c)	 	5.02(c)
	313(a)	 	5.04(a)
	313(b)	 	5.04(b)
	313(c)	 	5.04(a)
	 	 	5.04(b)
	 	 	5.04(c)
	313(d)	 	5.04(b)
	 	 	5.04(c)
	314(a)	 	5.03
	 	 	13.05(c)
	314(b)	 	Inapplicable
	314(c)	 	13.05
	314(d)	 	Inapplicable
	314(e)	 	13.05
	314(f)	 	Inapplicable
	315(a)(1)	 	7.01(b)
	315(a)(2)	 	7.02
	315(b)	 	5.04(d)
	315(c)	 	7.01
	315(d)	 	7.01
	 	 	7.02
	315(e)	 	6.07
	316(a)	 	6.06
	 	 	8.04
	316(b)	 	6.04
	316(c)	 	8.01
	317(a)	 	6.02
	317(b)	 	4.03
	318(a)	 	13.07

 

 

	(1)
	This
Cross-Reference Table does not constitute part of the Indenture and shall not have any bearing on the interpretation of any of its terms or provisions. 

 

 

 

 
 

  TABLE OF CONTENTS(2)    
    

 

 

				
	 
	 	Page 
	 ARTICLE I DEFINITIONS
	 	1
	 	 SECTION 1.01 Definitions of Terms
	 	

1
	 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES
	 	

4
	 	 SECTION 2.01 Designation and Terms of Securities
	 	

4
	 	 SECTION 2.02 Form of Securities and Trustee's Certificate
	 	

5
	 	 SECTION 2.03 Denominations; Provisions for Payment
	 	

6
	 	 SECTION 2.04 Execution and Authentications
	 	

7
	 	 SECTION 2.05 Registration of Transfer and Exchange
	 	

7
	 	 SECTION 2.06 Temporary Securities
	 	

8
	 	 SECTION 2.07 Mutilated, Destroyed, Lost or Stolen Securities
	 	

8
	 	 SECTION 2.08 Cancellation
	 	

9
	 	 SECTION 2.09 Benefits of Indenture
	 	

9
	 	 SECTION 2.10 Authenticating Agent
	 	

9
	 	 SECTION 2.11 Global Securities
	 	

10
	 ARTICLE III REDEMPTION OF SECURITIES AND SINKING FUND PROVISIONS
	 	

11
	 	 SECTION 3.01 Redemption
	 	

11
	 	 SECTION 3.02 Notice of Redemption
	 	

11
	 	 SECTION 3.03 Payment Upon Redemption
	 	

12
	 	 SECTION 3.04 Sinking Fund
	 	

12
	 	 SECTION 3.05 Satisfaction of Sinking Fund Payments with Securities
	 	

12
	 	 SECTION 3.06 Redemption of Securities for Sinking Fund
	 	

13
	 ARTICLE IV COVENANTS
	 	

13
	 	 SECTION 4.01 Payment of Principal, Premium and Interest
	 	

13
	 	 SECTION 4.02 Maintenance of Office or Agency
	 	

13
	 	 SECTION 4.03 Paying Agents
	 	

13
	 	 SECTION 4.04 Appointment to Fill Vacancy in Office of Trustee
	 	

14
	 ARTICLE V SECURITYHOLDERS' LISTS AND REPORTS BY THE COMPANY AND THE TRUSTEE
	 	

14
	 	 SECTION 5.01 Company to Furnish Trustee Names and Addresses of Securityholders
	 	

14
	 	 SECTION 5.02 Preservation Of Information; Communications With Securityholders
	 	

15
	 	 SECTION 5.03 Reports by the Company
	 	

15
	 	 SECTION 5.04 Reports by the Trustee
	 	

15

 

 i

 
 

 

				
	 
	 	Page 
	 ARTICLE VI REMEDIES OF THE TRUSTEE AND SECURITYHOLDERS ON EVENT OF DEFAULT
	 	16
	 	 SECTION 6.01 Events of Default
	 	

16
	 	 SECTION 6.02 Suits for Enforcement by Trustee
	 	

17
	 	 SECTION 6.03 Application of Moneys Collected
	 	

18
	 	 SECTION 6.04 Limitation on Suits
	 	

18
	 	 SECTION 6.05 Rights and Remedies Cumulative; Delay or Omission Not Waiver
	 	

19
	 	 SECTION 6.06 Control by Securityholders
	 	

19
	 	 SECTION 6.07 Undertaking to Pay Costs
	 	

20
	 ARTICLE VII CONCERNING THE TRUSTEE
	 	

20
	 	 SECTION 7.01 Certain Duties and Responsibilities of Trustee
	 	

20
	 	 SECTION 7.02 Certain Rights of Trustee
	 	

21
	 	 SECTION 7.03 Trustee Not Responsible for Recitals or Issuance or Securities
	 	

22
	 	 SECTION 7.04 May Hold Securities
	 	

22
	 	 SECTION 7.05 Moneys Held in Trust
	 	

22
	 	 SECTION 7.06 Compensation and Reimbursement
	 	

23
	 	 SECTION 7.07 Reliance on Officers' Certificate
	 	

23
	 	 SECTION 7.08 Disqualification; Conflicting Interests
	 	

23
	 	 SECTION 7.09 Corporate Trustee Required; Eligibility
	 	

23
	 	 SECTION 7.10 Resignation and Removal; Appointment of Successor
	 	

24
	 	 SECTION 7.11 Acceptance of Appointment By Successor
	 	

25
	 	 SECTION 7.12 Merger, Conversion, Consolidation or Succession to Business
	 	

26
	 	 SECTION 7.13 Preferential Collection of Claims Against the Company
	 	

26
	 ARTICLE VIII CONCERNING THE SECURITYHOLDERS
	 	

26
	 	 SECTION 8.01 Evidence of Action by Securityholders
	 	

26
	 	 SECTION 8.02 Proof of Execution by Securityholders
	 	

27
	 	 SECTION 8.03 Who May be Deemed Owners
	 	

27
	 	 SECTION 8.04 Certain Securities Owned by Company Disregarded
	 	

27
	 	 SECTION 8.05 Actions Binding on Future Securityholders
	 	

27
	 ARTICLE IX SUPPLEMENTAL INDENTURES
	 	

28
	 	 SECTION 9.01 Supplemental Indentures Without the Consent of Securityholders
	 	

28
	 	 SECTION 9.02 Supplemental Indentures With Consent of Securityholders
	 	

28
	 	 SECTION 9.03 Effect of Supplemental Indentures
	 	

29
	 	 SECTION 9.04 Securities Affected by Supplemental Indentures
	 	

29

 

 ii

 
 

 

				
	 
	 	Page 
	 	 SECTION 9.05 Execution of Supplemental Indentures
	 	29
	 ARTICLE X SUCCESSOR ENTITY
	 	

30
	 	 SECTION 10.01 Company May Consolidate, Etc
	 	

30
	 	 SECTION 10.02 Successor Entity Substituted
	 	

30
	 	 SECTION 10.03 Evidence of Consolidation, Etc. to Trustee
	 	

30
	 ARTICLE XI SATISFACTION AND DISCHARGE
	 	

31
	 	 SECTION 11.01 Satisfaction and Discharge of Indenture
	 	

31
	 	 SECTION 11.02 Discharge of Obligations
	 	

31
	 	 SECTION 11.03 Deposited Moneys to be Held in Trust
	 	

31
	 	 SECTION 11.04 Payment of Moneys Held by Paying Agents
	 	

32
	 	 SECTION 11.05 Repayment to Company
	 	

32
	 ARTICLE XII IMMUNITY OF INCORPORATORS, STOCKHOLDERS, OFFICERS AND DIRECTORS
	 	

32
	 	 SECTION 12.01 No Recourse
	 	

32
	 ARTICLE XIII MISCELLANEOUS PROVISIONS
	 	

32
	 	 SECTION 13.01 Effect on Successors and Assigns
	 	

32
	 	 SECTION 13.02 Actions by Successor
	 	

33
	 	 SECTION 13.03 Notices
	 	

33
	 	 SECTION 13.04 Governing Law
	 	

33
	 	 SECTION 13.05 Compliance Certificates and Opinions
	 	

33
	 	 SECTION 13.06 Payments on Business Days
	 	

33
	 	 SECTION 13.07 Conflict with Trust Indenture Act
	 	

34
	 	 SECTION 13.08 Counterparts
	 	

34
	 	 SECTION 13.09 Separability
	 	

34
	 	 SECTION 13.10 Assignment
	 	

34
	 ARTICLE XIV SUBORDINATION OF SECURITIES
	 	

34
	 	 SECTION 14.01 Subordination Terms
	 	

34

 

 

	(2)
	This
Table of Contents does not constitute part of the Indenture and shall not have any bearing on the interpretation of any of its terms or provisions. 

 

 iii

 

        INDENTURE, dated as of [      ], 201[  ], between Golden Minerals Company, a Delaware corporation (the "Company"), and
[      ], as trustee (the "Trustee"): 

        WHEREAS,
for its lawful corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance of unsecured subordinated debt
securities (hereinafter referred to as the "Securities") in an unlimited aggregate principal amount to be issued from time to time in one or more series as in this Indenture provided, as registered
Securities without coupons, to be authenticated by the certificate of the Trustee; 

        WHEREAS,
to provide the terms and conditions upon which the Securities are to be authenticated, issued and delivered, the Company has duly authorized the execution of this Indenture; and 

        WHEREAS,
all things necessary to make this Indenture a valid agreement of the Company, in accordance with its terms, have been done. 

        NOW,
THEREFORE, in consideration of the premises and the purchase of the Securities by the holders thereof, it is mutually covenanted and agreed as follows for the equal and ratable
benefit of the holders of Securities: 

 
 

  ARTICLE I    
    
    DEFINITIONS    
    

SECTION 1.01    Definitions of Terms.    

        The
terms defined in this Section (except as in this Indenture otherwise expressly provided or unless the context otherwise requires) for all purposes of this Indenture and of any
indenture supplemental hereto shall have the respective meanings specified in this Section and shall include the plural as well as the singular. All other terms used in this Indenture that are defined
in the Trust Indenture Act of 1939, as amended, or that are by reference in such Act defined in the Securities Act of 1933, as amended (except as herein otherwise expressly provided or unless the
context otherwise requires), shall have the meanings assigned to such terms in said Trust Indenture Act and in said Securities Act as in force at the date of the execution of this instrument. 

        "Authenticating
Agent" means an authenticating agent with respect to all or any of the series of Securities appointed with respect to all or any series of the Securities by the Trustee
pursuant to Section 2.10. 

        "Bankruptcy
Law" means Title 11, U.S. Code, or any similar federal or state law for the relief of debtors. 

        "Board
of Directors" means the Board of Directors of the Company or any duly authorized committee of such Board of Directors. 

        "Board
Resolution" means a copy of a resolution certified by the Secretary or an Assistant Secretary of the Company to have been duly adopted by the Board of Directors and to be in full
force and effect on the date of such certification. 

        "Business
Day" means, with respect to any series of Securities, any day other than a day on which Federal or State banking institutions in the United States (or in any city in which the
paying agent
appointed pursuant to Section 4.03 has an office), are authorized or obligated by law, executive order or regulation to close. 

        "Certificate"
means a certificate signed by the principal executive officer, the principal financial officer or the principal accounting officer of the Company. The Certificate need not
comply with the provisions of Section 13.05. 

        "Company"
means Golden Minerals Company, a corporation duly organized and existing under the laws of the State of Delaware, and, subject to the provisions of Article Ten, shall also
include its successors and assigns. 

 

        "Corporate
Trust Office" means the office of the Trustee at which, at any particular time, its corporate trust business shall be principally administered, which office at the date hereof
is located at [      ], except that whenever a provision herein refers to an office or agency of the Trustee in the United States, such office is located, at the date
hereof, at [      ]. 

        "Custodian"
means any receiver, trustee, assignee, liquidator, or similar official under any Bankruptcy Law. 

        "Default"
means any event, act or condition that with notice or lapse of time, or both, would constitute an Event of Default. 

        "Depositary"
means, with respect to Securities of any series, for which the Company shall determine that such Securities will be issued as a Global Security, The Depository Trust
Company, New York, New York, another clearing agency, or any successor registered as a clearing agency under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or other applicable
statute or regulation, which, in each case, shall be designated by the Company pursuant to either Section 2.01 or 2.11. 

        "Event
of Default" means, with respect to Securities of a particular series any event specified in Section 6.01, continued for the period of time, if any, therein designated. 

        "Global
Security" means, with respect to any series of Securities, a Security executed by the Company and delivered by the Trustee to the Depositary or pursuant to the Depositary's
instruction, all in accordance with the Indenture, which shall be registered in the name of the Depositary or its nominee. 

        "Governmental
Obligations" means securities that are (i) direct obligations of the United States of America for the payment of which its full faith and credit is pledged or
(ii) obligations of a Person controlled or supervised by and acting as an agency or instrumentality of the United States of America, the payment of which is unconditionally guaranteed as a full
faith and credit obligation by the United States of America that, in either case, are not callable or redeemable at the option of the issuer thereof, and shall also include a depositary receipt issued
by a bank (as defined in Section 3(a)(2) of the Securities Act of 1933, as amended) as custodian with respect to any such Governmental Obligation or a specific payment of principal of or
interest on any such Governmental Obligation held by such custodian for the account of the holder of such depositary receipt; provided, however, that (except as required by law) such custodian is not
authorized to make any deduction from the amount payable to the holder of such depositary receipt from any amount received by the custodian in respect of the Governmental Obligation or the specific
payment of principal of or interest on the Governmental Obligation evidenced by such depositary receipt. 

        "Herein,"
"hereof" and "hereunder," and other words of similar import, refer to this Indenture as a whole and not to any particular Article, Section or other subdivision. 

        "Indenture"
means this instrument as originally executed or as it may from time to time be supplemented or amended by one or more indentures supplemental hereto entered into in
accordance with the terms hereof. 

        "Interest
Payment Date," when used with respect to any installment of interest on a Security of a particular series, means the date specified in such Security or in a Board Resolution or
in an indenture supplemental hereto with respect to such series as the fixed date on which an installment of interest with respect to Securities of that series is due and payable. 

        "Officers'
Certificate" means in the case of the Company, a certificate signed by the Chairman, Vice Chairman, Chief Executive Officer, President, Chief Financial Officer, Chief
Operating Officer, an Executive Vice President or a Senior Vice President and by the Treasurer or an Assistant Treasurer or the Controller or an Assistant Controller or the Secretary or an Assistant
Secretary of the Company 

2

 

that
is delivered to the Trustee in accordance with the terms hereof. Each such certificate shall include the statements provided for in Section 13.05, if and to the extent required by the
provisions thereof. 

        "Opinion
of Counsel" means an opinion in writing of legal counsel, who may be an employee of or counsel for the Company that is delivered to the Trustee in accordance with the terms
hereof. Each such opinion shall include the statements provided for in Section 13.05, if and to the extent required by the provisions thereof. 

        "Outstanding,"
when used with reference to Securities of any series, means, subject to the provisions of Section 8.04, as of any particular time, all Securities of that series
theretofore authenticated and delivered by the Trustee under this Indenture, except (a) Securities theretofore canceled by the Trustee or any paying agent, or delivered to the Trustee or any
paying agent for cancellation or that have previously been canceled; (b) Securities or portions thereof for the payment or redemption of which moneys or Governmental Obligations in the
necessary amount shall have been deposited in trust with the Trustee or with any paying agent (other than the Company) or shall have been set aside and segregated in trust by the Company (if the
Company shall act as its own paying agent); provided, however, that if such Securities or portions of such Securities are to be redeemed prior to the maturity thereof, notice of such redemption shall
have been given as in Article Three provided, or provision satisfactory to the Trustee shall have been made for giving such notice; and (c) Securities in lieu of or in substitution for which
other Securities shall have been authenticated and delivered pursuant to the terms of Section 2.07. 

        "Person"
means any individual, corporation, partnership, joint venture, joint-stock company, unincorporated organization or government or any agency or political subdivision thereof. 

        "Predecessor
Security" of any particular Security means every previous Security evidencing all or a portion of the same debt as that evidenced by such particular Security; and, for the
purposes of this definition, any Security authenticated and delivered under Section 2.07 in lieu of a lost, destroyed or stolen Security shall be deemed to evidence the same debt as the lost,
destroyed or stolen Security. 

        "Responsible
Officer" when used with respect to the Trustee means the President, any Senior Vice President, the Secretary, the Treasurer, any trust officer, any corporate trust officer
or any other officer or assistant officer of the Trustee customarily performing functions similar to those performed by the Persons who at the time shall be such officers, respectively, or to whom any
corporate trust matter is referred because of his or her knowledge of and familiarity with the particular subject. 

        "Securities"
means the debt Securities authenticated and delivered under this Indenture. 

        "Securityholder,"
"holder of Securities," "registered holder" or other similar term, means the Person or Persons in whose name or names a particular Security shall be registered on the
books of the Company kept for that purpose in accordance with the terms of this Indenture. 

        "Senior
Indebtedness" means indebtedness issued pursuant to a senior indenture, as supplemented or amended by one or more indentures supplemental thereto, payment of which shall be
senior to the payment of the Securities issued hereunder, pursuant to ARTICLE XIV hereof. 

        "Subsidiary"
means, with respect to any Person, (i) any corporation at least a majority of whose outstanding Voting Stock shall at the time be owned, directly or indirectly, by
such Person or by one or more of its Subsidiaries or by such Person and one or more of its Subsidiaries, (ii) any general partnership, joint venture or similar entity, at least a majority of
whose outstanding partnership or similar interests shall at the time be owned by such Person, or by one or more of its Subsidiaries, or by such Person and one or more of its Subsidiaries and
(iii) any limited partnership of which such Person or any of its Subsidiaries is a general partner. 

        "Trustee"
means [      ], and, subject to the provisions of Article Seven, shall also include its successors and assigns, and, if at any time there is
more than one Person acting in such capacity 

3

 

hereunder,
"Trustee" shall mean each such Person. The term "Trustee" as used with respect to a particular series of the Securities shall mean the trustee with respect to that series. 

        "Trust
Indenture Act" means the Trust Indenture Act of 1939, as amended, subject to the provisions of Sections 9.01, 9.02 and 10.01, as in effect at the date of execution of this
instrument. 

        "Voting
Stock," as applied to stock of any Person, means shares, interests, participations or other equivalents in the equity interest (however designated) in such Person having ordinary
voting power for the election of the directors (or the equivalent) of such Person, other than shares, interests, participations or other equivalents having such power only by reason of the occurrence
of a contingency. 

 
 

  ARTICLE II    
    
    ISSUE, DESCRIPTION, TERMS, EXECUTION,
  REGISTRATION AND EXCHANGE OF SECURITIES    
    

SECTION 2.01    Designation and Terms of Securities.    

        (a)   The
aggregate principal amount of Securities that may be authenticated and delivered under this Indenture is unlimited. The Securities may be issued in one or more
series up to the aggregate principal amount of Securities of that series from time to time authorized by or pursuant to a Board Resolution of the Company or pursuant to one or more indentures
supplemental hereto. Prior to the initial issuance of Securities of any series, there shall be established in or pursuant to a Board Resolution of the Company, and set forth in an Officers'
Certificate, or established in one or more indentures supplemental hereto: 

        (1)   the
title of the Security of the series (which shall distinguish the Securities of the series from all other Securities); 

        (2)   any
limit upon the aggregate principal amount of the Securities of that series that may be authenticated and delivered under this Indenture (except for Securities
authenticated and delivered upon registration of transfer of, or in exchange for, or in lieu of, other Securities of that series); 

        (3)   the
date or dates on which the principal of the Securities of the series is payable and the place(s) of payment; 

        (4)   the
rate or rates at which the Securities of the series shall bear interest or the manner of calculation of such rate or rates, if any; 

        (5)   the
date or dates from which such interest shall accrue, the Interest Payment Dates on which such interest will be payable or the manner of determination of such
Interest Payment Dates, the place(s) of payment, and the record date for the determination of holders to whom interest is payable on any such Interest Payment Dates; 

        (6)   the
right, if any, to extend the interest payment periods and the duration of such extension; 

        (7)   the
period or periods within which, the price or prices at which and the terms and conditions upon which, Securities of the series may be redeemed, in whole or in part,
at the option of the Company; 

        (8)   the
obligation, if any, of the Company to redeem or purchase Securities of the series pursuant to any sinking fund or analogous provisions (including payments made in
cash in satisfaction of future sinking fund obligations) or at the option of a holder thereof and the period or periods within which, the price or prices at which, and the terms and conditions upon
which, 

4

 

Securities
of the series shall be redeemed or purchased, in whole or in part, pursuant to such obligation; 

        (9)   the
form of the Securities of the series including the form of the certificate of authentication for such series; 

        (10) if
other than denominations of one thousand U.S. dollars ($1,000) or any integral multiple thereof, the denominations in which the Securities of the series shall be
issuable; 

        (11) any
and all other terms with respect to such series (which terms shall not be inconsistent with the terms of this Indenture, as amended by any supplemental indenture)
including any terms which may be required by or advisable under United States laws or regulations or advisable in connection with the marketing of Securities of that series; 

        (12) whether
the Securities are issuable as a Global Security and, in such case, the identity of the Depositary for such series; 

        (13) whether
the Securities will be convertible into shares of common stock or other securities of the Company and, if so, the terms and conditions upon which such
Securities will be so convertible, including the conversion price and the conversion period; 

        (14) if
other than the principal amount thereof, the portion of the principal amount of Securities of the series which shall be payable upon declaration of acceleration of
the maturity thereof pursuant to Section 6.01; 

        (15) the
subordination terms of the Securities of the series; and 

        (16) any
additional or different Events of Default or restrictive covenants provided for with respect to the Securities of the series. 

        All
Securities of any one series shall be substantially identical except as to denomination and except as may otherwise be provided in or pursuant to any such Board Resolution or in any
indentures supplemental hereto. 

        If
any of the terms of the series are established by action taken pursuant to a Board Resolution, a copy of an appropriate record of such action shall be certified by the Secretary or an
Assistant Secretary of the Company delivered to the Trustee at or prior to the delivery of the Officers' Certificate setting forth the terms of the series. 

        Securities
of any particular series may be issued at various times, with different dates on which the principal or any installment of principal is payable, with different rates of
interest, if any, or different methods by which rates of interest may be determined, with different dates on which such interest may be payable and with different redemption dates. 

SECTION 2.02    Form of Securities and Trustee's Certificate.    

        The
Securities of any series and the Trustee's certificate of authentication to be borne by such Securities shall be substantially of the tenor and purport as set forth in one or more
indentures supplemental hereto or as provided in a Board Resolution and as set forth in an Officers' Certificate and may have such letters, numbers or other marks of identification or designation and
such legends or endorsements printed, lithographed or engraved thereon as the Company may deem appropriate and as are not inconsistent with the provisions of this Indenture, or as may be required to
comply with any law or with any rule or regulation made pursuant thereto or with any rule or regulation of any stock exchange on which Securities of that series may be listed, or to conform to usage. 

5

 

SECTION 2.03    Denominations; Provisions for Payment.    

        The
Securities shall be issuable as registered Securities and in the denominations of one thousand U.S. dollars ($1,000) or any integral multiple thereof, subject to
Section 2.01(10). The Securities of a particular series shall bear interest payable on the dates and at the rate specified with respect to that series. The principal of and the interest on the
Securities of any series, as well as any premium thereon in case of redemption thereof prior to maturity, shall be payable in the coin or currency of the United States of America that at the time is
legal tender for public and private debt, at the office or agency of the Company maintained for that purpose in the United States. Each Security shall be dated the date of its authentication. Interest
on the Securities shall be computed on the basis of a 360-day year composed of twelve 30-day months. 

        The
interest installment on any Security that is payable, and is punctually paid or duly provided for, on any Interest Payment Date for Securities of that series shall be paid to the
Person in whose name said Security (or one or more Predecessor Securities) is registered at the close of business on the regular record date for such interest installment. In the event that any
Security of a particular series or portion thereof is called for redemption and the redemption date is subsequent to a regular record date with respect to any Interest Payment Date and prior to such
Interest Payment Date, interest on such Security will be paid upon presentation and surrender of such Security as provided in Section 3.03. 

        Any
interest on any Security that is payable, but is not punctually paid or duly provided for, on any Interest Payment Date for Securities of the same series (herein called "Defaulted
Interest") shall forthwith cease to be payable to the registered holder on the relevant regular record date by virtue of having been such holder; and such Defaulted Interest shall be paid by the
Company, at its election, as provided in clause (1) or clause (2) below: 

        (1)   The
Company may make payment of any Defaulted Interest on Securities to the Persons in whose names such Securities (or their respective Predecessor Securities) are
registered at the close of business on a special record date for the payment of such Defaulted Interest, which shall be fixed in the following manner: the Company shall notify the Trustee in writing
of the amount of Defaulted Interest proposed to be paid on each such Security and the date of the proposed payment, and at the same time the Company shall deposit with the Trustee an amount of money
equal to the aggregate amount proposed to be paid in respect of such Defaulted Interest or shall make arrangements satisfactory to the Trustee for such deposit prior to the date of the proposed
payment, such money when deposited to be held in trust for the benefit of the Persons entitled to such Defaulted Interest as in this clause provided. Thereupon the Trustee shall fix a special record
date for the payment of such Defaulted Interest which shall not be more than 15 nor less than 10 days prior to the date of the proposed payment and not less than 10 days after the
receipt by the Trustee of the notice of the proposed
payment. The Trustee shall promptly notify the Company of such special record date and, in the name and at the expense of the Company, shall cause notice of the proposed payment of such Defaulted
Interest and the special record date therefor to be mailed, first class postage prepaid, to each Securityholder at his or her address as it appears in the Security Register (as hereinafter defined),
not less than 10 days prior to such special record date. Notice of the proposed payment of such Defaulted Interest and the special record date therefor having been mailed as aforesaid, such
Defaulted Interest shall be paid to the Persons in whose names such Securities (or their respective Predecessor Securities) are registered on such special record date. 

        (2)   The
Company may make payment of any Defaulted Interest on any Securities in any other lawful manner not inconsistent with the requirements of any securities exchange on
which such Securities may be listed, and upon such notice as may be required by such exchange, if, after notice given by the Company to the Trustee of the proposed payment pursuant to this clause,
such manner of payment shall be deemed practicable by the Trustee. 

6

 

        Unless
otherwise set forth in a Board Resolution or one or more indentures supplemental hereto establishing the terms of any series of Securities pursuant to Section 2.01 hereof,
the term "regular record date" as used in this Section with respect to a series of Securities with respect to any Interest Payment Date for such series shall mean either the fifteenth day of the month
immediately preceding the month in which an Interest Payment Date established for such series pursuant to Section 2.01 hereof shall occur, if such Interest Payment Date is the first day of a
month, or the last day of the month immediately preceding the month in which an Interest Payment Date established for such series pursuant to Section 2.01 hereof shall occur, if such Interest
Payment Date is the fifteenth day of a month, whether or not such date is a Business Day. 

        Subject
to the foregoing provisions of this Section, each Security of a series delivered under this Indenture upon transfer of or in exchange for or in lieu of any other Security of such
series shall carry the rights to interest accrued and unpaid, and to accrue, that were carried by such other Security. 

SECTION 2.04    Execution and Authentications.    

        The
Securities shall be signed on behalf of the Company by its Chairman, Vice Chairman, Chief Executive Officer, President, Chief Financial Officer, Chief Operating Officer, or one of
its Executive Vice Presidents or Senior Vice Presidents, or its Treasurer, or one of its Assistant Treasurers, or its Secretary, or one of its Assistant Secretaries, under its corporate seal attested
by its Secretary or one of its Assistant Secretaries. The Company may use the facsimile signature of any Person who were at any time proper officers of the Company notwithstanding the fact that at the
time the Securities shall be
authenticated and delivered or disposed of such Person shall have ceased to hold such office. The seal of the Company may be in the form of a facsimile of such seal and may be impressed, affixed,
imprinted or otherwise reproduced on the Securities. The Securities may contain such notations, legends or endorsements required by law, stock exchange rule or usage. Each Security shall be dated the
date of its authentication by the Trustee. 

        No
Security shall be valid until authenticated manually by an authorized signatory of the Trustee, or by an Authenticating Agent. Such signature shall be conclusive evidence that the
Security so authenticated has been duly authenticated and delivered hereunder and that the holder is entitled to the benefits of this Indenture. At any time and from time to time after the execution
and delivery of this Indenture, the Company may deliver Securities of any series executed by the Company to the Trustee for authentication, together with a written order of the Company for the
authentication and delivery of such Securities, signed by an authorized officer and its Secretary or any Assistant Secretary, and the Trustee in accordance with such written order shall authenticate
and deliver such Securities. 

        In
authenticating such Securities and accepting the additional responsibilities under this Indenture in relation to such Securities, the Trustee shall be entitled to receive, and
(subject to Section 7.01) shall be fully protected in relying upon, an Opinion of Counsel stating that the form and terms thereof have been established in conformity with the provisions of this
Indenture. 

        The
Trustee shall not be required to authenticate such Securities if the issue of such Securities pursuant to this Indenture will affect the Trustee's own rights, duties or immunities
under the Securities and this Indenture or otherwise in a manner that is not reasonably acceptable to the Trustee. 

SECTION 2.05    Registration of Transfer and Exchange.    

        (a)   Securities
of any series may be exchanged upon presentation thereof at the office or agency of the Company designated for such purpose in the United States, for other
Securities of such series of authorized denominations, and for a like aggregate principal amount, upon payment of a sum sufficient to cover any tax or other governmental charge in relation thereto,
all as provided in this Section. In respect of any Securities so surrendered for exchange, the Company shall execute, the Trustee shall authenticate and such office or agency shall deliver in exchange
therefor the Security or Securities of the same series that the Securityholder making the exchange shall be entitled to receive, bearing numbers not contemporaneously outstanding. 

7

 

        (b)   The Company shall keep, or cause to be kept, at its office or agency designated for such purpose in the United States, or such other location designated by the Company a
register or registers (herein referred to as the "Security Register") in which, subject to such reasonable regulations as it may prescribe, the Company shall register the Securities and the transfers
of Securities as in this Article provided and which at all reasonable times shall be open for inspection by the Trustee. The registrar for the purpose of registering Securities and transfer of
Securities as herein provided shall be appointed as authorized by a Board Resolution (the "Security Registrar"). 

        Upon
surrender for transfer of any Security at the office or agency of the Company designated for such purpose, the Company shall execute, the Trustee shall authenticate and such office
or agency shall deliver in the name of the transferee or transferees a new Security or Securities of the same series as the Security presented for a like aggregate principal amount. 

        All
Securities presented or surrendered for exchange or registration of transfer, as provided in this Section, shall be accompanied (if so required by the Company or the Security
Registrar) by a written instrument or instruments of transfer, in form satisfactory to the Company or the Security Registrar, duly executed by the registered holder or by such holder's duly authorized
attorney in writing. 

        (c)   No
service charge shall be made for any exchange or registration of transfer of Securities, or issue of new Securities in case of partial redemption of any series, but
the Company may require payment of a sum sufficient to cover any tax or other governmental charge in relation thereto, other than exchanges pursuant to Section 2.06, Section 3.03(b) and
Section 9.04 not involving any transfer. 

        (d)   The
Company shall not be required (1) to issue, exchange or register the transfer of any Securities during a period beginning at the opening of business
15 days before the day of the mailing of a notice of redemption of less than all the Outstanding Securities of the same series and ending at the close of business on the day of such mailing,
nor (2) to register the transfer of or exchange any Securities of any series or portions thereof called for redemption. The provisions of this Section 2.05 are, with respect to any
Global Security, subject to Section 2.11 hereof. 

SECTION 2.06    Temporary Securities.    

        Pending
the preparation of definitive Securities of any series, the Company may execute, and the Trustee shall authenticate and deliver, temporary Securities (printed, lithographed or
typewritten) of any authorized denomination. Such temporary Securities shall be substantially in the form of the definitive Securities in lieu of which they are issued, but with such omissions,
insertions and variations as may be appropriate for temporary Securities, all as may be determined by the Company. Every temporary Security of any series shall be executed by the Company and be
authenticated by the Trustee upon the same conditions and in substantially the same manner, and with like effect, as the definitive Securities of such series. Without unnecessary delay the Company
will execute and will furnish definitive Securities of such series and thereupon any or all temporary Securities of such series may be surrendered in exchange therefor (without charge to the holders),
at the office or agency of the Company designated for the purpose in the United States, and the Trustee shall authenticate and such office or agency shall deliver in exchange for such temporary
Securities an equal aggregate principal amount of definitive Securities of such series, unless the Company advises the Trustee to the effect that definitive Securities need not be executed and
furnished until further notice from the Company. Until so exchanged, the temporary Securities of such series shall be entitled to the same benefits under this Indenture as definitive Securities of
such series authenticated and delivered hereunder. 

SECTION 2.07    Mutilated, Destroyed, Lost or Stolen Securities.    

        In
case any temporary or definitive Security shall become mutilated or be destroyed, lost or stolen, the Company (subject to the next succeeding sentence) shall execute, and upon the
Company's request, the Trustee (subject as aforesaid) shall authenticate and deliver, a new Security of the same series, bearing a number not contemporaneously outstanding, in exchange and
substitution for the mutilated 

8

 

Security,
or in lieu of and in substitution for the Security so destroyed, lost or stolen. In every case the applicant for a substituted Security shall furnish to the Company and the Trustee such
security or indemnity as may be required by them to save each of them harmless, and, in every case of destruction, loss or theft, the applicant shall also furnish to the Company and the Trustee
evidence to their satisfaction of the destruction, loss or theft of the applicant's Security and of the ownership thereof. The Trustee may authenticate any such substituted Security and deliver the
same upon the written request or authorization of any officer of the Company. Upon the issuance of any substituted Security, the Company may require the payment of a sum sufficient to cover any tax or
other governmental charge that may be imposed in relation thereto and any other expenses (including the fees and
expenses of the Trustee) connected therewith. In case any Security that has matured or is about to mature shall become mutilated or be destroyed, lost or stolen, the Company may, instead of issuing a
substitute Security, pay or authorize the payment of the same (without surrender thereof except in the case of a mutilated Security) if the applicant for such payment shall furnish to the Company and
the Trustee such security or indemnity as they may require to save each of them harmless, and, in case of destruction, loss or theft, evidence to the satisfaction of the Company and the Trustee of the
destruction, loss or theft of such Security and of the ownership thereof. 

        Every
replacement Security issued pursuant to the provisions of this Section shall constitute an additional contractual obligation of the Company, whether or not the mutilated,
destroyed, lost or stolen Security shall be found at any time, or be enforceable by anyone, and shall be entitled to all the benefits of this Indenture equally and proportionately with any and all
other Securities of the same series duly issued hereunder. All Securities shall be held and owned upon the express condition that the foregoing provisions are exclusive with respect to the replacement
or payment of mutilated, destroyed, lost or stolen Securities, and shall preclude (to the extent lawful) any and all other rights or remedies, notwithstanding any law or statute existing or hereafter
enacted to the contrary with respect to the replacement or payment of negotiable instruments or other securities without their surrender. 

SECTION 2.08    Cancellation.    

        All
Securities surrendered for the purpose of payment, redemption, exchange or registration of transfer shall, if surrendered to the Company or any paying agent, be delivered to the
Trustee for cancellation, or, if surrendered to the Trustee, shall be cancelled by it, and no Securities shall be issued in lieu thereof except as expressly required or permitted by any of the
provisions of this Indenture. On request of the Company at the time of such surrender, the Trustee shall deliver to the Company canceled Securities held by the Trustee. In the absence of such request
the Trustee may dispose of canceled Securities in accordance with its standard procedures and deliver a certificate of disposition to the Company. If the Company shall otherwise acquire any of the
Securities, however, such acquisition shall not operate as a redemption or satisfaction of the indebtedness represented by such Securities unless and until the same are delivered to the Trustee for
cancellation. 

SECTION 2.09    Benefits of Indenture.    

        Nothing
in this Indenture or in the Securities, express or implied, shall give or be construed to give to any Person, other than the parties hereto and the holders of the Securities
(and, with respect to the provisions of ARTICLE XIV, the holders of Senior Indebtedness), any legal or equitable right, remedy or claim under or in respect of this Indenture, or under any covenant,
condition or provision herein contained; all such covenants, conditions and provisions being for the sole benefit of the parties hereto and of the holders of the Securities (and, with respect to the
provisions of ARTICLE XIV, the holders of Senior Indebtedness). 

SECTION 2.10    Authenticating Agent.    

        So
long as any of the Securities of any series remain Outstanding there may be an Authenticating Agent for any or all such series of Securities which the Trustee shall have the right to
appoint. Said 

9

 

Authenticating
Agent shall be authorized to act on behalf of the Trustee to authenticate Securities of such series issued upon exchange, transfer or partial redemption thereof, and Securities so
authenticated shall be entitled to the benefits of this Indenture and shall be valid and obligatory for all purposes as if authenticated by the Trustee hereunder. All references in this Indenture to
the authentication of Securities by the Trustee shall be deemed to include authentication by an Authenticating Agent for such series. Each Authenticating Agent shall be acceptable to the Company and
shall be a corporation that has a combined capital and surplus, as most recently reported or determined by it, sufficient under the laws of any jurisdiction under which it is organized or in which it
is doing business to conduct a trust business, and that is otherwise authorized under such laws to conduct such business and is subject to supervision or examination by Federal or State authorities.
If at any time any Authenticating Agent shall cease to be eligible in accordance with these provisions, it shall resign immediately. 

        Any
Authenticating Agent may at any time resign by giving written notice of resignation to the Trustee, to the Company. The Trustee may at any time (and upon request by the Company
shall) terminate the agency of any Authenticating Agent by giving written notice of termination to such Authenticating Agent, to the Company. Upon resignation, termination or cessation of eligibility
of any Authenticating Agent, the Trustee may appoint an eligible successor Authenticating Agent acceptable to the Company. Any successor Authenticating Agent, upon acceptance of its appointment
hereunder, shall become vested with all the rights, powers and duties of its predecessor hereunder as if originally named as an Authenticating Agent pursuant hereto. 

SECTION 2.11    Global Securities.    

        (a)   If
the Company shall establish pursuant to Section 2.01 that the Securities of a particular series are to be issued as a Global Security, then the Company shall
execute and the Trustee shall, in accordance with Section 2.04, authenticate and deliver, a Global Security that (1) shall represent, and shall be denominated in an amount equal to the
aggregate principal amount of, all of the Outstanding Securities of such series, (2) shall be registered in the name of the Depositary or its nominee, (3) shall be delivered by the
Trustee to the Depositary or pursuant to the Depositary's instruction and (4) shall bear a legend substantially to the following effect: "Except as otherwise provided in Section 2.11 of
the Indenture, this Security may be transferred, in whole but not in part, only to another nominee of the Depositary or to a successor Depositary or to a nominee of such successor Depositary." 

        (b)   Notwithstanding
the provisions of Section 2.05, the Global Security of a series may be transferred, in whole but not in part and in the manner provided in
Section 2.05, only to another nominee of the Depositary for such series, or to a successor Depositary for such series selected or approved by the Company or to a nominee of such successor
Depositary. 

        (c)   If
at any time the Depositary for a series of the Securities notifies the Company that it is unwilling or unable to continue as Depositary for such series or if at any
time the Depositary for such series shall no longer be registered or in good standing under the Exchange Act, or other applicable statute or regulation, and a successor Depositary for such series is
not appointed by the Company within 90 days after the Company receives such notice or becomes aware of such condition, as the case may be, this Section 2.11 shall no longer be applicable
to the Securities of such series and the Company will execute and, subject to Section 2.05, the Trustee will authenticate and deliver the Securities of such series in definitive registered form
without coupons, in authorized denominations, and in an aggregate principal amount equal to the principal amount of the Global Security of such series in exchange for such Global Security. In
addition, the Company may at any time determine that the Securities of any series shall no longer be represented by a Global Security and that the provisions of this Section 2.11 shall no
longer apply to the Securities of such series. In such event the Company will execute and, subject to Section 2.05, the Trustee, upon receipt of an Officers' Certificate evidencing such
determination by the Company, will authenticate and deliver the Securities of such series in 

10

 

definitive
registered form without coupons, in authorized denominations, and in an aggregate principal amount equal to the principal amount of the Global Security of such series in exchange for such
Global Security. Upon the exchange of the Global Security for such Securities in definitive registered form without coupons, in authorized denominations, the Global Security shall be canceled by the
Trustee. Such Securities in definitive registered form issued in exchange for the Global Security pursuant to this Section 2.11(c) shall be registered in such names and in such authorized
denominations as the Depositary, pursuant to instructions from its direct or indirect participants or otherwise, shall instruct the Trustee. The Trustee shall deliver such Securities to the Depositary
for delivery to the Persons in whose names such Securities are so registered. 

 
 

  ARTICLE III    
    
    REDEMPTION OF SECURITIES AND SINKING FUND PROVISIONS    
    

SECTION 3.01    Redemption.    

        The
Company may redeem the Securities of any series issued hereunder on and after the dates and in accordance with the terms established for such series pursuant to Section 2.01
hereof. 

SECTION 3.02    Notice of Redemption.    

        (a)   In
case the Company shall desire to exercise such right to redeem all or, as the case may be, a portion of the Securities of any series in accordance with the right
reserved so to do, the Company shall, or shall cause the Trustee to, give notice of such redemption to holders of the Securities of such series to be redeemed by mailing, first class postage prepaid,
a notice of such redemption not less than 30 days and not more than 90 days before the date fixed for redemption of that series to such holders at their last addresses as they shall
appear upon the Security Register unless a shorter period is specified in the Securities to be redeemed. Any notice that is mailed in the manner herein provided shall be conclusively presumed to have
been duly given, whether or not the registered holder receives the notice. In any case, failure duly to give such notice to the holder of any Security of any series designated for redemption in whole
or in part, or any defect in the notice, shall not affect the validity of the proceedings for the redemption of any other Securities of such series or any other series. In the case of any redemption
of Securities prior to the expiration of any restriction on such redemption provided in the terms of such Securities or elsewhere in this Indenture, the Company shall furnish the Trustee with an
Officers' Certificate evidencing compliance with any such restriction. 

        Each
such notice of redemption shall specify the date fixed for redemption and the redemption price at which Securities of that series are to be redeemed, and shall state that payment of
the redemption price of such Securities to be redeemed will be made at the office or agency of the Company in the United States, upon presentation and surrender of such Securities, that interest
accrued to the date fixed for redemption will be paid as specified in said notice, that from and after said date interest will cease to accrue and that the redemption is for a sinking fund, if such is
the case. If less than all the Securities of a series are to be redeemed, the notice to the holders of Securities of that series to be redeemed in whole or in part shall specify the particular
Securities to be so redeemed. In case any Security is to be redeemed in part only, the notice that relates to such Security shall state the portion of the principal amount thereof to be redeemed, and
shall state that on and after the redemption date, upon surrender of such Security, a new Security or Securities of such series in principal amount equal to the unredeemed portion thereof will be
issued. 

        (b)   If
less than all the Securities of a series are to be redeemed, the Company shall give the Trustee at least 45 days' notice in advance of the date fixed for
redemption as to the aggregate principal amount of Securities of the series to be redeemed, and thereupon the Trustee shall select, by lot or in such other manner as it shall deem appropriate and fair
in its discretion and that may provide for the selection of a portion or portions (equal to one thousand U.S. dollars ($1,000) or any integral 

11

 

multiple
thereof) of the principal amount of such Securities of a denomination larger than $1,000, the Securities to be redeemed and shall thereafter promptly notify the Company in writing of the
numbers
of the Securities to be redeemed, in whole or in part. The Company may, if and whenever it shall so elect, by delivery of instructions signed on its behalf by its Chairman, Vice Chairman, Chief
Executive Officer, President, Chief Financial Officer, Chief Operating Officer, or any Executive Vice President or Senior Vice President, instruct the Trustee or any paying agent to call all or any
part of the Securities of a particular series for redemption and to give notice of redemption in the manner set forth in this Section, such notice to be in the name of the Company or its own name as
the Trustee or such paying agent may deem advisable. In any case in which notice of redemption is to be given by the Trustee or any such paying agent, the Company shall deliver or cause to be
delivered to, or permit to remain with, the Trustee or such paying agent, as the case may be, such Security Register, transfer books or other records, or suitable copies or extracts therefrom,
sufficient to enable the Trustee or such paying agent to give any notice by mail that may be required under the provisions of this Section. 

SECTION 3.03    Payment Upon Redemption.    

        (a)   If
the giving of notice of redemption shall have been completed as above provided, the Securities or portions of Securities of the series to be redeemed specified in
such notice shall become due and payable on the date and at the place stated in such notice at the applicable redemption price, together with interest accrued to the date fixed for redemption and
interest on such Securities or portions of Securities shall cease to accrue on and after the date fixed for redemption, unless the Company shall default in the payment of such redemption price and
accrued interest with respect to any such Security or portion thereof. On presentation and surrender of such Securities on or after the date fixed for redemption at the place of payment specified in
the notice, said Securities shall be paid and redeemed at the applicable redemption price for such series, together with interest accrued thereon to the date fixed for redemption (but if the date
fixed for redemption is an interest payment date, the interest installment payable on such date shall be payable to the registered holder at the close of business on the applicable record date
pursuant to Section 2.03). 

        (b)   Upon
presentation of any Security of such series that is to be redeemed in part only, the Company shall execute and the Trustee shall authenticate and the office or
agency where the Security is presented shall deliver to the holder thereof, at the expense of the Company, a new Security of the same series of authorized denominations in principal amount equal to
the unredeemed portion of the Security so presented. 

SECTION 3.04    Sinking Fund.    

        The
provisions of Sections 3.04, 3.05 and 3.06 shall be applicable to any sinking fund for the retirement of Securities of a series, except as otherwise specified as contemplated
by Section 2.01 for Securities of such series. The minimum amount of any sinking fund payment provided for by the terms of Securities of any series is herein referred to as a "mandatory sinking
fund payment," and any payment in excess of such minimum amount provided for by the terms of Securities of any series is herein referred to as an "optional sinking fund payment". If provided for by
the terms of Securities of any series, the cash amount of any sinking fund payment may be subject to reduction as provided in Section 3.05. Each sinking fund payment shall be applied to the
redemption of Securities of any series as provided for by the terms of Securities of such series. 

SECTION 3.05    Satisfaction of Sinking Fund Payments with Securities.    

        The
Company (a) may deliver Outstanding Securities of a series (other than any Securities previously called for redemption) and (b) may apply as a credit Securities of a
series that have been redeemed either at the election of the Company pursuant to the terms of such Securities or through the application of permitted optional sinking fund payments pursuant to the
terms of such Securities, in each case in satisfaction of all or any part of any sinking fund payment with respect to the Securities of 

12

 

such
series required to be made pursuant to the terms of such Securities, provided that such Securities have not been previously so credited. Such Securities shall be received and credited for such
purpose by the Trustee at the redemption price specified in such Securities for redemption through operation of the sinking fund and the amount of such sinking fund payment shall be reduced
accordingly. 

SECTION 3.06    Redemption of Securities for Sinking Fund.    

        Not
less than 45 days prior to each sinking fund payment date for any series of Securities, the Company will deliver to the Trustee an Officers' Certificate specifying the amount
of the next ensuing sinking fund payment for that series pursuant to the terms of the series, the portion thereof, if any, that is to be satisfied by delivering and crediting Securities of that series
pursuant to Section 3.05 and the basis for such credit and will, together with such Officers' Certificate, deliver to the Trustee any Securities to be so delivered. Not less than 30 days
before each such sinking fund payment date the Trustee shall select the Securities to be redeemed upon such sinking fund payment date in the manner specified in Section 3.02 and cause notice of
the redemption thereof to be given in the name of and at the expense of the Company in the manner provided in Section 3.02. Such notice having been duly given, the redemption of such Securities
shall be made upon the terms and in the manner stated in Section 3.03. 

 
 

  ARTICLE IV    
    
    COVENANTS    
    

SECTION 4.01    Payment of Principal, Premium and Interest.    

        The
Company will duly and punctually pay or cause to be paid the principal of (and premium, if any) and interest on the Securities of that series at the time and place and in the manner
provided herein and established with respect to such Securities. 

SECTION 4.02    Maintenance of Office or Agency.    

        So
long as any series of the Securities remain Outstanding, the Company agrees to maintain an office or agency in the United States, with respect to each such series and at such other
location or locations as may be designated as provided in this Section 4.02, where (a) Securities of that series may be presented for payment, (b) Securities of that series may be
presented as herein above authorized for registration of transfer and exchange, and (c) notices and demands to or upon the Company in respect of the Securities of that series and this Indenture
may be given or served, such designation to continue with respect to such office or agency until the Company shall, by written notice signed by its Chairman, Vice Chairman, Chief Executive Officer,
President, Chief Financial Officer, Chief Operating Officer, or an Executive Vice President or Senior Vice President and delivered to the Trustee, designate some other office or agency for such
purposes or any of them. If at any time the Company shall fail to maintain any such required office or agency or shall fail to furnish the Trustee with the address thereof, such presentations, notices
and demands may be made or served at the Corporate Trust Office of the Trustee, and the Company hereby appoints the Trustee as its agent to receive all such presentations, notices and demands. 

SECTION 4.03    Paying Agents.    

        (a)   If
the Company shall appoint one or more paying agents for all or any series of the Securities, other than the Trustee, the Company will cause each such paying agent to
execute and deliver to the Trustee an instrument in which such agent shall agree with the Trustee, subject to the provisions of this Section: 

        (1)   that
it will hold all sums held by it as such agent for the payment of the principal of (and premium, if any) or interest on the Securities of that series (whether such
sums have been paid to 

13

 

it
by the Company or by any other obligor of such Securities) in trust for the benefit of the Persons entitled thereto; 

        (2)   that
it will give the Trustee notice of any failure by the Company (or by any other obligor of such Securities) to make any payment of the principal of (and premium, if
any) or interest on the Securities of that series when the same shall be due and payable; 

        (3)   that
it will, at any time during the continuance of any failure referred to in the preceding paragraph (a)(2) above, upon the written request of the Trustee,
forthwith pay to the Trustee all sums so held in trust by such paying agent; and 

        (4)   that
it will perform all other duties of paying agent as set forth in this Indenture. 

        (b)   If
the Company shall act as its own paying agent with respect to any series of the Securities, it will on or before each due date of the principal of (and premium, if
any) or interest on Securities of that series, set aside, segregate and hold in trust for the benefit of the Persons entitled thereto a sum sufficient to pay such principal (and premium, if any) or
interest so becoming due on Securities of that series until such sums shall be paid to such Persons or otherwise disposed of as herein provided and will promptly notify the Trustee of such action, or
any failure (by it or any other obligor on such Securities) to take such action. Whenever the Company shall have one or more paying agents for any series of Securities, it will, prior to each due date
of the principal of (and premium, if any) or interest on any Securities of that series, deposit with the paying agent a sum sufficient to pay the principal (and premium, if any) or interest so
becoming due, such sum to be held in trust for the benefit of the Persons entitled to such principal, premium or interest, and (unless such paying agent is the Trustee) the Company will promptly
notify the Trustee of this action or failure so to act. 

        (c)   Notwithstanding
anything in this Section to the contrary, (1) the agreement to hold sums in trust as provided in this Section is subject to the provisions of
Section 11.05, and (2) the Company may at any time, for the purpose of obtaining the satisfaction and discharge of this Indenture or for any other purpose, pay, or direct any paying
agent to pay, to the Trustee all sums held in trust by the Company or such paying agent, such sums to be held by the Trustee upon the same terms and conditions as those upon which such sums were held
by the Company or such paying agent; and, upon such payment by any paying agent to the Trustee, such paying agent shall be released from all further liability with respect to such money. 

SECTION 4.04    Appointment to Fill Vacancy in Office of Trustee.    

        The
Company, whenever necessary to avoid or fill a vacancy in the office of Trustee, will appoint, in the manner provided in Section 7.10, a Trustee, so that there shall at all
times be a Trustee hereunder. 

 
 

  ARTICLE V    
    
    SECURITYHOLDERS' LISTS AND REPORTS
  BY THE COMPANY AND THE TRUSTEE    
    

SECTION 5.01    Company to Furnish Trustee Names and Addresses of Securityholders.    

        The
Company will furnish or cause to be furnished to the Trustee (a) on each regular record date (as defined in Section 2.03), but in each case will be no more than six
months apart, a list, in such form as the Trustee may reasonably require, of the names and addresses of the holders of each series of Securities as of such regular record date, provided that the
Company shall not be obligated to furnish or cause to be furnished such list at any time that the list shall not differ in any respect from the most recent list furnished to the Trustee by the Company
and (b) at such other times as the Trustee may request in writing within 30 days after the receipt by the Company of any such request, a list of similar 

14

 

form
and content as of a date not more than 15 days prior to the time such list is furnished; provided, however, that, in either case, no such list need be furnished for any series for which
the Trustee shall be the Security Registrar. 

SECTION 5.02    Preservation Of Information; Communications With Securityholders.    

        (a)   The
Trustee shall preserve, in as current a form as is reasonably practicable, all information as to the names and addresses of the holders of Securities contained in
the most recent list furnished to it as provided in Section 5.01 and as to the names and addresses of holders of Securities received by the Trustee in its capacity as Security Registrar (if
acting in such capacity). 

        (b)   The
Trustee may destroy any list furnished to it as provided in Section 5.01 upon receipt of a new list so furnished. 

        (c)   Securityholders
may communicate as provided in Section 312(b) of the Trust Indenture Act with other Securityholders with respect to their rights under this
Indenture or under the Securities. The Company, the Trustee, the Security Registrar and any other Person shall have the protection of the Trust Indenture Act Section 312(c). 

SECTION 5.03    Reports by the Company.    

        (a)   The
Company covenants and agrees to file with the Trustee, within 15 days after the Company files the same with the Commission, copies of the annual reports and
of the information, documents and other reports (or copies of such portions of any of the foregoing as the Commission may from time to time by rules and regulations prescribe) that the Company may be
required to file with the Commission pursuant to Section 13 or Section 15(d) of the Exchange Act; or, if the Company is not required to file information, documents or reports pursuant to
either of such sections, then to file with the Trustee and the Commission, in accordance with the rules and regulations prescribed from time to time by the Commission, such of the supplementary and
periodic information, documents and reports that may be required pursuant to Section 13 of the Exchange Act, in respect of a security listed and registered on a national securities exchange as
may be prescribed from time to time in such rules and regulations. 

        (b)   The
Company covenants and agrees to file with the Trustee and the Commission, in accordance with the rules and regulations prescribed from to time by the Commission,
such additional information, documents and reports with respect to compliance by the Company with the conditions and covenants provided for in this Indenture as may be required from time to time by
such rules and regulations. 

        (c)   The
Company covenants and agrees to transmit by mail, first class postage prepaid, or reputable overnight delivery service that provides for evidence of receipt, to the
Securityholders, as their names and addresses appear upon the Security Register, within 30 days after the filing thereof with the Trustee, such summaries of any information, documents and
reports required to be filed by the Company pursuant to subsections (a) and (b) of this Section as may be required by rules and regulations prescribed from time to time by the
Commission. 

SECTION 5.04    Reports by the Trustee.    

        (a)   On
or before [        ] in each year in which any of the Securities are Outstanding, the Trustee shall transmit by mail, first class
postage prepaid, to the Securityholders, as their names and addresses appear upon the Security Register, a brief report dated as of the preceding [        ], if and to
the extent required under Section 313(a) of the Trust Indenture Act. 

        (b)   The
Trustee shall comply with Sections 313(b), 313(c) and 313(d) of the Trust Indenture Act. 

15

 

 

        (c)   A copy of each such report shall, at the time of such transmission to Securityholders, be filed by the Trustee with the Company, with each stock exchange upon which any
Securities are listed (if so listed) and also with the Commission. The Company agrees to notify the Trustee when any Securities become listed on any stock exchange. 

        (d)   If
an Event of Default occurs and is continuing and the Trustee receives actual notice of such Event of Default, the Trustee shall mail to each Securityholder notice of
the uncured Event of Default within 90 days after the occurrence thereof. Except in the case of an Event of Default in payment of principal of, or interest on, any Securities, or in the payment
of any sinking or purchase fund installment, the Trustee may withhold the notice if and so long as the board of directors, the executive committee or a trust committee of directors and/or Responsible
Officers of the Trustee in good faith determine that the withholding of such notice is in the interests of the Securityholders. 

 
 

  ARTICLE VI    
    
    REMEDIES OF THE TRUSTEE AND SECURITYHOLDERS ON EVENT OF DEFAULT    
    

SECTION 6.01    Events of Default.    

        (a)   Whenever
used herein with respect to Securities of a particular series, "Event of Default" means any one or more of the following events that has occurred and is
continuing: 

        (1)   the
Company defaults in the payment of any installment of interest upon any of the Securities of that series, as and when the same shall become due and payable, and such
default continues for a period of 90 days; provided, however, that a valid extension of an interest payment period by the Company in accordance with the terms of any indenture supplemental
hereto, shall not constitute a default in the payment of interest for this purpose; 

        (2)   the
Company defaults in the payment of the principal of (or premium, if any, on) any of the Securities of that series as and when the same shall become due and payable
whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to that series; provided, however, that a valid
extension of the maturity of such Securities in accordance with the terms of any indenture supplemental hereto shall not constitute a default in the payment of principal or premium, if any; 

        (3)   the
Company fails to observe or perform any other of its covenants or agreements with respect to that series contained in this Indenture or otherwise established with
respect to that series of Securities pursuant to Section 2.01 hereof (other than a covenant or agreement that has been expressly included in this Indenture solely for the benefit of one or more
series of Securities other than such series) for a period of 90 days after the date on which written notice of such failure, requiring the same to be remedied and stating that such notice is a
"Notice of Default" hereunder, shall have been given to the Company by the Trustee, by registered or certified mail, or to the Company and the Trustee by the holders of at least 25% in principal
amount of the Securities of that series at the time Outstanding; 

        (4)   the
Company pursuant to or within the meaning of any Bankruptcy Law (i) commences a voluntary case, (ii) consents to the entry of an order for relief
against it in an involuntary case, (iii) consents to the appointment of a Custodian of it or for all or substantially all of its property or (iv) makes a general assignment for the
benefit of its creditors; or 

        (5)   a
court of competent jurisdiction enters an order under any Bankruptcy Law that (i) is for relief against the Company in an involuntary case, (ii) appoints
a Custodian of the Company for all or substantially all of its property or (iii) orders the liquidation of the Company, and the order or decree remains unstayed and in effect for
90 days. 

16

 

        (b)   In
each and every such case, unless the principal of all the Securities of that series shall have already become due and payable, either the Trustee or the holders of
not less than 25% in aggregate principal amount of the Securities of that series then Outstanding hereunder, by notice in writing to the Company (and to the Trustee if given by such Securityholders),
may declare the principal of all the Securities of that series to be due and payable immediately, and upon any such declaration the same shall become and shall be immediately due and payable. 

        (c)   At
any time after the principal of the Securities of that series shall have been so declared due and payable, and before any judgment or decree for the payment of the
moneys due shall have been obtained or entered as hereinafter provided, the holders of a majority in aggregate principal amount of the Securities of that series then Outstanding hereunder, by written
notice to the Company and the Trustee, may rescind and annul such declaration and its consequences if: (1) the Company has paid or deposited with the Trustee a sum sufficient to pay all matured
installments of interest upon all the Securities of that series and the principal of (and premium, if any, on) all Securities of that series that shall have become due otherwise than by acceleration
(with interest upon such principal and premium, if any, and, to the extent that such payment is enforceable under applicable law, upon overdue installments of interest, at the rate per annum expressed
in the Securities of that series to the date of such payment or deposit) and any amount payable to the Trustee under Section 7.06, and (2) any and all other Events of Default under the
Indenture with respect to such series, other than the nonpayment of principal on Securities of that series that shall not have become due by their terms, shall have been remedied or waived as provided
in Section 6.06. 

        No
such rescission and annulment shall extend to or shall affect any subsequent default or impair any right consequent thereon. 

        (d)   In
case the Trustee shall have proceeded to enforce any right with respect to Securities of that series under this Indenture and such proceedings shall have been
discontinued or abandoned because of such rescission or annulment or for any other reason or shall have been determined adversely to the Trustee, then and in every such case, subject to any
determination in such proceedings, the Company and the Trustee shall be restored respectively to their former positions and rights hereunder, and all rights, remedies and powers of the Company and the
Trustee shall continue as though no such proceedings had been taken. 

SECTION 6.02    Suits for Enforcement by Trustee.    

        (a)   If
an Event of Default specified in Section 6.01(a)(1) or (2) hereof occurs and is continuing, the Trustee, in its own name and as trustee of an express
trust, shall be entitled and empowered to institute any action or proceedings at law or in equity for the collection of the sums so due and unpaid, and may prosecute any such action or proceeding to
judgment or final decree, and may enforce any such judgment or final decree against the Company or any other obligor upon the Securities of that series and collect the moneys adjudged or decreed to be
payable in the manner provided by law out of the property of the Company or any other obligor upon the Securities of that series, wherever situated. 

        (b)   In
case of any receivership, insolvency, liquidation, bankruptcy, reorganization, readjustment, arrangement, composition or judicial proceedings affecting the Company,
or its creditors or property, the Trustee shall have power to intervene in such proceedings and take any action therein that may be permitted by the court and shall (except as may be otherwise
provided by law) be entitled to file such proofs of claim and other papers and documents as may be necessary or advisable in order to have the claims of the Trustee and of the holders of Securities of
a series allowed for the entire amount due and payable by the Company under this Indenture at the date of institution of such proceedings and for any additional amount that may become due and payable
by the Company after such date, and to collect and receive any moneys or other property payable or deliverable on any such claim, and to distribute the same after the deduction of the amount payable
to the Trustee under Section 7.06; and any receiver, assignee or trustee in bankruptcy or reorganization is hereby authorized by each of the 

17

 

holders
of Securities of such series to make such payments to the Trustee, and, in the event that the Trustee shall consent to the making of such payments directly to such Securityholders, to pay to
the Trustee any amount due it under Section 7.06. 

        (c)   All
rights of action and of asserting claims under this Indenture, or under any of the terms established with respect to Securities of a series, may be enforced by the
Trustee without the possession of any of such Securities, or the production thereof at any trial or other proceeding relative thereto, and any such suit or proceeding instituted by the Trustee shall
be brought in its own name as trustee of an express trust, and any recovery of judgment shall, after provision for payment to the Trustee of any amounts due under Section 7.06, be for the
ratable benefit of the holders of the Securities of such series. 

        In
case of an Event of Default hereunder, the Trustee may in its discretion proceed to protect and enforce the rights vested in it by this Indenture by such appropriate judicial
proceedings as the Trustee shall deem most effectual to protect and enforce any of such rights, either at law or in equity or in bankruptcy or otherwise, whether for the specific enforcement of any
covenant or agreement contained in this Indenture or in aid of the exercise of any power granted in this Indenture, or to enforce any other legal or equitable right vested in the Trustee by this
Indenture or by law. 

        Nothing
contained herein shall be deemed to authorize the Trustee to authorize or consent to or accept or adopt on behalf of any Securityholder any plan of reorganization, arrangement,
adjustment or composition affecting the Securities of that series or the rights of any holder thereof or to authorize the Trustee to vote in respect of the claim of any Securityholder in any such
proceeding. 

SECTION 6.03    Application of Moneys Collected.    

        Any
moneys collected by the Trustee pursuant to this Article with respect to a particular series of Securities shall be applied in the following order, at the date or dates fixed by the
Trustee and, in case of the distribution of such moneys on account of principal (or premium, if any) or interest, upon presentation of the Securities of that series, and notation thereon the payment,
if only partially paid, and upon surrender thereof if fully paid: 

        FIRST:    To
the payment of costs and expenses of collection and of all amounts payable to the Trustee under Section 7.06; 

        SECOND:    To
the payment of all Senior Indebtedness of the Company if and to the extent required by ARTICLE XIV; and 

        THIRD:    To
the payment of the amounts then due and unpaid upon Securities of such series for principal (and premium, if any) and interest, in respect of which or for the
benefit of which such money has been collected, ratably, without preference or priority of any kind, according to the amounts due and payable on such Securities for principal (and premium, if any) and
interest, respectively. 

SECTION 6.04    Limitation on Suits.    

        No
holder of any Security of any series shall have any right by virtue or by availing of any provision of this Indenture to institute any suit, action or proceeding in equity or at law
upon or under or with respect to this Indenture or for the appointment of a receiver or trustee, or for any other remedy hereunder, unless (a) such holder previously shall have given to the
Trustee written notice of an Event of Default and of the continuance thereof with respect to the Securities of such series specifying such Event of Default, as hereinbefore provided; (b) the
holders of not less than 25% in aggregate principal amount of the Securities of such series then Outstanding shall have made written request upon the Trustee to institute such action, suit or
proceeding in its own name as trustee hereunder; (c) such holder or holders shall have offered to the Trustee such reasonable indemnity as it may require against the costs, expenses and
liabilities to be incurred therein or thereby; (d) the Trustee for 

18

 

60 days
after its receipt of such notice, request and offer of indemnity, shall have failed to institute any such action, suit or proceeding; and (e) during such 60-day
period, the holders of a majority in principal amount of the Securities of that series shall not have given the Trustee a direction inconsistent with the request. 

        Notwithstanding
anything contained herein to the contrary, the right of any holder of any Security to receive payment of the principal of (and premium, if any) and interest on such
Security, as therein provided, on or after the respective due dates expressed in such Security (or in the case of redemption,
on the redemption date), or to institute suit for the enforcement of any such payment on or after such respective dates or redemption date, shall not be impaired or affected without the consent of
such holder. By accepting a Security hereunder it is expressly understood, intended and covenanted by the taker and holder of every Security of such series with every other such taker and holder and
the Trustee, that no one or more holders of Securities of such series shall have any right in any manner whatsoever by virtue or by availing of any provision of this Indenture to affect, disturb or
prejudice the rights of the holders of any other of such Securities, or to obtain or seek to obtain priority over or preference to any other such holder, or to enforce any right under this Indenture,
except in the manner herein provided and for the equal, ratable and common benefit of all holders of Securities of such series. For the protection and enforcement of the provisions of this Section,
each and every Securityholder and the Trustee shall be entitled to such relief as can be given either at law or in equity. 

SECTION 6.05    Rights and Remedies Cumulative; Delay or Omission Not Waiver.    

        (a)   All
powers and remedies given by this Article to the Trustee or to the Securityholders shall, to the extent permitted by law, be deemed cumulative and not exclusive of
any other powers and remedies available to the Trustee or the holders of the Securities, by judicial proceedings or otherwise, to enforce the performance or observance of the covenants and agreements
contained in this Indenture or otherwise established with respect to such Securities. 

        (b)   No
delay or omission of the Trustee or of any holder of any of the Securities to exercise any right or power accruing upon any Event of Default occurring and continuing
as aforesaid shall impair any such right or power, or shall be construed to be a waiver of any such default or on acquiescence therein; and, subject to the provisions of Section 6.04, every
power and remedy given by this Article or by law to the Trustee or the Securityholders may be exercised from time to time, and as often as shall be deemed expedient, by the Trustee or by the
Securityholders. 

SECTION 6.06    Control by Securityholders.    

        The
holders of a majority in aggregate principal amount of the Securities of any series at the time Outstanding, determined in accordance with Section 8.01, shall have the right
to direct the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred on the Trustee with respect to such series;
provided, however, that such direction shall not be in conflict with any rule of law or with this Indenture or be unduly prejudicial to the rights of holders of Securities of any other series at the
time Outstanding determined in accordance with Section 8.01. Subject to the provisions of Section 7.01, the Trustee shall have the right to decline to follow any such direction if the
Trustee in good faith shall, by a Responsible Officer or Officers of the Trustee, determine that the proceeding so directed would involve the Trustee in personal liability. The holders of a majority
in aggregate principal amount of the Securities of any series at the time Outstanding affected thereby, determined in accordance with Section 8.01, may on behalf of the holders of all of the
Securities of such series waive any past default in the performance of any of the covenants contained herein or established pursuant to Section 2.01 with respect to such series and its
consequences, except an uncured default in the payment of the principal of (or premium, if any) or interest on, any of the Securities of that series as and when the same shall become due by the terms
of such Securities otherwise than by acceleration (unless such default has been cured and a sum sufficient to pay all matured installments of interest and principal and any premium has been deposited
with the 

19

 

Trustee
(in accordance with Section 6.01(c)). Upon any such waiver, the default covered thereby shall be deemed to be cured for all purposes of this Indenture and the Company, the Trustee and
the holders of the Securities of such series shall be restored to their former positions and rights hereunder, respectively; but no such waiver shall extend to any subsequent or other default or
impair any right consequent thereon. 

SECTION 6.07    Undertaking to Pay Costs.    

        All
parties to this Indenture agree, and each holder of any Securities by such holder's acceptance thereof shall be deemed to have agreed, that any court may in its discretion require,
in any suit for the enforcement of any right or remedy under this Indenture, or in any suit against the Trustee for any action taken or omitted by it as Trustee, the filing by any party litigant in
such suit of an undertaking to pay the costs of such suit, and that such court may in its discretion assess reasonable costs, including reasonable attorneys' fees, against any party litigant in such
suit, having due regard to the merits and good faith of the claims or defenses made by such party litigant; but the provisions of this Section shall not apply to any suit instituted by the Trustee, to
any suit instituted by any Securityholder, or group of Securityholders, holding more than 10% in aggregate principal amount of the Outstanding Securities of any series, or to any suit instituted by
any Securityholder for the enforcement of the payment of the principal of (or premium, if any) or interest on any Security of such series, on or after the respective due dates expressed in such
Security or established pursuant to this Indenture. 

 
 

  ARTICLE VII    
    
    CONCERNING THE TRUSTEE    
    

SECTION 7.01    Certain Duties and Responsibilities of Trustee.    

        (a)   The
Trustee, prior to the occurrence of an Event of Default with respect to the Securities of a series and after the curing of all Events of Default with respect to the
Securities of that series that may have occurred, shall undertake to perform with respect to the Securities of such series such duties and only such duties as are specifically set forth in this
Indenture, and no implied covenants shall be read into this Indenture against the Trustee. In case an Event of Default with respect to the Securities of a series has occurred (that has not been cured
or waived), the Trustee shall exercise with respect to Securities of that series such of the rights and powers vested in it by this Indenture, and use the same degree of care and skill in their
exercise, as a prudent person would exercise or use under the circumstances in the conduct of his own affairs. 

        (b)   No
provision of this Indenture shall be construed to relieve the Trustee from liability for its own negligent action, its own negligent failure to act, or its own
willful misconduct, except that: 

        (1)   prior
to the occurrence of an Event of Default with respect to the Securities of a series and after the curing or waiving of all such Events of Default with respect to
that series that may have occurred: 

          (i)  the
duties and obligations of the Trustee shall with respect to the Securities of such series be determined solely by the express provisions of this Indenture, and the
Trustee shall not be liable with respect to the Securities of such series except for the performance of such duties and obligations as are specifically set forth in this Indenture, and no implied
covenants or obligations shall be read into this Indenture against the Trustee; and 

         (ii)  in
the absence of bad faith on the part of the Trustee, the Trustee may with respect to the Securities of such series conclusively rely, as to the truth of the
statements and the correctness of the opinions expressed therein, upon any certificates or opinions furnished to the Trustee and conforming to the requirements of this Indenture; but in the case of
any such certificates or opinions that by any provision hereof are specifically required to be furnished to 

20

 

the
Trustee, the Trustee shall be under a duty to examine the same to determine whether or not they conform to the requirements of this Indenture; 

        (2)   the
Trustee shall not be liable for any error of judgment made in good faith by a Responsible Officer or Responsible Officers of the Trustee, unless it shall be proved
that the Trustee was negligent in ascertaining the pertinent facts; 

        (3)   the
Trustee shall not be liable with respect to any action taken or omitted to be taken by it in good faith in accordance with the direction of the holders of not less
than a majority in principal amount of the Securities of any series at the time Outstanding relating to the time, method and place of conducting any proceeding for any remedy available to the Trustee,
or exercising any trust or power conferred upon the Trustee under this Indenture with respect to the Securities of that series; and 

        (4)   none
of the provisions contained in this Indenture shall require the Trustee to expend or risk its own funds or otherwise incur personal financial liability in the
performance of any of its duties or in the exercise of any of its rights or powers, if there is reasonable ground for believing that the repayment of such funds or liability is not reasonably assured
to it under the terms of this Indenture or adequate indemnity against such risk is not reasonably assured to it. 

SECTION 7.02    Certain Rights of Trustee.    

        Except
as otherwise provided in Section 7.01: 

        (a)   The
Trustee may rely and shall be protected in acting or refraining from acting upon any resolution, certificate, statement, instrument, opinion, report, notice,
request, consent, order, approval, bond, security or other paper or document believed by it to be genuine and to have been signed or presented by the proper party or parties; 

        (b)   Any
request, direction, order or demand of the Company mentioned herein shall be sufficiently evidenced by a Board Resolution or an instrument signed in the name of the
Company, by the
Chairman, Vice Chairman, Chief Executive Officer, President, Executive Vice President or any Senior Vice President and by the Secretary or an Assistant Secretary or the Treasurer or an Assistant
Treasurer thereof (unless other evidence in respect thereof is specifically prescribed herein); 

        (c)   The
Trustee may consult with counsel and the written advice of such counsel or any Opinion of Counsel shall be full and complete authorization and protection in respect
of any action taken or suffered or omitted hereunder in good faith and in reliance thereon; 

        (d)   The
Trustee shall be under no obligation to exercise any of the rights or powers vested in it by this Indenture at the request, order or direction of any of the
Securityholders, pursuant to the provisions of this Indenture, unless such Securityholders shall have offered to the Trustee reasonable security or indemnity against the costs, expenses and
liabilities that may be incurred therein or thereby; nothing contained herein shall, however, relieve the Trustee of the obligation, upon the occurrence of an Event of Default with respect to a series
of the Securities (that has not been cured or waived) to exercise with respect to Securities of that series such of the rights and powers vested in it by this Indenture, and to use the same degree of
care and skill in their exercise, as a prudent person would exercise or use under the circumstances in the conduct of his own affairs; 

        (e)   The
Trustee shall not be liable for any action taken or omitted to be taken by it in good faith and believed by it to be authorized or within the discretion or rights or
powers conferred upon it by this Indenture; 

21

 

        (f)    The
Trustee shall not be bound to make any investigation into the facts or matters stated in any resolution, certificate, statement, instrument, opinion, report, notice,
request, consent, order, approval, bond, security or other papers or documents, unless requested in writing so to do by the holders of not less than a majority in principal amount of the Outstanding
Securities of the particular series affected thereby (determined as provided in Section 8.04); provided, however, that if the payment within a reasonable time to the Trustee of the costs,
expenses or liabilities likely to be incurred by it in the making of such investigation is, in the opinion of the Trustee, not reasonably assured to the Trustee by the security afforded to it by the
terms of this Indenture, the Trustee may require reasonable indemnity against such costs, expenses or liabilities as a condition to so proceeding. The reasonable expense of every such examination
shall be paid by the Company or, if paid by the Trustee, shall be repaid by the Company upon demand; and 

        (g)   The
Trustee may execute any of the trusts or powers hereunder or perform any duties hereunder either directly or by or through agents or attorneys and the Trustee shall
not be responsible for any misconduct or negligence on the part of any agent or attorney appointed with due care by it hereunder. 

SECTION 7.03    Trustee Not Responsible for Recitals or Issuance or Securities.    

        (a)   The
recitals contained herein and in the Securities shall be taken as the statements of the Company and the Trustee assumes no responsibility for the correctness of the
same. 

        (b)   The
Trustee makes no representations as to the validity or sufficiency of this Indenture or of the Securities. 

        (c)   The
Trustee shall not be accountable for the use or application by the Company of any of the Securities or of the proceeds of such Securities, or for the use or
application of any moneys paid over by the Trustee in accordance with any provision of this Indenture or established pursuant to Section 2.01, or for the use or application of any moneys
received by any paying agent other than the Trustee. 

SECTION 7.04    May Hold Securities.    

        The
Trustee or any paying agent or Security Registrar, in its individual or any other capacity, may become the owner or pledgee of Securities with the same rights it would have if it
were not Trustee, paying agent or Security Registrar. 

SECTION 7.05    Moneys Held in Trust.    

        Subject
to the provisions of Section 11.05, all moneys received by the Trustee shall, until used or applied as herein provided, be held in trust for the purposes for which they
were received, but need not be segregated from other funds except to the extent required by law. The Trustee shall be under no liability for interest on any moneys received by it hereunder except such
as it may agree with the Company to pay thereon. 

22

 

SECTION 7.06    Compensation and Reimbursement.    

        (a)   The
Company covenants and agrees to pay to the Trustee, and the Trustee shall be entitled to, such reasonable compensation (which shall not be limited by any provision
of law in regard to the compensation of a trustee of an express trust), as the Company and the Trustee may from time to time agree in writing, for all services rendered by it in the execution of the
trusts hereby created and in the exercise and performance of any of the powers and duties hereunder of the Trustee, and, except as otherwise expressly provided herein, the Company will pay or
reimburse the Trustee upon its request for all reasonable expenses, disbursements and advances incurred or made by the Trustee in accordance with any of the provisions of this Indenture (including the
reasonable compensation and the expenses and disbursements of its counsel and of all Persons not regularly in its employ) except any such expense, disbursement or advance as may arise from its
negligence or bad faith. The Company also covenants to indemnify the Trustee (and its officers, agents, directors and employees) for, and to hold it harmless against, any loss, liability or expense
incurred without negligence or bad faith on the part of the Trustee and arising out of or in connection with the acceptance or administration of this trust, including the costs and expenses of
defending itself against any claim of liability in the premises. 

        (b)   The
obligations of the Company under this Section to compensate and indemnify the Trustee and to pay or reimburse the Trustee for expenses, disbursements and advances
shall constitute additional indebtedness hereunder. Such additional indebtedness shall be secured by a lien prior to that of the Securities upon all property and funds held or collected by the Trustee
as such, except funds held in trust for the benefit of the holders of particular Securities. 

SECTION 7.07    Reliance on Officers' Certificate.    

        Except
as otherwise provided in Section 7.01, whenever in the administration of the provisions of this Indenture the Trustee shall deem it necessary or desirable that a matter be
proved or established prior to taking or suffering or omitting to take any action hereunder, such matter (unless other evidence in
respect thereof be herein specifically prescribed) may, in the absence of negligence or bad faith on the part of the Trustee, be deemed to be conclusively proved and established by an Officers'
Certificate delivered to the Trustee and such certificate, in the absence of negligence or bad faith on the part of the Trustee, shall be full warrant to the Trustee for any action taken, suffered or
omitted to be taken by it under the provisions of this Indenture upon the faith thereof. 

SECTION 7.08    Disqualification; Conflicting Interests.    

        If
the Trustee has or shall acquire any "conflicting interest" within the meaning of Section 310(b) of the Trust Indenture Act, the Trustee and the Company shall in all respects
comply with the provisions of Section 310(b) of the Trust Indenture Act. 

SECTION 7.09    Corporate Trustee Required; Eligibility.    

        There
shall at all times be a Trustee with respect to the Securities issued hereunder which shall at all times be a corporation organized and doing business under the laws of the United
States of America or any State or Territory thereof or of the District of Columbia, or a corporation or other Person permitted to act as trustee by the Commission, authorized under such laws to
exercise corporate trust powers, having a combined capital and surplus of at least 50 million U.S. dollars ($50,000,000), and subject to supervision or examination by Federal, State,
Territorial or District of Columbia authority. If such corporation publishes reports of condition at least annually, pursuant to law or to the requirements of the aforesaid supervising or examining
authority, then for the purposes of this Section, the combined capital and surplus of such corporation shall be deemed to be its combined capital and surplus as set forth in its most recent report of
condition so published. The Company may not, nor may any Person directly or indirectly controlling, controlled by or under common control with the Company, serve as Trustee. In case at any time the
Trustee shall cease to be eligible in accordance with the 

23

 

provisions
of this Section, the Trustee shall resign immediately in the manner and with the effect specified in Section 7.10. 

SECTION 7.10    Resignation and Removal; Appointment of Successor.    

        (a)   The
Trustee or any successor hereafter appointed, may at any time resign with respect to the Securities of one or more series by giving written notice thereof to the
Company and by transmitting notice of resignation by mail, first class postage prepaid, to the Securityholders of such series, as their names and addresses appear upon the Security Register. Upon
receiving such notice of resignation, the Company shall promptly appoint a successor trustee with respect to Securities of such series by written instrument, in duplicate, executed by order of the
Board of Directors, one copy of which instrument shall be delivered to the resigning Trustee and one copy to the successor trustee. If no successor trustee shall have been so appointed and have
accepted appointment within 30 days after the mailing of such notice of resignation, the resigning Trustee may petition any court of competent jurisdiction for the appointment of a successor
trustee with respect to Securities of such series, or any Securityholder of that series who has been a bona fide holder of a Security or Securities for at least six months may on behalf of himself and
all others similarly situated, petition any such court for the appointment of a successor trustee. Such court may thereupon after such notice, if any, as it may deem proper and prescribe, appoint a
successor trustee. 

        (b)   In
case at any time any one of the following shall occur: 

        (1)   the
Trustee shall fail to comply with the provisions of Section 7.08 after written request therefor by the Company or by any Securityholder who has been a bona
fide holder of a Security or Securities for at least six months; or 

        (2)   the
Trustee shall cease to be eligible in accordance with the provisions of Section 7.09 and shall fail to resign after written request therefor by the Company or
by any such Securityholder; or 

        (3)   the
Trustee shall become incapable of acting, or shall be adjudged a bankrupt or insolvent, or commence a voluntary bankruptcy proceeding, or a receiver of the Trustee
or of its property shall be appointed or consented to, or any public officer shall take charge or control of the Trustee or of its property or affairs for the purpose of rehabilitation, conservation
or liquidation, 

then,
in any such case, the Company may remove the Trustee with respect to all Securities and appoint a successor trustee by written instrument, in duplicate, executed by order of the Board of
Directors, one copy of which instrument shall be delivered to the Trustee so removed and one copy to the successor trustee, or, unless the Trustee's duty to resign is stayed as provided herein, any
Securityholder who has been a bona fide holder of a Security or Securities for at least six months may, on behalf of that holder and all others similarly situated, petition any court of competent
jurisdiction for the removal of the Trustee and the appointment of a successor trustee. Such court may thereupon after such notice, if any, as it may deem proper and prescribe, remove the Trustee and
appoint a successor trustee. 

        (c)   The
holders of a majority in aggregate principal amount of the Securities of any series at the time Outstanding may at any time remove the Trustee with respect to such
series by so notifying the Trustee and the Company and may appoint a successor Trustee for such series with the consent of the Company. 

        (d)   Any
resignation or removal of the Trustee and appointment of a successor trustee with respect to the Securities of a series pursuant to any of the provisions of this
Section shall become effective upon acceptance of appointment by the successor trustee as provided in Section 7.11. 

24

 

        (e)   Any
successor trustee appointed pursuant to this Section may be appointed with respect to the Securities of one or more series or all of such series, and at any time
there shall be only one Trustee with respect to the Securities of any particular series. 

SECTION 7.11    Acceptance of Appointment By Successor.    

        (a)   In
case of the appointment hereunder of a successor trustee with respect to all Securities, every such successor trustee so appointed shall execute, acknowledge and
deliver to the Company and to the retiring Trustee an instrument accepting such appointment, and thereupon the resignation or removal of the retiring Trustee shall become effective and such successor
trustee, without any further act, deed or conveyance, shall become vested with all the rights, powers, trusts and duties of the retiring Trustee; but, on the request of the Company or the successor
trustee, such retiring Trustee shall, upon payment of its charges, execute and deliver an instrument transferring to such successor trustee all the rights, powers and trusts of the retiring Trustee
and shall duly assign, transfer and deliver to such successor trustee all property and money held by such retiring Trustee hereunder. 

        (b)   In
case of the appointment hereunder of a successor trustee with respect to the Securities of one or more (but not all) series, the Company, the retiring Trustee and
each successor trustee with respect to the Securities of one or more series shall execute and deliver an indenture supplemental hereto wherein each successor trustee shall accept such appointment and
which (1) shall contain such provisions as shall be necessary or desirable to transfer and confirm to, and to vest in, each successor trustee all the rights, powers, trusts and duties of the
retiring Trustee with respect to the Securities of that or those series to which the appointment of such successor trustee relates, (2) shall contain such provisions as shall be deemed
necessary or desirable to confirm that all the rights, powers, trusts and duties of the retiring Trustee with respect to the Securities of that or those series as to which the retiring Trustee is not
retiring shall continue to be vested in the retiring Trustee, and (3) shall add to or change any of the provisions of this Indenture as shall be necessary to provide for or facilitate the
administration of the trusts hereunder by more than one Trustee, it being understood that nothing herein or in such supplemental indenture shall constitute such Trustees co-trustees of the
same trust, that each such Trustee shall be trustee of a trust or trusts hereunder separate and apart from any trust or trusts hereunder administered by any other such Trustee and that no Trustee
shall be responsible for any act or failure to act on the part of any other Trustee hereunder; and upon the execution and delivery of such supplemental indenture the resignation or removal of the
retiring Trustee shall become effective to the extent provided therein, such retiring Trustee shall with respect to the Securities of that or those series to which the appointment of such successor
trustee relates have no further responsibility for the exercise of rights and powers or for the performance of the duties and obligations vested in the Trustee under this Indenture, and each such
successor trustee, without any further act, deed or conveyance, shall become vested with all the rights, powers, trusts and duties of the retiring Trustee with respect to the Securities of that or
those series to which the appointment of such successor trustee relates; but, on request of the Company or any successor trustee, such retiring Trustee shall duly assign, transfer and deliver to such
successor trustee, to the extent contemplated by such supplemental indenture, the property and money held by such retiring Trustee hereunder with respect to the Securities of that or those series to
which the appointment of such successor trustee relates. 

        (c)   Upon
request of any such successor trustee, the Company shall execute any and all instruments for more fully and certainly vesting in and confirming to such successor
trustee all such rights, powers and trusts referred to in paragraph (a) or (b) of this Section, as the case may be. 

        (d)   No
successor trustee shall accept its appointment unless at the time of such acceptance such successor trustee shall be qualified and eligible under this Article. 

        (e)   Upon
acceptance of appointment by a successor trustee as provided in this Section, the Company shall transmit notice of the succession of such trustee hereunder by mail,
first class postage prepaid, to the Securityholders, as their names and addresses appear upon the Security Register. If the 

25

 

Company
fails to transmit such notice within ten days after acceptance of appointment by the successor trustee, the successor trustee shall cause such notice to be transmitted at the expense of the
Company. 

SECTION 7.12    Merger, Conversion, Consolidation or Succession to Business.    

        Any
corporation into which the Trustee may be merged or converted or with which it may be consolidated, or any corporation resulting from any merger, conversion or consolidation to which
the Trustee shall be a party, or any corporation succeeding to the corporate trust business of the Trustee, shall be the successor of the Trustee hereunder, provided that such corporation shall be
qualified under the provisions of Section 7.08 and eligible under the provisions of Section 7.09, without the execution or filing of any paper or any further act on the part of any of
the parties hereto, anything herein to the contrary notwithstanding. In case any Securities shall have been authenticated, but not delivered, by the Trustee then in office, any successor by merger,
conversion or consolidation to such authenticating Trustee may adopt such authentication and deliver the Securities so authenticated with the same effect as if such successor Trustee had itself
authenticated such Securities. 

SECTION 7.13    Preferential Collection of Claims Against the Company.    

        The
Trustee shall comply with Section 311(a) of the Trust Indenture Act, excluding any creditor relationship described in Section 311(b) of the Trust Indenture Act. A
Trustee who has resigned or been removed shall be subject to Section 311(a) of the Trust Indenture Act to the extent included therein. 

 
 

  ARTICLE VIII    
    
    CONCERNING THE SECURITYHOLDERS    
    

SECTION 8.01    Evidence of Action by Securityholders.    

        Whenever
in this Indenture it is provided that the holders of a majority or specified percentage in aggregate principal amount of the Securities of a particular series may take any
action (including the making of any demand or request, the giving of any notice, consent or waiver or the taking of any other action), the fact that at the time of taking any such action the holders
of such majority or specified percentage of that series have joined therein may be evidenced by any instrument or any number of instruments of similar tenor executed by such holders of Securities of
that series in Person or by agent or proxy appointed in writing. 

        If
the Company shall solicit from the Securityholders of any series any request, demand, authorization, direction, notice, consent, waiver or other action, the Company may, at its
option, as evidenced by an Officers' Certificate, fix in advance a record date for such series for the determination of Securityholders entitled to give such request, demand, authorization, direction,
notice, consent, waiver or other action, but the Company shall have no obligation to do so. If such a record date is fixed, such request, demand, authorization, direction, notice, consent, waiver or
other action may be given before or after the record date, but only the Securityholders of record at the close of business on the record date shall be deemed to be Securityholders for the purposes of
determining whether Securityholders of the requisite proportion of Outstanding Securities of that series have authorized or agreed or consented to such request, demand, authorization, direction,
notice, consent, waiver or other action, and for that purpose the Outstanding Securities of that series shall be computed as of the record date; provided, however, that no such authorization,
agreement or consent by such Securityholders on the record date shall be deemed effective unless it shall become effective pursuant to the provisions of this Indenture not later than six months after
the record date. 

26

 

SECTION 8.02    Proof of Execution by Securityholders.    

        Subject
to the provisions of Section 7.01, proof of the execution of any instrument by a Securityholder (such proof will not require notarization) or his agent or proxy and proof
of the holding by any Person of any of the Securities shall be sufficient if made in the following manner: 

        (a)   The
fact and date of the execution by any such Person of any instrument may be proved in any reasonable manner acceptable to the Trustee. 

        (b)   The
ownership of Securities shall be proved by the Security Register of such Securities or by a certificate of the Security Registrar thereof. 

        (c)   The
Trustee may require such additional proof of any matter referred to in this Section as it shall deem necessary. 

SECTION 8.03    Who May be Deemed Owners.    

        Prior
to the due presentment for registration of transfer of any Security, the Company, the Trustee, any paying agent and any Security Registrar may deem and treat the Person in whose
name such Security shall be registered upon the books of the Company as the absolute owner of such Security (whether or not such Security shall be overdue and notwithstanding any notice of ownership
or writing thereon made by anyone other than the Security Registrar) for the purpose of receiving payment of or on account of the principal of (and premium, if any) and (subject to
Section 2.03) interest on such Security and for all other purposes; and neither the Company nor the Trustee nor any paying agent nor any Security Registrar shall be affected by any notice to
the contrary. 

SECTION 8.04    Certain Securities Owned by Company Disregarded.    

        In
determining whether the holders of the requisite aggregate principal amount of Securities of a particular series have concurred in any direction, consent or waiver under this
Indenture, the Securities of that series that are owned by the Company or any other obligor on the Securities of that series or by any Person directly or indirectly controlling or controlled by or
under common control with the Company or any other obligor on the Securities of that series shall be disregarded and deemed not to be Outstanding for the purpose of any such determination, except that
for the purpose of determining whether the Trustee shall be protected in relying on any such direction, consent or waiver, only Securities of such series that the Trustee actually knows are so owned
shall be so disregarded. The Securities so owned that have been pledged in good faith may be regarded as Outstanding for the purposes of this Section, if the pledgee shall establish to the
satisfaction of the Trustee the pledgee's right so to act with respect to such Securities and that the pledgee is not a Person directly or indirectly controlling or controlled by or under direct or
indirect common control with the Company or any such other obligor. In case of a dispute as to such right, any decision by the Trustee taken upon the advice of counsel shall be full protection to the
Trustee. 

SECTION 8.05    Actions Binding on Future Securityholders.    

        At
any time prior to (but not after) the evidencing to the Trustee, as provided in Section 8.01, of the taking of any action by the holders of the majority or percentage in
aggregate principal amount of the Securities of a particular series specified in this Indenture in connection with such action, any holder of a Security of that series that is shown by the evidence to
be included in the Securities the holders of which have consented to such action may, by filing written notice with the Trustee, and upon proof of holding as provided in Section 8.02, revoke
such action so far as concerns such Security. Except as aforesaid any such action taken by the holder of any Security shall be conclusive and binding upon such holder and upon all future holders and
owners of such Security, and of any Security issued in exchange therefor, on registration of transfer thereof or in place thereof, irrespective of whether or not any notation in regard thereto is made
upon such Security. Any action taken by the holders of the majority or percentage in aggregate principal amount of the Securities of a particular series specified in 

27

 

this
Indenture in connection with such action shall be conclusively binding upon the Company, the Trustee and the holders of all the Securities of that series. 

 
 

  ARTICLE IX    
    
    SUPPLEMENTAL INDENTURES    
    

SECTION 9.01    Supplemental Indentures Without the Consent of Securityholders.    

        In
addition to any supplemental indenture otherwise authorized by this Indenture, the Company and the Trustee may from time to time and at any time enter into an indenture or indentures
supplemental hereto (which shall conform to the provisions of the Trust Indenture Act as then in effect), without the consent of the Securityholders, for one or more of the following purposes: 

        (a)   to
cure any ambiguity, defect or inconsistency herein or in the Securities of any series; 

        (b)   to
comply with Article Ten; 

        (c)   to
provide for uncertificated Securities in addition to or in place of certificated Securities; 

        (d)   to
add to the covenants of the Company for the benefit of the holders of all or any series of Securities (and if such covenants are to be for the benefit of less than
all series of Securities, stating that such covenants are expressly being included solely for the benefit of such series) or to surrender any right or power herein conferred upon the Company; 

        (e)   to
add to, delete from or revise the conditions, limitations and restrictions on the authorized amount, terms, purposes of issue, authentication and delivery of
Securities, as herein set forth; 

        (f)    to
make any change that does not adversely affect the rights of any Securityholder in any material respect; or 

        (g)   to
provide for the issuance of and establish the form and terms and conditions of the Securities of any series as provided in Section 2.01, to establish the form
of any certifications required to be furnished pursuant to the terms of this Indenture or any series of Securities, or to add to the rights of the holders of any series of Securities. 

        The
Trustee is hereby authorized to join with the Company in the execution of any such supplemental indenture, and to make any further appropriate agreements and stipulations that may be
therein contained, but the Trustee shall not be obligated to enter into any such supplemental indenture that affects the Trustee's own rights, duties or immunities under this Indenture or otherwise. 

        Any
supplemental indenture authorized by the provisions of this Section may be executed by the Company and the Trustee without the consent of the holders of any of the Securities at the
time Outstanding, notwithstanding any of the provisions of Section 9.02. 

SECTION 9.02    Supplemental Indentures With Consent of Securityholders.    

        With
the consent (evidenced as provided in Section 8.01) of the holders of not less than a majority in aggregate principal amount of the Securities of each series affected by such
supplemental indenture or indentures at the time Outstanding, the Company, when authorized by Board Resolutions, and the Trustee may from time to time and at any time enter into an indenture or
indentures supplemental hereto (which shall conform to the provisions of the Trust Indenture Act as then in effect) for the purpose of adding any provisions to or changing in any manner or eliminating
any of the provisions of this Indenture or of any supplemental indenture or of modifying in any manner not covered by Section 9.01 the rights of the holders of the Securities of such series
under this Indenture; provided, however, that no such supplemental indenture shall, without the consent of the holders of each Security then Outstanding and affected thereby, (i) extend the
fixed maturity of any Securities of any series, or 

28

 

reduce
the principal amount thereof, or reduce the rate of interest thereon, or reduce any premium payable upon the redemption thereof, or (ii) reduce the aforesaid percentage of Securities,
the holders of which are required to consent to any such supplemental indenture. 

        It
shall not be necessary for the consent of the Securityholders of any series affected thereby under this Section to approve the particular form of any proposed supplemental indenture,
but it shall be sufficient if such consent shall approve the substance thereof. 

SECTION 9.03    Effect of Supplemental Indentures.    

        Upon
the execution of any supplemental indenture pursuant to the provisions of this Article or of Section 10.01, this Indenture shall, with respect to such series, be and be
deemed to be modified and amended in accordance therewith and the respective rights, limitations of rights, obligations, duties and immunities under this Indenture of the Trustee, the Company and the
holders of Securities of the series affected thereby shall thereafter be determined, exercised and enforced hereunder subject in all respects to such modifications and amendments, and all the terms
and conditions of any such supplemental indenture shall be and be deemed to be part of the terms and conditions of this Indenture for any and all purposes. 

SECTION 9.04    Securities Affected by Supplemental Indentures.    

        Securities
of any series affected by a supplemental indenture, authenticated and delivered after the execution of such supplemental indenture pursuant to the provisions of this Article
or of Section 10.01, may bear a notation in form approved by the Company, provided such form meets the requirements of any exchange upon which such series may be listed, as to any matter
provided for in such supplemental indenture. If the Company shall so determine, new Securities of that series so modified as to conform, in the opinion of the Board of Directors, to any modification
of this Indenture contained in any such supplemental indenture may be prepared by the Company, authenticated by the Trustee and delivered in exchange for the Securities of that series then
Outstanding. 

SECTION 9.05    Execution of Supplemental Indentures.    

        Upon
the request of the Company, accompanied by Board Resolutions authorizing the execution of any such supplemental indenture, and upon the filing with the Trustee of evidence of the
consent of Securityholders required to consent thereto as aforesaid, the Trustee shall join with the Company in the execution of such supplemental indenture unless such supplemental indenture affects
the Trustee's own rights, duties or immunities under this Indenture or otherwise, in which case the Trustee may in its discretion but shall not be obligated to enter into such supplemental indenture.
The Trustee, subject to the provisions of Section 7.01, may receive an Opinion of Counsel as conclusive evidence that any supplemental indenture executed pursuant to this Article is authorized
or permitted by, and conforms to, the terms of this Article and that it is proper for the Trustee under the provisions of this Article to join in the execution thereof; provided, however, that such
Opinion of Counsel need not be provided in connection with the execution of a supplemental indenture that establishes the terms of a series of Securities pursuant to Section 2.01 hereof. 

        Promptly
after the execution by the Company and the Trustee of any supplemental indenture pursuant to the provisions of this Section, the Trustee shall transmit by mail, first class
postage prepaid, a notice, setting forth in general terms the substance of such supplemental indenture, to the Securityholders of all series affected thereby as their names and addresses appear upon
the Security Register. Any failure
of the Trustee to mail such notice, or any defect therein, shall not, however, in any way impair or affect the validity of any such supplemental indenture. 

29

 

 
 

  ARTICLE X    
    
    SUCCESSOR ENTITY    
    

SECTION 10.01    Company May Consolidate, Etc.    

        Nothing
contained in this Indenture or in any of the Securities shall prevent any consolidation or merger of the Company with or into any other Person (whether or not affiliated with the
Company) or successive consolidations or mergers in which the Company or its successor or successors shall be a party or parties, or shall prevent any sale, conveyance, transfer or other disposition
of the property of the Company or its successor or successors as an entirety, or substantially as an entirety, to any other corporation (whether or not affiliated with the Company or its successor or
successors) authorized to acquire and operate the same; provided, however, the Company hereby covenants and agrees that, upon any such consolidation or merger (in each case, if the Company is not the
survivor of such transaction), sale, conveyance, transfer or other disposition, the due and punctual payment of the principal of (premium, if any) and interest on all of the Securities of all series
in accordance with the terms of each series, according to their tenor, and the due and punctual performance and observance of all the covenants and conditions of this Indenture with respect to each
series or established with respect to such series pursuant to Section 2.01 to be kept or performed by the Company shall be expressly assumed by supplemental indenture (which shall conform to
the provisions of the Trust Indenture Act as then in effect) satisfactory in form to the Trustee executed and delivered to the Trustee by the entity formed by such consolidation, or into which the
Company shall have been merged, or by the entity which shall have acquired such property. 

SECTION 10.02    Successor Entity Substituted.    

        (a)   In
case of any such consolidation, merger, sale, conveyance, transfer or other disposition and upon the assumption by the successor entity by supplemental indenture,
executed and delivered to the Trustee and satisfactory in form to the Trustee, of the due and punctual payment of the principal of (and premium, if any) and interest on all of the Securities of all
series Outstanding and the due and punctual performance of all of the covenants and conditions of this Indenture or established with respect to each series of the Securities pursuant to
Section 2.01 to be performed by the Company with respect to each series, such successor entity shall succeed to and be substituted for the Company with the same effect as if it had been named
as the Company herein, and thereupon the predecessor corporation shall be relieved of all obligations and covenants under this Indenture and the Securities. 

        (b)   In
case of any such consolidation, merger, sale, conveyance, transfer or other disposition, such changes in phraseology and form (but not in substance) may be made in
the Securities thereafter to be issued as may be appropriate. 

        (c)   Nothing
contained in this Article shall apply to limit or impose any requirements upon the consolidation or merger of any Person into the Company where the Company is
the survivor of such transaction, or the acquisition by the Company, by purchase or otherwise, of all or any part of the property of any other Person (whether or not affiliated with the Company). 

SECTION 10.03    Evidence of Consolidation, Etc. to Trustee.    

        The
Trustee, subject to the provisions of Section 7.01, may receive an Opinion of Counsel as conclusive evidence that any such consolidation, merger, sale, conveyance, transfer or
other disposition, and any such assumption, comply with the provisions of this Article. 

30

 
 
 

  ARTICLE XI    
    
    SATISFACTION AND DISCHARGE    
    

SECTION 11.01    Satisfaction and Discharge of Indenture.    

        If
at any time: (a) the Company shall have delivered to the Trustee for cancellation all Securities of a series theretofore authenticated (other than any Securities that have been
destroyed, lost or stolen and that have been replaced or paid as provided in Section 2.07) and Securities for whose payment money or Governmental Obligations have theretofore been deposited in
trust or segregated and held in trust by the Company (and thereupon repaid to the Company or discharged from such trust, as provided in Section 11.05); or (b) all such Securities of a
particular series not theretofore delivered to the Trustee for cancellation shall have become due and payable, or are by their terms to become due and payable within one year or are to be called for
redemption within one year under arrangements satisfactory to the Trustee for the giving of notice of redemption, and the Company shall deposit or cause to be deposited with the Trustee as trust funds
the entire amount in moneys or Governmental Obligations or a combination thereof, sufficient in the opinion of a nationally recognized firm of independent public accountants expressed in a written
certification thereof delivered to the Trustee, to pay at maturity or upon redemption all Securities of that series not theretofore delivered to the Trustee for cancellation, including principal (and
premium, if any) and interest due or to become due to such date of maturity or date fixed for redemption, as the case may be, and if the Company shall also pay or cause to be paid all other sums
payable hereunder with respect to such series by the Company then this Indenture shall thereupon cease to be of further effect with respect to such series except for the provisions of
Sections 2.03, 2.05, 2.07, 4.01, 4.02, 4.03 and 7.10, that shall survive until the date of maturity or redemption date, as the case may be, and Sections 7.06 and 11.05, that shall
survive to such date and thereafter, and the Trustee, on demand of the Company and at the cost and expense of the Company, shall execute proper instruments acknowledging satisfaction of and
discharging this Indenture with respect to such series. 

SECTION 11.02    Discharge of Obligations.    

        If
at any time all such Securities of a particular series not heretofore delivered to the Trustee for cancellation or that have not become due and payable as described in
Section 11.01 shall have been paid by the Company by depositing irrevocably with the Trustee as trust funds moneys or an amount of Governmental Obligations sufficient to pay at maturity or upon
redemption all such Securities of that series not theretofore delivered to the Trustee for cancellation, including principal (and premium, if any) and interest due or to become due to such date of
maturity or date fixed for redemption, as the case may be, and if the Company shall also pay or cause to be paid all other sums payable hereunder
by the Company with respect to such series, then after the date such moneys or Governmental Obligations, as the case may be, are deposited with the Trustee, the obligations of the Company under this
Indenture with respect to such series shall cease to be of further effect except for the provisions of Sections 2.03, 2.05, 2.07, 4.01, 4.02, 4.03, 7.06, 7.10 and 11.05 hereof that shall
survive until such Securities shall mature and be paid. Thereafter, Sections 7.06 and 11.05 shall survive. 

SECTION 11.03    Deposited Moneys to be Held in Trust.    

        All
moneys or Governmental Obligations deposited with the Trustee pursuant to Sections 11.01 or 11.02 shall be held in trust and shall be available for payment as due, either
directly or through any paying agent (including the Company acting as its own paying agent), to the holders of the particular series of Securities for the payment or redemption of which such moneys or
Governmental Obligations have been deposited with the Trustee. 

31

 

SECTION 11.04    Payment of Moneys Held by Paying Agents.    

        In
connection with the satisfaction and discharge of this Indenture all moneys or Governmental Obligations then held by any paying agent under the provisions of this Indenture shall,
upon demand of the Company, be paid to the Trustee and thereupon such paying agent shall be released from all further liability with respect to such moneys or Governmental Obligations. 

SECTION 11.05    Repayment to Company.    

        Any
moneys or Governmental Obligations deposited with any paying agent or the Trustee, or then held by the Company, in trust for payment of principal of (and premium, if any) or interest
on the Securities of a particular series that are not applied but remain unclaimed by the holders of such Securities for at least two years after the date upon which the principal of (and premium, if
any) or interest on such Securities shall have respectively become due and payable, shall be repaid to the Company or (if then held by the Company) shall be discharged from such trust; and thereupon
the paying agent and the Trustee shall be released from all further liability with respect to such moneys or Governmental Obligations, and the holder of any of the Securities entitled to receive such
payment shall thereafter, as an unsecured general creditor, look only to the Company for the payment thereof. 

 
 

  ARTICLE XII    
    
    IMMUNITY OF INCORPORATORS, STOCKHOLDERS, OFFICERS AND DIRECTORS    
    

SECTION 12.01    No Recourse.    

        No
recourse under or upon any obligation, covenant or agreement of this Indenture, or of any Security, or for any claim based thereon or otherwise in respect thereof, shall be had
against any incorporator, stockholder, officer or director, past, present or future as such, of the Company or of any predecessor or successor Person, either directly or through the Company or any
such predecessor or successor Person, whether by virtue of any constitution, statute or rule of law, or by the enforcement of any assessment or penalty or otherwise; it being expressly understood that
this Indenture and the obligations issued hereunder are solely corporate obligations, and that no such personal liability whatever shall attach to, or is or shall be incurred by, the incorporators,
stockholders, officers or directors as such, of the Company or of any predecessor or successor Person, or any of them, because of the creation of the indebtedness hereby authorized, or under or by
reason of the obligations, covenants or agreements contained in this Indenture or in any of the Securities or implied therefrom; and that any and all such personal liability of every name and nature,
either at common law or in equity or by constitution or statute, of, and any and all such rights and claims against, every such incorporator, stockholder, officer or director as such, because of the
creation of the indebtedness hereby authorized, or under or by reason of the obligations, covenants or agreements contained in this Indenture or in any of the Securities or implied therefrom, are
hereby expressly waived and released as a condition of, and as a consideration for, the execution of this Indenture and the issuance of such Securities. 

 
 

  ARTICLE XIII    
    
    MISCELLANEOUS PROVISIONS    
    

SECTION 13.01    Effect on Successors and Assigns.    

        All
the covenants, stipulations, promises and agreements in this Indenture contained by or on behalf of the Company shall bind its successors and assigns, whether so expressed or not. 

32

 

SECTION 13.02    Actions by Successor.    

        Any
act or proceeding by any provision of this Indenture authorized or required to be done or performed by any board, committee or officer of the Company shall and may be done and
performed with like force and effect by the corresponding board, committee or officer of any corporation that shall at the time be the lawful successor of the Company. 

SECTION 13.03    Notices.    

        Except
as otherwise expressly provided herein any notice or demand that by any provision of this Indenture is required or permitted to be given or served by the Trustee or by the holders
of Securities to or on the Company may be given or served by being deposited first class postage prepaid in a post-office letterbox addressed (until another address is filed in writing by
the Company with the Trustee), as follows: [            ]. Any notice, election, request or demand by the Company or any Securityholder to or upon the Trustee shall be
deemed to have been sufficiently given or made, for all purposes, if given or made in writing at the Corporate Trust Office of the Trustee. 

SECTION 13.04    Governing Law.    

        This
Indenture and each Security shall be deemed to be a contract made under the internal laws of the State of New York, and for purposes shall be construed in accordance with the laws
of said State. 

SECTION 13.05    Compliance Certificates and Opinions.    

        (a)   Upon
any application or demand by the Company to the Trustee to take any action under any of the provisions of this Indenture, the Company shall furnish to the Trustee
an Officers' Certificate stating that all conditions precedent provided for in this Indenture relating to the proposed action have been complied with and an Opinion of Counsel stating that in the
opinion of such counsel all such conditions precedent have been complied with, except that in the case of any such application or demand as to which the furnishing of such documents is specifically
required by any provision of this Indenture relating to such particular application or demand, no additional certificate or opinion need be furnished. 

        (b)   Each
certificate or opinion provided for in this Indenture and delivered to the Trustee with respect to compliance with a condition or covenant in this Indenture shall
include (1) a statement that the Person making such certificate or opinion has read such covenant or condition; (2) a brief statement as to the nature and scope of the examination or
investigation upon which the statements or opinions contained in such certificate or opinion are based; (3) a statement that, in the opinion of such Person, he has made such examination or
investigation as is necessary to enable him to express an informed opinion as to whether or not such covenant or condition has been complied with; and (4) a statement as to whether or not, in
the opinion of such Person, such condition or covenant has been complied with. 

        (c)   The
Company shall furnish to the Trustee, on [            ] of each year, a brief certificate from the principal executive officer, principal
financial officer or principal accounting officer as to his or her knowledge of such obligor's compliance with all conditions and covenants under this Indenture. For purposes of this subsection, such
compliance shall be determined without regard to any period of grace or requirement of notice provided hereunder. 

SECTION 13.06    Payments on Business Days.    

        Except
as provided pursuant to Section 2.01 pursuant to a Board Resolution, and as set forth in an Officers' Certificate, or established in one or more indentures supplemental to
this Indenture, in any case where the date of maturity of interest or principal of any Security or the date of redemption of any Security shall not be a Business Day, then payment of interest or
principal (and premium, if any) 

33

 

may
be made on the next succeeding Business Day with the same force and effect as if made on the nominal date of maturity or redemption, and no interest shall accrue for the period after such nominal
date. 

SECTION 13.07    Conflict with Trust Indenture Act.    

        If
and to the extent that any provision of this Indenture limits, qualifies or conflicts with the duties imposed by Sections 310 to 317, inclusive, of the Trust Indenture Act,
such imposed duties shall control. 

SECTION 13.08    Counterparts.    

        This
Indenture may be executed in any number of counterparts, each of which shall be an original, but such counterparts shall together constitute but one and the same instrument. 

SECTION 13.09    Separability.    

        In
case any one or more of the provisions contained in this Indenture or in the Securities of any series shall for any reason be held to be invalid, illegal or unenforceable in any
respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Indenture or of such Securities, but this Indenture and such Securities shall be construed as if
such invalid or illegal or unenforceable provision had never been contained herein or therein. 

SECTION 13.10    Assignment.    

        The
Company will have the right at all times to assign any of its rights or obligations under this Indenture to a direct or indirect wholly owned Subsidiary of the Company, provided
that, in the event of any such assignment, the Company will remain liable for all such obligations. Subject to the foregoing, the Indenture is binding upon and inures to the benefit of the parties
thereto and their respective successors and assigns. This Indenture may not otherwise be assigned by the parties thereto. 

 
 

  ARTICLE XIV    
    
    SUBORDINATION OF SECURITIES    
    

SECTION 14.01    Subordination Terms.    

        The
payment by the Company of the principal of (and premium, if any) and interest on any series of Securities issued hereunder shall be subordinated to the extent set forth in an
indenture supplemental hereto relating to such Securities. 

        IN
WITNESS WHEREOF, the parties hereto have caused this Indenture to be duly executed all as of the day and year first above written. 

 

 

					
	 	 	GOLDEN MINERALS COMPANY
	

 	
 	
By:	
 	

 
	 	 	Name:	 	

 
	 	 	Title:	 	

 
	

 	
 	
[                                ],

as Trustee
	

 	
 	
By:	
 	

 
	 	 	Name:	 	

 
	 	 	Title:	 	

 

 

 34

QuickLinks

Exhibit 4.3

CROSS-REFERENCE TABLE(1)

TABLE OF CONTENTS(2)

ARTICLE I DEFINITIONS

ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES

ARTICLE III REDEMPTION OF SECURITIES AND SINKING FUND PROVISIONS

ARTICLE IV COVENANTS

ARTICLE V SECURITYHOLDERS' LISTS AND REPORTS BY THE COMPANY AND THE TRUSTEE

ARTICLE VI REMEDIES OF THE TRUSTEE AND SECURITYHOLDERS ON EVENT OF DEFAULT

ARTICLE VII CONCERNING THE TRUSTEE

ARTICLE VIII CONCERNING THE SECURITYHOLDERS

ARTICLE IX SUPPLEMENTAL INDENTURES

ARTICLE X SUCCESSOR ENTITY

ARTICLE XI SATISFACTION AND DISCHARGE

ARTICLE XII IMMUNITY OF INCORPORATORS, STOCKHOLDERS, OFFICERS AND DIRECTORS

ARTICLE XIII MISCELLANEOUS PROVISIONS

ARTICLE XIV SUBORDINATION OF SECURITIESExhibit 10.3

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

[*] COLLABORATIVE DEVELOPMENT PROGRAM AGREEMENT

 

This [*]COLLABORATIVE DEVELOPMENT PROGRAM AGREEMENT (“Agreement”) is made as of March 15, 2010 (“Effective Date”) by and among TOSHIBA CORPORATION doing business at 1-1, Shibaura 1-chome, Minato-ku, Tokyo 105-8001, Japan (together with its Affiliates, “Toshiba”), SANDISK CORPORATION doing business at 601 McCarthy Boulevard, Milpitas, CA 95035 USA (together with its Affiliates, “SanDisk”), and INTERMOLECULAR, INC.  doing business at 2865 Zanker Road, San Jose, CA 95134 USA (together with its Affiliates, “Intermolecular”).  Toshiba, SanDisk and Intermolecular shall be referred to herein individually as a party or collectively as the parties.

 

BACKGROUND

 

WHEREAS, Toshiba, SanDisk and Intermolecular desire to enter into a collaborative development program for the further development of certain [*] (“[*]”) technology as specified in this Agreement, and based on (a) the prior work between SanDisk and Intermolecular to develop [*] from [*] through [*], (b) subsequent [*] development work conducted independently by Intermolecular from [*] through [*], (c) work provided by Toshiba and SanDisk, and (d) the collaborative efforts of the parties under this Agreement;

 

NOW THEREFORE, in consideration of the mutual promises and covenants contains herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, intending to be legally bound, the parties agree as follows:

 

1.             DEFINITIONS

 

1.1           “Affiliate” shall mean any entity controlling, controlled by or under common control with, a party to this Agreement.  For purposes of this Agreement, the direct or indirect ownership of more than fifty percent (50%) of the outstanding securities of, or voting interest in, an entity shall be deemed to constitute control.

 

1.2           “Category One IP” shall mean the patents and patent applications owned by [*] covering [*] including that listed in Exhibit A.  Exhibit A may be updated and/or amended from time to time as approved in writing by [*].

 

1.3           “Category Two IP” shall mean (a) [*] specifically designated by [*] for [*] in a Collaborative Development Program, or (b) [*] agreed upon by [*] for [*] in the CDP.

 

1.4           “Category Three IP” shall mean [*], as among the parties hereto, [*] by [*] and based [*] on [*] or other [*] or [*]; provided that any [*] activities that may result in Technology or Intellectual Property Rights in this category shall be pre-approved in writing by the parties in accordance with Section 2.1.2.

 

1.5           “Category Four IP” shall mean [*], as among the parties hereto, [*] by [*] and based [*] on [*] (or other [*] or [*] as determined and confirmed by the IP Committee)..

 

Intermolecular Confidential

 

 

1.6           “Category Five IP” shall mean [*], as among the parties hereto, [*] by [*] and based [*] on [*] (or other [*] or [*] as determined and confirmed by the IP Committee).

 

1.7           “Category Six IP” shall mean [*], as among the parties hereto, [*] by [*] and based [*] on [*] (or other [*] or [*] as determined and confirmed by the IP Committee).

 

1.8           “Category Seven IP” shall mean [*] on the one hand and [*] on the other hand, and based [*] on [*] (or other [*] or [*] as determined and confirmed by the IP Committee).

 

1.9           “Category Eight IP” shall mean [*] by [*] on the one hand and [*]on the other hand, and based [*] on [*] (or other [*] or [*] as determined and confirmed by the IP Committee)..

 

1.10         “CDP IP” shall mean collectively or separately [*] and [*].

 

1.11         “CDP Chip” shall mean [*].

 

1.12         “Non-CDP Chip” shall mean one or more Die packaged or otherwise connected together, utilizing CDP IP outside the CDP Field.

 

1.13         “Collaborative Development Program” or “CDP” shall mean the activities that are conducted by Toshiba, SanDisk and Intermolecular under this Agreement in accordance with the Development Plan.

 

1.14         “CDP Field” shall mean [*] semiconductor integrated circuit [*] chips.

 

1.15         “Confidential Information” shall mean any information disclosed by one party to any other party in connection with this Agreement, whether in electronic, written, graphic, oral, machine readable or other tangible or intangible form, that is marked or identified at the time of disclosure as “confidential” or “proprietary” or in some other manner so as to clearly indicate its confidential nature.  Except as specifically provided in Section 6 below, the terms and conditions of this Agreement shall constitute Confidential Information of each of the parties.

 

1.16         “Development Plan” shall mean the written plan describing the activities to be conducted by each party and the target specifications to be met for deliverables during the CDP that is attached hereto as Exhibit B.

 

1.17         “Die” shall mean a semiconductor integrated circuit in die form.

 

1.18         “Foreground IP” shall mean the [*] and [*] developed under the CDP as [*] and [*]; provided however, that Foreground IP excludes HPC Technology, HPC Derivatives, Non [*] Foreground IP and [*] Design IP.  For purposes of categorization, conventional inventorship rules apply (except for [*] and [*], which shall be subject to Sections 3.2.2 and 3.2.3).

 

1.19         “FTE” shall mean an Intermolecular employee assigned to the CDP, based on approximately one hundred sixty-six (166) hours of professional services performed by one

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

2

 

qualified person during a one month period, or the same number of hours in aggregate performed by two or more qualified persons during a one month period

 

1.20         “HPC Derivatives” shall mean all improvements, derivatives and modifications to any HPC Technology, developed by any party during the course of the CDP based on access to or use of Intermolecular-provided tools, software or information enabling the use of HPC Technology.

 

1.21         “HPC Technology” shall mean all Technology, including the Workflow Infrastructure, and without reference to any Toshiba or SanDisk Confidential Information or any Toshiba and SanDisk Contributed Background IP, used for the simultaneous, parallel, or rapid serial:  (i) design, (ii) synthesis, (iii) processing, (iv) process sequencing, (v) process integration, (vi) device integration, (vii) analysis, or (viii) characterization of more than two (2) compounds, compositions, mixtures, processes, or synthesis conditions, or the structures derived from such on a single wafer.  It is understood that any such test vehicles include physical and/or electrical characterization devices such as test structures or chips used in the design, process development, manufacturing process qualification, and manufacturing process control of integrated circuit devices to the extent that such devices are used in simultaneous, parallel, and rapid serial processing.  Nothing in this Agreement shall limit the use of test wafers used in research and development using nominally uniform processing.  It is also understood that HPC Technology does not include the use of commercially available equipment in commercial manufacturing for nominally uniform processing of one or more identical integrated circuits on a single substrate, or the use of such equipment in research and development for nominally uniform processing of one or more integrated circuits on a single substrate.  Toshiba and/or SanDisk existing or practiced technology or methodologies, and/or publicly known tools and methods, are excluded from the definition of HPC Technology.  HPC Technology excludes [*] Design IP.

 

1.22         “IM [*] Developed Technology” mean the [*] Technology developed independently by Intermolecular subsequent to [*] and prior to [*] that is attached hereto as Exhibit C.  Such exhibit shall not restrict or modify Toshiba’s and SanDisk’s rights with respect to their respective independent ownership rights of intellectual property rights and technology independently developed by them respectively.

 

1.23         “Informatics Software” shall mean the Intermolecular-proprietary software platform enabling the operation of Dry and Wet Workflows and the gathering and sharing of CDP information through a web-based interface.

 

1.24         “Initial Term” means the two (2) year period from the Effective Date.

 

1.25         “Intellectual Property Rights” shall mean all U.S.  and foreign rights in and to all (i) patents and patent applications, including all divisions, substitutions, continuations, continuation-in-part applications, and reissues, re-examinations and extensions thereof, (ii) copyrights and other rights in works of authorship, (iii) unpatented information, trade secrets, know-how, invention disclosures, engineering notebooks, confidential information, data, or materials, (iv) mask work rights, and (v) any other intellectual or other proprietary rights of any kind now known or hereafter recognized in any jurisdiction.

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

3

 

1.26         “Intermolecular Background IP” shall mean (i) the Original CDP Developed Technology; (ii) the IM [*] Developed Technology; (iii) all Intellectual Property Rights in subsections (i) and (ii); and (iv) Technology and Intellectual Property Rights created, conceived or developed by or for Intermolecular outside of or independently from the Collaborative Development Program, provided that each of (i), (ii), (iii) and (iv) are to the extent unanimously preapproved in writing by the IP Committee for submission to the CDP.  If Toshiba and/or SanDisk do not approve for submission any Technology or Intellectual Property Rights proposed for inclusion by Intermolecular under categories (i), (ii) and (iii) above, such Technology or Intellectual Property Rights shall not be deemed licensed under Section 4 below and shall be excluded from the covenant set forth in Section [*] and, if a patent or patent application, shall not be subject to the provisions of Section [*].  Intermolecular Background IP excludes HPC Technology.

 

1.27         “Intermolecular Customer” shall mean a Third Party that engages in a development program with Intermolecular where Intermolecular performs development services in the field of semiconductors, including but not limited to semiconductor materials, semiconductor device technology, and/or semiconductor manufacturing equipment, process and characterization technology on behalf of and/or in collaboration with such Third Party, in a manner similar to the development program described in this Agreement.

 

1.28         “Licensed IP” shall mean [*] and [*].

 

1.29         “[*]” shall mean [*].

 

1.30         “[*] Foreground IP” shall mean the materials, process, structure and other Technology included in [*] developed pursuant to the CDP, but not [*] Design IP, and all Intellectual Property Rights therein or thereto.

 

1.31         “Non [*] Foreground IP” shall mean the materials, process, structure and other Technology included in [*] that are not [*] based and all Intellectual Property Rights therein or thereto.  The parties agree that no such Non [*] Foreground IP are intended to be developed pursuant to the CDP.

 

1.32         “[*] Technology” means [*] derived from CDP IP, that [*]  per physical [*]; provided that such [*] Technology-based devices (i) provide similar functional capabilities as the [*] -based [*] technology produced by SanDisk and Toshiba as of the Effective Date and (ii) are used for [*]  per physical [*] at the time of shipment by SanDisk or Toshiba.

 

1.33         “New [*] Concepts” shall mean Intellectual Property Rights and Technology that is contributed by Toshiba and/or SanDisk that the parties agree to develop pursuant to the CDP that does not contain, and is not a derivative, modification, improvement and enhancement of, the Intermolecular Background IP or the Toshiba and SanDisk Contributed Background IP.

 

1.34         “Original CDP Developed Technology” shall mean the [*] and [*] Documentation as agreed upon by SanDisk and Intermolecular on [*], and attached hereto as Exhibit D.  Such exhibit shall not restrict or modify Toshiba’s and SanDisk’s rights with respect

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

4

 

to their respective independent ownership rights of intellectual property rights and technology independently developed by them respectively.

 

1.35         “CDP Product” shall mean a product containing one or more CDP Chips manufactured and offered for sale by or for Toshiba or SanDisk.  CDP Products may be delivered to customers in any form including wafer form, packaged and unpackaged [*] Die, and finished goods.

 

1.36         “Non-CDP Product” shall mean a product containing one or more Non-CDP Chips manufactured and offered for sale by or for Toshiba or SanDisk.  Non-CDP Products may be delivered to customers in any form including wafer form, packaged and unpackaged Die, and finished goods.

 

1.37         “[*]” shall mean a [*], including the [*], and [*] if any are needed, and the [*].

 

1.38         “[*] Design IP” shall mean any of the following arising or resulting from the Development Program, including any Intellectual Property Rights or Technology therein:  (i) [*] Technology device designs; (ii) [*] Technology circuit designs; (iii) [*] Technology chip architectures; (iv) [*] process integration technology; (v) [*] steering elements (e.g.  [*]); (vi) device and chip operation and testing; and (vii) any and all [*].

 

1.39         [intentionally left blank]

 

1.40         “Technology” shall mean tangible embodiments of Intellectual Property Rights, whether in electronic, written or other media, including techniques, methodologies, processes, designs, test vehicles, synthetic procedures, systems, or any of combinations of the foregoing, as well as any directories, source code, object code, firmware, technical documentation, specifications, requirements, designs, design drawings, design files, and quality control data, schemes, schematics, diagrams, bills of material, netlists, build instructions, test reports, mask works, data sheets, reference designs, net lists, RTL, algorithms, formulae, photomasks, databases, lab notebooks, manuscripts, records, prototypes, samples, studies, and invention disclosure forms.

 

1.41         “Term” shall mean the Initial Term and any renewals thereof pursuant to Section 11.1.

 

1.42         “Toshiba and SanDisk Contributed Background IP” shall mean Intellectual Property Rights and Technology related [*] owned by Toshiba and/or SanDisk that is provided by Toshiba and/or SanDisk to Intermolecular at any time under the CDP.  All such Technology or Intellectual Property Rights shall be specified in the Development Plan or specified by Toshiba or SanDisk during the CDP under Section 2.2.

 

1.43         “Third Party” shall mean any person or entity other than Toshiba, SanDisk and Intermolecular, and any permitted assigns.

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

5

 

1.44         “Third Party Licensee” shall mean an entity other than Toshiba, any Toshiba Affiliate, SanDisk or any SanDisk Affiliate to whom a license to all or a portion of the Licensed IP or a license to any Joint IP, as applicable, is granted under Section 5.10.

 

1.45         “Third Party CDP Product” shall mean a product (which is neither a CDP Product nor a Non-CDP Product) containing one or more CDP Chips manufactured and offered for sale by or for a Third Party Licensee to a customer other than SanDisk and/or Toshiba. Third Party CDP Products may be delivered to customers in any form including [*].

 

1.46         “Third Party Non-CDP Product” shall mean a product (which is neither a CDP Product nor a Non-CDP Product) containing one or more Non-CDP Chips manufactured and offered for sale by or for a Third Party Licensee to a customer other than SanDisk and/or Toshiba.  [*].

 

1.47         “Workflow Infrastructure” shall mean the HPC processing tools implemented by Intermolecular ([*]), characterization infrastructure (including physical metrology and electrical test equipment), and the Informatics Software designed or optimized by Intermolecular and installed at Intermolecular’s facilities for use by the parties to perform the development activities specified in the Development Plan, as more fully described in Exhibit E attached hereto.

 

2.             COLLABORATIVE DEVELOPMENT PROGRAM

 

2.1           CDP.

 

2.1.1        Pre-CDP Workshop.  Immediately after the Effective Date of this Agreement, Intermolecular, Toshiba and SanDisk shall set up a technical workshop in a manner and schedule to be agreed by the parties for informing Toshiba and SanDisk of the Technology which are described in Exhibits C and D attached hereto.  Exhibits C and D are to be provided to Toshiba and SanDisk on the Effective Date.  Promptly but no later than [*] days following such technical workshop, the Operating Committee will determine which items will be listed on Exhibit H (which shall be the Intermolecular Background IP for the CDP).  The parties confirm and agree that items not initially included in Exhibit H (but listed in Exhibit C or D) may at any time prior to the licensing election described in Section 4.2.2, upon Toshiba’s and SanDisk’s approval, be added to and included in Exhibit H.  In addition, at any time prior to the licensing election described in Section 4.2.2, Exhibit H may be updated in accordance with Section 1.26(iv).

 

2.1.2        Development Plan.  Subject to the terms and conditions set forth herein, Toshiba, SanDisk and Intermolecular will conduct this Collaborative Development Program in accordance with the Development Plan within the scope of the CDP Field.  The Development Plan shall contain the activities to be conducted by each party, the information sharing processes to be used during the CDP, the deliverables to be produced in the CDP, the target specifications to be met for such deliverables and metrics to be met by each party.  For the avoidance of doubt, no Toshiba and SanDisk Contributed Background IP shall be considered part of the CDP unless expressly identified as “Toshiba and SanDisk Contributed Background IP” in the Development Plan, or otherwise pre-approved by Toshiba and SanDisk in writing.

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

6

 

2.1.3        Intermolecular.  Intermolecular agrees to provide [*] Intermolecular FTEs and use of its Workflow Infrastructure for Intermolecular to perform the specified activities at Intermolecular facilities under the Development Plan.  The fees to support these resources are set forth in Section 5.  In return for the services to be performed by Intermolecular and for the Workflow Infrastructure provided by Intermolecular for use in the CDP, Toshiba and SanDisk agree to pay the fees as set forth in Sections 5.1 and 5.2 in accordance with the terms of this Agreement.

 

2.1.4        Change Orders.  Any of the parties may propose to the other parties from time to time to change the Development Plan, provided the change is within the CDP Field.  As part of such change process, Intermolecular, Toshiba and/or SanDisk may propose the introduction of new [*] concepts and materials that are not part of the initial Development Plan, including without limitation New [*] Concepts.  Any such party suggesting a change shall provide a written proposal to the other parties detailing the proposed change and the anticipated effect on scheduling and cost.  The parties agree to promptly discuss and decide upon any proposed changes to the Development Plan, including introduction of New [*] Concepts.  All changes to the Development Plan, including new forms of experiments, must be approved by Toshiba and SanDisk in writing; provided that Toshiba and SanDisk agree to consider Intermolecular’s requested changes in good faith.  Any such decision to amend the Development Plan shall include any changes to pricing, cost allocations, licensing terms, activities, responsibilities, development schedule or other provisions related to implementation of any such change.  If the proposed change by SanDisk and/or Toshiba requires additional capital expenditures or substantial additional resources by Intermolecular beyond the then-current CDP for the then-current Development Plan, the amended Development Plan will be subject to Intermolecular’s approval.  If Toshiba and SanDisk do not agree in writing to a change to the Development Plan, the Development Plan in existence prior to the proposed change shall continue in full force and effect.

 

2.2           Committees.

 

2.2.1        Operating Committee.  The parties will establish an operating committee (the “Operating Committee”) to oversee the performance of the Collaborative Development Program, monitor progress of the CDP, resolve any disputes or disagreements between the Project Managers (as defined below) and escalate any remaining disputes, as necessary, and ensure open communications among the parties.  The Operating Committee will initially be comprised of at least one (1) representative from each party, including the Project Manager of each party, or such other equal number of representatives as the parties may from time to time agree in writing, with each party’s representatives selected by that party, provided that the Project Manager of such party remains on the Operating Committee.  Any party may replace any of its Operating Committee members at any time, upon written notice to the other party.  The Operating Committee will meet on a quarterly basis or as otherwise agreed by the parties, at locations or in a manner agreed by the parties.  All decisions of the Operating Committee shall be made by SanDisk and Toshiba, subject to Section 2.1.4.

 

2.2.2        IP Committee.  The parties will also establish a committee (the “IP Committee”), reporting to the Operating Committee, that will be responsible for reviewing invention disclosures, patent filing decisions and Intellectual Property Rights ownership

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

7

 

decisions resulting from activities under the CDP, including without limitation, determination of the Intellectual Property Rights, if any, in all Technology developed in the CDP.  The IP Committee will meet on at least a calendar quarterly basis or as otherwise agreed to by the parties.  The IP Committee shall consist of two (2) members from each party, one from its technical employee and the other one from its patent attorney, agent or IP staff member.  All decisions of the IP Committee must be made by unanimous vote of the parties, with each party having a single vote.  If there is disagreement among the parties regarding the existence or ownership of Intellectual Property Rights or Technology, the parties will escalate the dispute as appropriate within their respective organizations as promptly as possible for resolution; provided, however, that no party shall publicly disclose or otherwise publish any information, or otherwise jeopardize the opportunity to file a patent application, regarding an invention claimed by another party hereunder resulting from or relating to CDP activities during any period where the ownership of such claimed invention has not yet been determined.  Each party agrees that it will not unreasonably delay or prolong resolution of any ownership, inventorship or other claim regarding the Technology or Intellectual Property Rights.

 

2.3           Access to Information.  The parties acknowledge and agree that each party shall provide the other parties timely and sufficient access to information reasonably necessary to carry out their obligations under all phases of the Collaborative Development Program.  Further, Intermolecular agrees that it shall immediately provide both Toshiba and SanDisk with any information made available to it during the course of its activities in the CDP as set forth in Section 2.1.2.  The parties agree to comply with all information sharing processes set forth in the Development Plan.

 

2.4           Project Managers.  Each party hereby appoints the initial principal point of contact set forth in the Development Plan to be its project manager for the CDP, who shall coordinate and act as a liaison with the other parties with respect to the Development Plan (each a “Project Manager”).  A party may from time to time change its Project Manager upon written notice to the other parties.

 

2.5           Development Records.  Each party agrees to maintain reasonable records of the activities it performs under the Development Plan, and cause such records to be maintained in sufficient detail and in good scientific manner as will properly reflect all material work done and results achieved, including information sufficient to establish dates of conception and reduction to practice of inventions.

 

3.             IP OWNERSHIP

 

3.1           Prior and Independent Technology.  Each party shall retain all right, title and interest in and to all materials, Technology, concepts, know-how, inventions, discoveries, works of authorship, and all related Intellectual Property Rights created, conceived or developed by or for that party prior to the Effective Date.  For Toshiba and SanDisk, this includes all Toshiba and SanDisk Contributed Background IP, and for Intermolecular this includes all Intermolecular Background IP, including [*].  In addition, each party shall retain all right, title and interest in and to all materials, Technology, concepts, know-how, inventions, discoveries, works of authorship, and all related Intellectual Property Rights created, conceived or developed by or for that party outside of or independently from the Collaborative Development Program without use or incorporation of any Confidential Information,

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

8

 

Technology or Intellectual Property Rights of or received from any other party pursuant to the Agreement.

 

3.2           Foreground IP.

 

3.2.1        Intermolecular Sole Ownership of Foreground IP.  Intermolecular shall be the sole owner of [*].

 

3.2.2        Toshiba and SanDisk Sole Ownership of Foreground IP.  Toshiba and SanDisk shall be the sole owners of (a) all [*] and [*], and (b) all Technology and Intellectual Property Rights (other than patents and patent applications) in and to [*].  The actual division of ownership of such Technology and Intellectual Property Rights shall be determined between Toshiba and SanDisk based on separate agreements between Toshiba and SanDisk.

 

3.2.3        Joint Ownership Among the Parties.  Intermolecular, Toshiba and SanDisk shall jointly own (a) all Technology and Intellectual Property Rights in [*] and (b) any patents and patent applications resulting solely from inventions under [*] (collectively, all of the foregoing constitute “Joint IP”).  Except as expressly provided elsewhere in this Agreement, each party has the right to use, fully exploit, disclose or otherwise dispose of such Joint IP for any purpose without consent of or accounting to the other party.

 

3.2.4        [*] Design IP and [*]Foreground IP.  Notwithstanding anything to the contrary in this Agreement, as among the parties and regardless of creator, Toshiba and SanDisk based on existing agreements between Toshiba and SanDisk, shall own all right, title and interest, including Intellectual Property Rights, in and to the [*] Design IP and Non [*] Foreground IP and any derivatives, modifications, improvements to and enhancements thereto and any Intellectual Property Rights in any of the foregoing.  Intermolecular hereby assigns, and agrees to assign to Toshiba and SanDisk, as applicable, in the future when they are first fixed in a tangible medium or reduced to practice, as applicable, all Intellectual Property Rights in and to any [*] Design IP and [*] Foreground IP that Intermolecular may obtain as a result of Intermolecular’s activities under the CDP.

 

3.3           HPC Technology and Derivatives.  Notwithstanding any other provision to the contrary, as among the parties and regardless of creator, Intermolecular shall own all right, title and interest, including Intellectual Property Rights, in and to HPC Technology and any HPC Derivatives, and all Intellectual Property Rights in any of the foregoing. [*].

 

3.4           Cooperation.  Each party agrees to execute all papers, including patent applications and invention assignments, and otherwise agrees to assist the other party, as reasonably required and at the other party’s reasonable expense, to perfect in the applicable party the rights, title and other interests in their respective inventions which this Agreement designates such party to own.  Without limiting the foregoing, the parties agree to use reasonable efforts to keep the other parties informed as to the status of patent matters with respect to any Joint IP, [*] and [*].

 

3.5           Patent Prosecution.  Intermolecular shall have the first right to prepare, file, prosecute and maintain, at its own expense and in consultation with the other parties, any patent applications claiming inventions in the Foreground IP owned solely by Intermolecular.  The IP Committee will determine on a case-by-case basis which party shall be responsible for preparing,

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

9

 

filing, prosecuting and maintaining, in consultation with the other parties, any patent applications claiming inventions in the Foreground IP that constitute Joint IP, and the cost allocation will be determined at such time by the parties.  In the event that Intermolecular makes a decision (and in such event Intermolecular shall promptly inform the applicable parties) that Intermolecular will not file, prosecute or maintain any such patent or patent application in a Joint IP, [*] or [*]  invention, or undertake such other activities described above, then the applicable party that jointly owns (or desires to further prosecute) such invention shall have the right to assume such activities at its own expense but without affecting the ownership and license provisions set forth in Sections 3 and 4 hereof.  Nothing in this Agreement shall limit or restrict a party’s rights to file or prosecute any solely-owned invention unless that party has agreed to assign such invention and Intellectual Property Rights therein to another party pursuant to the terms and conditions of this Agreement.

 

3.6           Enforcement.

 

3.6.1        Joint IP.  With prior consultation to Toshiba and SanDisk, Intermolecular shall have the initial right, but not the obligation, to take reasonable legal action to enforce Intellectual Property Rights in any Joint IP against commercially material infringements.  If Intermolecular does not take action sufficient to halt such infringement within [*] following receipt of notice of such infringement, then either Toshiba or SanDisk, as applicable, shall have the right, but not the obligation, to take action to stop such infringement at its sole expense.  Notwithstanding the foregoing, if Toshiba and SanDisk elect to receive [*] license under Section 4.2 below, then either Toshiba or SanDisk, as applicable based on inventorship or upon written agreement between Toshiba and SanDisk, shall have the initial right, but not the obligation, to take reasonable legal action to enforce any Intellectual Property Rights in Joint IP against commercially material infringements.

 

3.6.2        [*] Licensed Intellectual Property Rights. During the Initial Term, and after the Initial Term if Toshiba and SanDisk both exercise their option to take [*] license in accordance with Section 4.2, Toshiba and/or SanDisk shall have the right, but not the obligation, to take reasonable legal action to enforce the Licensed IP without consultation with Intermolecular.  If one or both of such parties decides to take legal action to enforce such Licensed IP against a Third Party, then the enforcing party may request that Intermolecular participate (and Intermolecular shall participate) in such action as may be reasonably necessary to enforce such rights; provided, however, that Intermolecular’s participation shall be conditioned upon the enforcing party bearing Intermolecular’s reasonable costs to participate in such enforcement action and indemnifying Intermolecular against any liabilities, losses, damages, costs and expenses, including reasonable attorneys’ fees, incurred by Intermolecular as a result of participating in any such action.

 

3.6.3        Cooperation; Costs. Each party agrees to render such reasonable assistance in connection with enforcement activities described in this Section 3.6 as the enforcing party may request.  Costs of maintaining any such action shall be paid by and shall be the responsibility of the party bringing the action.

 

3.6.4        Recoveries. Subject to the payment obligations set forth in Section 5, any damages or settlement recovered from any action under this Section 3.6 shall belong to the party bringing the action.

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

10

 

4.             LICENSES

 

4.1           Collaboration Licenses.

 

4.1.1        Intermolecular License to Toshiba and SanDisk. Subject to the terms and conditions of this Agreement, including payment of applicable license fees, Intermolecular grants to Toshiba and SanDisk for the Term [*] non-transferable [*] license under and to the Intermolecular Background IP (including the [*]), HPC Technology, HPC Derivatives and any other Technology and/or Intellectual Property Rights Intermolecular contributes to the development efforts under the CDP (including the [*]), to engage in the CDP and perform the activities set forth in the Development Plan.  Notwithstanding the foregoing [*] license, Intermolecular reserves the right to use the Technology and Intellectual Property Rights licensed in this Section 4.1.1 solely for the purpose of Intermolecular performing its duties under the CDP, and not for the benefit of any Third Party.

 

4.1.2        Toshiba and/or SanDisk License to Intermolecular. Subject to the terms and conditions of this Agreement, Toshiba and SanDisk each grant to Intermolecular for the Term [*] non-transferable [*] license under and to the Toshiba and SanDisk Contributed Background IP and to and any other Technology and/or Intellectual Property Rights either party contributes to the development efforts under the CDP, solely to engage in the CDP and perform the activities set forth in the Development Plan, and not for the benefit of any Third Party.

 

4.2           Technology License.

 

4.2.1        Technology License.

 

A.    Within CDP Field. Subject to the terms and conditions of this Agreement, including but not limited to Section 4.2.2 and Section 6 below, Intermolecular grants Toshiba and SanDisk a worldwide, [*] (except as to Intermolecular for purposes of performing its activities related to this Agreement), [*], non-transferable license within the CDP Field, without right of sublicense, under and to Intermolecular Background IP, the Licensed IP and any other Technology and/or Intellectual Property Rights Intermolecular contributes to the development efforts under the CDP to (i) use and modify such Technology and/or applicable Intellectual Property Rights including know-how; and (ii) use, make, have made, import, offer to sell, sell, lease, copy, modify, distribute, and otherwise dispose of, and exploit, the CDP Products.

 

B.    Outside CDP Field. In addition to Section 4.2.1(A), and subject to the terms and conditions of this Agreement, including but not limited to Section 4.2.2 and Section 6 below, Toshiba’s and/or SanDisk’s license shall be extended at its respective discretion to activities outside the CDP Field, without right of sublicense, under this Section 4.2.1(B) for Non-CDP Products in fields to be agreed upon by

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

11

 

Intermolecular and the applicable party in advance as set forth in this Section 4.2.1(B).  On a case-by-case basis, Toshiba and SanDisk shall (i) notify Intermolecular in writing in advance for each instance where Toshiba or SanDisk, as applicable, desires to extend the use of the Technology licensed under Section 4.2.1(A) into a new field of use on [*] basis and the license under Section 4.2.1(A) will be extended to that field and apply to the specified Non-CDP Products unless Intermolecular notifies Toshiba or SanDisk promptly in writing that such proposed Non-CDP Product or field of use is subject to a pre-existing obligation of Intermolecular to grant [*] license to such Non-CDP Product or field to a Third Party; and (ii) obtain Intermolecular’s prior written approval to extend the use of the Technology licensed under Section 4.2.1(A) into a new field of use or new Non-CDP Product on [*] basis, as applicable.  If extended, Toshiba and SanDisk shall be granted a worldwide, [*] non-transferable license under and to the applicable Intermolecular Background IP and to the Licensed IP Intermolecular contributes to the development efforts under the CDP to (i) use and modify such Technology; and (ii) use, make, have made, import, offer to sell, sell, lease, copy, modify, distribute, and otherwise dispose of, and exploit, the specified Non-CDP Products outside the CDP Field in the applicable field; provided however, that Non-CDP Product Fee [*] and [*] under this Section 4.2.1(B) shall be [*] percent ([*]%) of the [*] and [*] applicable to Section 4.2.1(A), and the fees payable to Intermolecular for Third Party CDP Products and Third Party Non-CDP Products for such extensions shall be subject to Section 5.10 below.  Such [*], and [*] applicable to this Section 4.2.1(B) shall be separately accounted from [*], and [*]  applicable within the CDP Field.

 

4.2.2        License Election.  Each of Toshiba and SanDisk shall have the right to elect during or within [*] days after [*] to either:

 

A.    receive [*] license under Section 4.2.1 after the Term to (i) the Intermolecular Background IP, and (ii) the Licensed IP, and (iii) any other Technology and/or Intellectual Property Rights Intermolecular contributes to the development efforts under the CDP in accordance with Section 1.26(iv) above.  If Toshiba and/or SanDisk make an election under this subsection (a), then the license in Section 4.2.1 shall convert to [*] license at the end of the Term;

 

B.    terminate the license to the Licensed IP, provided that if such election is made, (a) SanDisk shall

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

12

 

continue to have a license to the Original CDP Developed Technology under all the terms and conditions (including without limitation the economic terms) of the Collaborative Development and License Agreement by and between Intermolecular, Inc.  and SanDisk Corporation effective as of August 25, 2006 as amended (the “2006 Agreement”), and (b) Toshiba and SanDisk shall continue to have the right to license Joint IP to Third Party Licensees;

 

C.    retain [*] license under Section 4.2.1 in the CDP Field after the Term to (i) Intermolecular Background IP, and (ii) the Licensed IP and (iii) any other Technology and/or Intellectual Property Rights Intermolecular contributes to the development efforts under the CDP in accordance with Section 1.26(iv) above, in which case Intermolecular shall not exercise any ownership rights in any Joint IP in the CDP Field (including not granting licenses to any third parties under such Joint IP).  In the event only Toshiba or SanDisk but not both, make an election under this subsection (c), the party electing to retain the [*] license shall ensure that Intermolecular is properly compensated under Intermolecular’s rights as [*] licensor under this Agreement, to the same extent as if both Toshiba and SanDisk had elected to retain the [*] license and the party not electing to retain the exclusive license will retain [*] license; or

 

D.            retain [*] license under Section 4.2.1 only to (i) the Intermolecular Background IP (other than the [*]) and (ii) the [*] and (iii) any other Technology and/or Intellectual Property Rights Intermolecular contributes to the development efforts under the CDP in accordance with Section 1.26(iv) above, and to have Intermolecular not exercise its ownership rights in Joint IP (including not granting licenses to any third parties under such Joint IP), but not take [*]  license under or to [*].  In the event Toshiba and SanDisk make an election under this subsection (D), then upon such election, Toshiba and SanDisk will retain [*] license to all Intellectual Property Rights licensed under Section 4.2.1 for which Toshiba and SanDisk did not elect to retain [*] license.

 

4.2.3        Option.  Notwithstanding anything to the contrary in this Agreement, after Toshiba and/or SanDisk has elected a license pursuant to Section 4.2.2 and has identified whether such license is [*] or [*], Toshiba and SanDisk shall each have the one time option at any point after the Term, to [*] such license as applicable, from [*] to [*], or from [*] to [*], as long as (1) Toshiba and/or SanDisk continues to make any payments due and payable to Intermolecular under this Agreement, (2) the applicable [*] and [*] under Section 5.4 below associated with the license so elected by Toshiba and/or SanDisk, shall replace the [*] and [*] previously applicable prior to such election (for example, if SanDisk and/or Toshiba elected to [*] to [*], the [*] for [*] SanDisk and Toshiba shall be [*] from [*], as applicable, to [*] and no further [*] will apply); provided, that if SanDisk or Toshiba elect to [*] the [*] from [*] to [*],

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

13

 

CDP Product Fees and Non-CDP Product Fees already due or paid to Intermolecular prior to the election to convert to [*] are non-refundable, even if such CDP Product Fees or Non-CDP Product Fees exceed the [*] or [*], as applicable; and (3) if an election is made by Toshiba and/or SanDisk from [*] to [*], the resulting [*] license shall be made subject to any licenses made by Intermolecular to a Third Party prior to such election.

 

4.2.4        Third Party Licensees.  Licenses to Third Party Licensees shall be governed in accordance with Section 5.10 below.

 

4.2.5        No Limitation to SanDisk/Toshiba Technology.  Nothing in this Section 4 shall limit in any manner the rights of Toshiba or SanDisk to use, transfer and otherwise exploit [*] patents and patent applications, [*],[*] Design IP, Non [*] Foreground IP and any other Intellectual Property Rights and Technology of either Toshiba or SanDisk, as applicable; provided, however, that this Section 4.2.5 shall not be deemed a license, either express or implied, to any Intermolecular Technology or Intellectual Property Rights.

 

4.2.6        [*] License.  If Toshiba and SanDisk either (i) do not elect [*] license under Section 4.2.2 or (ii) elect to terminate the license in accordance with Section 4.2.2(B), Toshiba and SanDisk each acknowledge that Intermolecular may exercise its rights in any Joint IP, subject to payment of a mutually-agreed pass-through payment to Toshiba and SanDisk.

 

4.2.7        No Sublicense Right of [*] to [*].  [*]not granted any sublicensing rights with respect to [*] under this Agreement.

 

4.3           Reservation of Rights.  Except for the rights expressly granted by each party to the other under this Agreement, all other rights are reserved.

 

4.4           Other Engagements.  The parties each agree that nothing in this Agreement, except for the exclusivity provisions of this Section 4, restrict any party from engaging in development or commercialization projects with Third Parties.

 

4.5           Favorable per-CDP Product Terms.  If [*] grants a license to the Licensed IP to any Third Party for use in competing [*] applications and/or products with any program fees (including but not limited to fees associated with the CDP), product fees and/or per-chip royalties or their equivalent and/or other licensing fees and/or [*] on terms that are more favorable to the licensee than the terms contained in this Agreement, [*] shall immediately provide written notice to [*] setting forth the details of such more favorable terms, and shall offer to [*] to incorporate those terms in this Agreement on a going-forward basis into this Agreement effective as of such notification date.  [*].

 

4.6           Bankruptcy.  Intermolecular acknowledges that the Intermolecular Intellectual Property Rights licensed pursuant to this Agreement constitute “intellectual property” to the extent provided under the United States Bankruptcy Code (the “Bankruptcy Code”) or similar foreign laws, and it is the express intent of the parties to this Agreement that if Intermolecular is subject to a proceeding under the Bankruptcy Code or similar foreign laws and rejects this Agreement or any portion thereof, then SanDisk and Toshiba may elect to retain their respective rights to such Intermolecular Intellectual Property Rights under this Agreement to the maximum extent provided under Section 365(n) and other provisions of the Bankruptcy Code, other

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

14

 

applicable U.S. and state laws and applicable foreign laws.  If Toshiba and/or SanDisk seek to register the licenses to be granted by Intermolecular under this Agreement with the Japan Patent Office, any foreign patent offices, governing agencies or authorities, Intermolecular shall cooperate with the party requesting such registration.  Such cooperation expenses shall be borne (a) by Intermolecular for any such U.S.  or Japanese registration, and (b) by Toshiba and/or SanDisk for any other such registrations.

 

5.             SUBSCRIPTION, SERVICE, LICENSE AND PRODUCT FEES

 

5.1           Service Fees.  Toshiba and SanDisk each will fund for the CDP under the Development Plan and agrees to pay Intermolecular [*] US Dollars (US$[*]) for a cumulative total of [*] US Dollars (US$[*]) for Intermolecular’s performance of the services described in the Development Plan.  Subject to Section 5.7, these amounts shall be paid by each of Toshiba and SanDisk in equal monthly payments of [*]  US Dollars (US$[*]) over the Initial Term starting upon the Effective Date.  Intermolecular shall ensure that these service fees fully cover and support the Development Plan to build an infrastructure and workflow as set forth in Exhibit E.  These service fees also include any expenses that Intermolecular incurs for a transfer of the process or technology to the development and production facilities of Toshiba and SanDisk (including associated travel and lodging costs except for extended stays in Japan over [*]  days).  In addition to the amounts set forth above, Toshiba and SanDisk agree to provide or pay, each on an equal basis with the other, for all of the following that is pre-approved by SanDisk and Toshiba in writing:  out-of-pocket expenses for consumables (e.g., wafers and mask sets), outsourced metrology (to the extent not part of the regular work flow), analytical services and characterization not supported internally by Intermolecular, and other mutually agreed out-of-pocket costs to support the CDP.  For costs associated with targets and materials required during the duration of the CDP, Intermolecular shall make commercially reasonable efforts to procure and/or obtain such targets and/or materials at costs which are as inexpensive as possible and shall bear [*] as part of the service fees under this Section 5.1, the first US$[*] per [*] (the first [*] being pro-rated), of such costs when verified.  Upon such verification, SanDisk and Toshiba shall bear in equal amounts, such costs arising during the [*] in question in excess of such US$[*] threshold.

 

5.2           Workflow Infrastructure Subscription Fee.  Toshiba and SanDisk will fund for the CDP under the Development Plan and each agrees to pay Intermolecular [*] US Dollars (US$[*]) for a cumulative total of [*] US Dollars (US$[*]) for all access necessary for performing under the Development Plan to and Intermolecular’s use of the Workflow Infrastructure as part of the Collaborative Development Program as set forth below.  Subject to Section 5.7, these amounts shall be paid by each of Toshiba and SanDisk in equal [*] payments of [*] US Dollars (US$[*]) over the Initial Term starting upon the Effective Date.  These subscription fees also include all costs associated with or related to Workflow Infrastructure, including but not limited to any rent, storage, utility and like costs relating to the Workflow Infrastructure that Intermolecular incurs.  Notwithstanding anything to the contrary in this Agreement in the event that the CDP is renewed after the Initial Term and/or Toshiba and SanDisk maintain [*] license to Licensed IP under Section 4.2.1, SanDisk and Toshiba will have [*] for use of the [*] after the Initial Term if Toshiba and SanDisk have extended the CDP, or entered into a new collaborative development program with Intermolecular.  During the Term and subject to the full, timely payment of the above subscription fee by both Toshiba and

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

15

 

SanDisk, Intermolecular will provide (i) access at all times to the Workflow Infrastructure to perform the activities contemplated by the Development Plan, (ii) [*], non-transferable license without right of sublicense for Toshiba and SanDisk to use at all times the HPC Technology and HPC Derivatives as incorporated in the Workflow Infrastructure in Intermolecular’s to carry out any of their activities pursuant to the Development Plan, and (iii) [*], non-transferable license, without right of sublicense, to access and use the Informatics Software via an Intermolecular-established secure portal solely for the purposes of performing activities pursuant to the Development Plan.  Intermolecular covenants that Intermolecular will not use the [*] dedicated specifically to the CDP for any purpose outside of the Development Plan and it will not allow any Third Party to use the dedicated [*] during the term of this Agreement without Toshiba and SanDisk’s prior written consent.  If Toshiba and SanDisk provide such consent for use during the Initial Term, the fees set forth in this Section 5.2 shall be reduced on a pro rata basis according to the number of days (or part thereof) that such Third Party uses the [*].  This license does not confer any ownership rights in the Workflow Infrastructure and Tempus AP-30.

 

5.3           Initial License Fees.  In addition to any other license fees payable by Toshiba and SanDisk under Section 5.4 of this Agreement, Toshiba and SanDisk each agree to pay Intermolecular [*] US Dollars (US$[*]) for a cumulative total of [*] US Dollars (US$[*]) for the Intermolecular Background IP license rights set forth in Section 4.1.1 as follows:  Intermolecular shall invoice each of Toshiba and SanDisk in the amount of [*] US Dollars (US$[*]) on (a) [*] days following the [*], and (b) [*] days following the [*] anniversary of the [*].  Toshiba and SanDisk each will pay Intermolecular based on such invoices, within [*] days from their respective receipt of such invoices.

 

5.4           CDP Product Fees; [*].

 

5.4.1        Toshiba and SanDisk each acknowledges and agrees that in addition to Section 5.3 above,

 

A.    Toshiba will pay Intermolecular a per-CDP Product fee (a “CDP Product Fee”) based on Table 1 below on the sale of CDP Products by Toshiba or Toshiba Affiliates to third parties unrelated to either Toshiba, SanDisk or the joint ventures between Toshiba and SanDisk (“Unrelated Third Party”) except for any payment by an Unrelated Third Party to Intermolecular under another applicable provision of this Agreement, and

 

B.    SanDisk will pay Intermolecular a CDP Product Fee based on Table 1 below on the sale of CDP Products by SanDisk or SanDisk Affiliates to Unrelated Third Parties, except for any payment by an Unrelated Third Party to Intermolecular under another applicable provision of this Agreement.

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

16

 

CDP Product Fee Rate Table (Table 1)

 

	
[*] Toshiba or SanDisk CDP
   Products Sold
    	
 
    	
CDP Product

containing [*]
    	
 
    	
CDP Product
   containing [*]
    	
 
    	
CDP Product
   containing [*]
    	
 
    
	
[*]
    	
 
    	
US   $
    	
[*]
    	
 
    	
$
    	
[*]
    	
 
    	
$
    	
[*]
    	
 
    
	
[*]
    	
 
    	
$
    	
[*]
    	
 
    	
$
    	
[*]
    	
 
    	
$
    	
[*]
    	
 
    
	
[*]
    	
 
    	
$
    	
[*]
    	
 
    	
$
    	
[*]
    	
 
    	
$
    	
[*]
    	
 
    
												

 

C.    Toshiba and SanDisk acknowledge that if a CDP Product incorporates different categories of Technology or Intellectual Property Rights that are subject to different [*], then in each such instance the highest [*] applicable to such CDP Product shall apply as the sole [*], as applicable.  For the avoidance of doubt, the [*] totals in the first column in Table 1 above represent the [*] total of CDP Products sold by Toshiba or SanDisk respectively.  Toshiba and SanDisk further acknowledge that if a Non-CDP Product incorporates different categories of Technology or Intellectual Property Rights that are subject to different [*], then in each such instance the highest [*] applicable to such Non-CDP Product shall apply as the sole [*], as applicable.  For the avoidance of doubt, for purposes of calculating the amounts due for Non-CDP Products, the [*] totals in the first column in Table 1 above represent the [*] total of Non-CDP Products sold by Toshiba or SanDisk respectively (however, the [*] are [*] as per Section 4.2.1(B)).

 

D.    In the event that SanDisk and Toshiba elect [*] or [*] license under Section 4.2.2(A), 4.2.2(C) or 4.2.2(D), then each of them shall pay Intermolecular US$[*] as non-refundable prepaid CDP Product Fees, which shall be paid in [*] equal installment payments of US$[*]over a [*] period, with each such installment payment being due and payable [*] after receipt of invoice (the first invoice of which can be issued upon the [*], the second invoice of which can be issued [*] after such [*] election, and each subsequent invoice of which can be issued [*] thereafter).  Each of SanDisk and Toshiba [*] due and owing by SanDisk or Toshiba to Intermolecular respectively, under any provision of Section 5.4 (including under Table 1 above).  Further, such [*] shall be [*] (i) the [*] (whether SanDisk and Toshiba elect [*] or [*] under Section 4.2.2(A), 4.2.2(C) or 4.2.2(D)) described in Section 5.4.2 below, and (ii) [*] as described in Section 5.4.2 below.

 

5.4.2        If Toshiba and SanDisk elect [*] license under Section 4.2.2(C) or 4.2.2(D), then the CDP Product Fee, [*] and [*] structure for each of Toshiba and SanDisk are set forth in Table 2 below [*].  If the [*] is [*] according to Section 2.1, then the [*] referenced below would reset to the [*] of the [*].

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

17

 

	
[*]
   (Table 2A)
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]CDP Product
   Fee [*]
    	
 
    	
US$[*]
    	
 
    	
US$ [*]
    	
 
    	
US$ [*]
    	
 
    	
US$ [*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
US$
    	
[*]
    	
 
    	
US$
    	
[*]
    	
 
    	
US$
    	
[*]
    	
 
    	
US$
    	
[*]
    	
 
    
														

 

Provided, that:

 

A.    Toshiba and SanDisk each have a [*] of (i) [*] US Dollars (US$[*]) if Toshiba and SanDisk make an election under Section 4.2.2(C) above; or (ii) [*] US Dollars (US$[*]) if Toshiba and SanDisk make an election under Section 4.2.2(D).

 

B.    SanDisk’s and/or Toshiba’s [*] and [*] displayed in Table 2A and Table 2B above, and the applicable [*] shall be [*] such amounts for that party if Toshiba or SanDisk [*] CDP Products [*] (all additional [*] constituting [*] and [*] shall be referred to as the “[*]”); provided, that such [*] shall be triggered solely and exclusively by the [*] by SanDisk and/or Toshiba as the case may be.

 

C.    Payments for the sale of CDP Products by Affiliates are included in, and not in addition to, the [*] and amounts described in this Section 5.4.2.

 

5.4.3        If Toshiba and SanDisk elect [*] license pursuant to Section 4.2.2(A) above, then the CDP Product Fee set forth in this Section 5.4 will be the rate set forth in Table 1 above.  For [*] license, each of Toshiba and SanDisk shall have a separate [*] of [*] US Dollars (US$[*]).  The [*] shall be [*] for each of Toshiba and SanDisk (i.e., US$[*]) if Toshiba and/or SanDisk, respectively, [*]; provided, that any resulting [*] shall be triggered solely and exclusively by the [*] of [*] Technology by SanDisk and/or Toshiba as the case may be.  Payments for the sale of CDP Products of Affiliates are included in, and are not in addition to, the [*]and amounts described in this Section 5.4.3.

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

18

 

5.4.4        [*] and [*] arising from SanDisk’s and/or Toshiba’s exercise of the license outside the CDP Field under Section 4.2.1(B) shall be [*] of the [*] and [*] set forth above.

 

5.4.5        Payments for CDP Product Fee obligations under this Section 5.4 shall be made as follows.  Within [*]  days after [*], SanDisk and Toshiba each shall notify Intermolecular in writing of CDP Product Fee amounts due and payable under this Section 5.4 (taking into account the credit described in subsection 5.4.1(d) above).  Following receipt of such written notification, Intermolecular shall provide SanDisk and Toshiba each with a written invoice matching and identifying such written notification.  SanDisk and Toshiba shall pay Intermolecular the amount stated in such invoice within [*] days from the date of invoice receipt.

 

5.4.6        Nothing in this Agreement, including the payment or nonpayment of royalties and/or fees by Toshiba or SanDisk, shall affect any obligations by or on behalf of Toshiba or SanDisk under their respective existing agreements with third parties and each other.

 

5.5           IP Buy-Out.  If Toshiba and SanDisk make the election to obtain [*] set forth in Section 4.2, then they will have the option (either jointly, or by mutual written agreement, one of them) to pay Intermolecular [*] US Dollars (US$[*]) for the assignment of [*]owned by [*] in the [*] (an “IP Buy Out”).  This option may be exercised [*] during the period SanDisk and/or Toshiba [*].  If Toshiba and SanDisk elect the IP Buy-Out, the parties acknowledge and agree that Toshiba and SanDisk shall not [*] under [*], including the [*] of [*] (including [*]), regardless of the change in ownership of [*].  Further, if this election is made, then the option to SanDisk and Toshiba to [*] from [*] to [*] shall [*].

 

5.6           Third Party Royalties.  Each party shall be responsible for all of its own costs of commercializing CDP Products and Non-CDP Products or sub-licensing Intellectual Property Rights, including any payments to Third Parties for work done by such Third Parties or for licenses necessary for the manufacture, sale, or use of CDP Products or Non-CDP Products by a party or its Affiliates or sub-licensees.

 

5.7           Payments. For the payments under Sections 5.1 and 5.2, at the conclusion of each calendar month, the Project Managers for SanDisk and Toshiba shall have up to [*] business days or otherwise mutually agreed upon period of time to review whether Intermolecular performed the work assigned by the Operating Committee in accordance with the Development Plan for such month .  Upon confirmation by SanDisk and Toshiba that such work has been performed (or upon the conclusion of the above-mentioned [*] business day period if neither Project Manager has issued a written notice of non-compliance), Intermolecular will invoice SanDisk and Toshiba.  If neither Project Manager has issued a written notice of non-compliance by the conclusion of such [*] business day period, the applicable work shall be deemed performed for purposes of this Section 5.7.  Disputes, if any, shall be referred to the dispute resolution process.  SanDisk and Toshiba shall pay Intermolecular the amount stated in such invoice within [*] days from the date of invoice receipt.  All payments hereunder shall be made in U.S.  dollars by Toshiba, SanDisk, or one of their U.S.  or Japanese Affiliates and are non-refundable.  All payments due to Intermolecular under this Agreement shall be made by bank wire transfer as follows:

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

19

 

	
Japan International Wire Transfer
    	
 
    	
U.S. Domestic Wire Transfer
    
	
 
    	
 
    	
 
    
	
To:  [*] 
    	
 
    	
To:  [*]   
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Routing &   Transit #: 
    	
[*]   
    	
 
    	
 
    	
 
    
	
Swift   Code: 
    	
[*]   
    	
 
    	
Routing &   Transit #: 
    	
[*]   
    
	
For   credit of: 
    	
Intermolecular, Inc.   
    	
 
    	
For   credit of: 
    	
Intermolecular, Inc.   
    
	
Credit   account #: 
    	
[*]   
    	
 
    	
Credit   account #: 
    	
[*]   
    
	
By order of:    [Name of   Sender]
    	
 
    	
By   order of:    [Name of Sender]
    

 

or another U.S.  bank account designated by Intermolecular in writing and provided to Toshiba and SanDisk.

 

5.8           Taxes.  The fees and license rates specified in this Agreement are exclusive of any sales, use, excise, value-added or similar taxes, and of any export and import duties, which may be levied upon or collectible by Intermolecular as a result of Intermolecular’s performance of its service activities or the grant of licenses under this Agreement.  Toshiba and SanDisk agree to pay and otherwise be fully responsible for any such taxes and duties.  In the case of Toshiba, Intermolecular shall provide Toshiba with necessary documents duly signed by Intermolecular or issued by U.S.  tax authorities, and otherwise fully cooperate with Toshiba in applying for exemption of withholding income tax under the tax convention between the U.S.  and Japan.  Should application for an exemption of withholding income tax be rejected by Japanese tax authorities in case of Toshiba, or should an applicable similar situation occur in the case of SanDisk, Toshiba and SanDisk shall withhold from amounts otherwise payable to Intermolecular, and pay on Intermolecular’s behalf, withholding taxes that may be required by applicable law to be withheld by Toshiba and SanDisk.  Toshiba and SanDisk, as applicable, shall provide Intermolecular with tax receipts to establish that all such taxes have been paid and are otherwise available to Intermolecular for credit for U.S.  income tax purposes or as otherwise available to Intermolecular.

 

5.9           Records; Inspection.  Toshiba and SanDisk shall keep complete, true and accurate books of account and records on its own behalf and on behalf of the Toshiba and SanDisk Affiliates for the purpose of determining the CDP Product Fee amounts, Non-CDP Product Fee amounts, and any amounts payable by Toshiba or SanDisk as applicable pursuant to Section 5.10, under this Agreement.  Such books and records shall be kept at Toshiba and SanDisk for at least [*] years following the end of the calendar quarter to which they pertain.  Such records will be open for inspection during such [*] year period by an independent auditor who is reasonably acceptable to the parties and agrees to be bound to confidentiality protections of similar scope to those set out in Section 8 hereof, solely for the purpose of verifying statements related to amounts payable hereunder.  Such auditor shall be instructed to report only as to whether there is a discrepancy, and if so, the amount of such discrepancy.  With reasonable prior notice in writing, such inspections may be made no more than once each calendar year 

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

20

 

during regular business hours (other than during quarter-end or year-end financial closing periods), to the extent not unreasonably hindering any operations of Toshiba and SanDisk.  Inspections conducted under this Section shall be at the expense of Intermolecular, unless a variation or error producing an increase exceeding [*] percent ([*]%) of the royalties payable for any period covered by the inspection is established and confirmed in the course of any such inspection, whereupon all reasonable and documented costs relating to the inspection for such period and any unpaid amounts that are discovered will be paid promptly by Toshiba and/or SanDisk, as applicable.  Further, if the foregoing inspection indicates a need for a follow-up inspection, Intermolecular will have the right thereafter to conduct additional inspections from time to time within one year (in such case, the scope of the inspection shall be limited to those issues which Intermolecular needs to confirm the implementation of any corrective action therefor).  Each party agrees to hold in confidence pursuant to Section 8 all information concerning payments and associated reports, and all information learned in the course of any audit or inspection, except to the extent necessary for that party to reveal such information in order to enforce its rights under this Agreement or if disclosure is required by law.

 

5.10         Third Party Licensees.

 

5.10.1      Licenses of [*] and [*] to Third Parties.

 

A.    Subject to [*] compliance with the obligations in this Section 5.10.1, [*] shall be [*] authorized party to grant licenses to [*] and [*] to Third Party Licensees. [*] shall have [*] to the [*] to [*].

 

B.    In the event [*] will have the right but not the obligation to request [*] to license [*] and/or [*] to Third Parties.  [*] when so requesting [*] is hereby referred to as the [*] each Third Party requested to be so licensed by the [*]shall be referred to as a [*].

 

i.              Following receipt of a written request from a [*] shall promptly enter into a written license agreement with [*] in form and substance approved in writing by the [*], provided such request is [*] (or with [*] than) Table 1 above and in accordance with the provisions of Section 5.10 (each, a “Third Party Agreement”).  In the event that [*] unable for any reason to enter into and have fully executed such Third Party Agreement within [*] of the initial request from a [*] would allow the [*]to participate in an active role in the negotiations in order to ensure that such negotiations are concluded in a Third Party Agreement consistent with the relevant provisions of this Agreement.  [*] that [*] shall enter into such Third Party Agreement if the terms are [*] the applicable terms of this Agreement (subject to modifications as required under applicable laws and regulations of the relevant jurisdiction(s)).  The following provisions of this Agreement are not applicable to be included in Third Party Agreements:  Sections [*] (other than Sections [*] and [*]),[*] (other than the [*] under Section [*]),[*] (other than [*], Sections [*], and the applicable provisions of Section [*] (other than the applicable provisions of Sections [*].  In addition, for each Third Party Agreement entered into, the

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

21

 

language governing [*] under Section [*] (including but not limited to the [*]expressly set forth in Section [*]) shall apply, except that subject to such [*],[*]shall be [*] U.S.  dollars (US$[*]).

 

ii.             [*] shall have the right but not the obligation upon request by a [*], to enter into a written license agreement with a [*] in the event the [*] are [*] than [*] above.

 

C.    In the event [*], then [*] shall not [*].  For the avoidance of doubt, a designation made under subsection B above shall not be deemed a waiver of the [*]election.

 

D.    In the event [*], each of the provisions of subsection B above shall apply.  In addition, [*]the right but not the obligation [*] the [*]and/or the [*] to Third Parties [*] (each such party, a [*].

 

5.10.2      Licenses which include [*].

 

A.    If [*] and [*]:  (i) which includes [*], (ii) the scope of which primarily covers [*] (or other identified scope(s) specified in the [*] license, if any, taken outside the CDP Field under Section 4.2.1(B)); and (iii) where [*] actually receives a payment from such Third Party Licensee in partial consideration of any licenses thereunder, then [*] has the right, but not the duty or obligation, to license the patents from [*] to such Third Party Licensee, subject to payment of the [*] or [*], as applicable to [*] by [*] (x) [*], or (y) the Third Party Licensee directly under written agreement with [*] (which establishes contractual privity between [*] and such Third Party Licensee).

 

B.    Notwithstanding anything to the contrary in this Agreement, (I) no license grant by [*] entered into prior to the Effective Date shall give rise to any financial obligations on [*] to [*] under this Agreement, and (II) if [*] to grant subsequent to the Effective Date a license with a Third Party wherein a substantial number of the patents and patent applications licensed are in a related field and are not [*], then such license shall not give rise to any financial obligation on [*] to [*] under this Agreement.

 

C.    If [*], and if any [*] is licensed [*] or [*] to a Third Party Licensee that has already been validly licensed as a [*] under Section 5.10.1 (either prior to or subsequent to the licensing of such [*]), then the additional license of such [*] to [*] shall [*] on [*] to [*].

 

D.    If [*] or a [*], any party may license [*] in which it [*] without consent of or [*] to other [*] and 

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

22

 

without incurring any obligations to any other party to this Agreement.

 

5.10.3      Payments.

 

A.    For purposes of Section 5.10.1, [*] shall pay to the [*], all revenues received from [*] under all Third Party Agreements (“Third Party 5.10.1 Revenue”), that [*] the [*] set forth above in Table 1 (the “[*]”), subject to the provisions for [*] set forth in Section 5.10.4.  Revenue arising from a Third Party License outside the CDP Field shall be [*] of the fees set forth above in Table 1, subject to the provisions for [*] set forth in Section 5.10.4.  [*] shall have no obligation to make any [*] or [*] to [*] under Section 5.10.1.

 

B.    For purposes of Section 5.10.2, “[*]” means [*] of the amount set forth in Table 1 applicable to CDP Product Fees, and “[*]” means [*] of a [*].  [*] and [*] are each subject to the provisions for [*] set forth in Section 5.10.4, but are not subject to the [*] set forth in Section 5.4.

 

C.    [*] may audit [*] as well as payment records associated with Third Party Agreements using Section 5.9’s procedures above (except that the rights and obligations for [*] and [*] in Section 5.9 are reversed).  Any accounting disputes arising from such audits shall be escalated to senior management of the parties for resolution.

 

5.10.4      [*].

 

Notwithstanding any provisions to the contrary in this Agreement:

 

A.    [*] in the CDP Field under Section 5.10.1 and [*] (or directly by a Third Party Licensee) to [*] under Section 5.10.2, shall be [*]as follows:

 

	
If aggregate revenue collected [*] by [*] under Section
   5.10.1 and 5.10.2 within the CDP Field exceeds:
    	
 
    	
Then, Table 1 Fee Rates used to calculate [*]
   by [*] under Section 5.10.1, and [*] CDP
   Product Fees payable by [*] (or directly by a
   Third Party Licensee) to [*] under Section
   5.10.2, shall be [*] as follows:
    
	
[*]   US dollars (US$[*] )
    	
 
    	
[*]
    
	
[*]   US dollars (US$[*])
    	
 
    	
[*]
    
	
[*]   US dollars (US$[*])
    	
 
    	
[*]
    

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

23

 

B.    For each field licensed out of the CDP Field under Section 4.2.1B above, [*] under Section 5.10.1 in that field and [*] by [*] (or directly by a Third Party Licensee) to [*] under Section 5.10.2 in that field shall be [*] as follows:

 

	
If aggregate revenue collected [*] by [*] under Section
   5.10.1 and 5.10.2 in each field outside the CDP Field
   exceeds:
    	
 
    	
Then, Table 1 Fee Rates used to calculate [*]
   by [*] in that field under Section 5.10.1, and
   [*] (or directly by a Third Party Licensee) to
   [*] in that field under Section 5.10.2, shall be
   [*] as follows:
    
	
[*]   US dollars (US$[*])
    	
 
    	
[*]
    
	
[*]   US dollars (US$[*])
    	
 
    	
[*]
    
	
[*]   US dollars (US$[*])
    	
 
    	
[*]
    

 

C.    [*] an affirmative duty to inform [*] in writing when each of the thresholds under this Section 5.10.3 has been reached.  Such [*] shall be [*] based on the [*] (including other [*] or [*] where applicable under this Agreement).

 

5.10.5      Acknowledgement.  In no event shall [*] be required to [*] to any third party under this Agreement.

 

5.10.6      Payment Terms.  [*] shall make payments to a [*] under Section 5.10.1, and [*] shall make payments to [*] under Section 5.10.2 as follows:  Within [*] days after each [*] close, the remitting party shall notify the receiving party in writing of their respective obligations to make payments if any, accompanied by a reporting record adequately supporting such obligation, to the other under this Section 5.10 (taking into account, when [*] the paying party, the credit described in subsection 5.4.1(D) above).  Following receipt of such written notification, the receiving party shall provide the remitting party as the case may be, with a written invoice matching and identifying such written notification.  The remitting party shall pay the receiving party the amount stated in such invoice within [*] days after receipt of such invoice.

 

6.             COVENANTS

 

6.1           Covenant Regarding [*] Obtained by [*].  Subject to the terms and conditions of this Agreement, [*] covenants [*] against [*] and [*] respective subsidiaries, customers and distributors (collectively [*]) any [*] if such [*] is based on [*] obtained by [*], or [*] to which [*] exposed, directly or indirectly, from [*] during the duration of or as a result of the CDP.  In addition, and subject to any pre-existing contractual obligations of [*] (and [*] hereby warrants that there are no such pre-existing contractual obligations of Intermolecular related to the CDP Field), and, except as otherwise required by law or by court or government order, [*] covenants

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

24

 

not to [*] any Third Party to [*] any [*] against the [*] to the extent that such [*] is based on [*] obtained by [*] or [*] to which [*] exposed, directly or indirectly, from [*] during the duration of or as a result of the CDP.  Except as otherwise required by law or by court or by government order, should [*] or [*], against the [*] shall prove that such [*] is not based on and is independent of [*] obtained by [*] or [*] to which [*] exposed, directly or indirectly, from [*] during the duration of or as a result of the CDP.  Notwithstanding the foregoing, [*]  acknowledge and agree that the covenant set forth in this Section 6.1 does not apply to [*], any [*] to [*], or to any material breach of the license grant or confidentiality provisions of this Agreement.

 

6.2           [*] Covenant.

 

6.2.1        For the period of time ending [*] from the date of [*] including regarding the [*] and/or [*] of the [*] (hereinafter “[*]”), and subject to the terms and conditions of this Agreement, [*] by [*] (or [*] before or during the [*]) shall be subject to the limitations set forth hereinafter.  Subject to the terms and conditions of this Agreement, [*] covenants [*] not to [*] against [*] any of [*] by [*] before or during the [*] (or [*] by [*] before or during the [*] [*]), but excluding [*] (and [*] where covenants [*]) that are covered under the below-defined “[*]” regarding [*]; provided, however, that if there is any specific field regarding the [*] that needs to be excluded from the covenant [*] hereunder due to potential breach by [*] of [*] contracts with any third party existing as of the Effective Date of the Agreement, [*] shall schedule such in Exhibit F hereto and such field will be excluded from the covenant [*] hereunder.  Further, [*] not to [*] any [*] to [*] any [*] by [*] (or [*] by [*]), regarding the [*].

 

6.2.2        For the avoidance of doubt, and subject to the [*] set forth in Section [*] of the Agreement, nothing in this Section 6.2 prohibits [*] from [*] in the future under [*] to any Third Party after the Effective Date of the Agreement (collectively with [*] which are [*]  as of the Effective Date and the [*] that [*] may transfer ownership of in accordance with this Section 6.2.2, “[*]”), or prohibits [*] in the future from [*] to [*] of any [*] relating to or resulting from a [*] in the normal course of business for [*] to the extent where [*] such [*] the opportunity to acquire [*] that [*] to such [*] as part of the [*].  If [*] such [*] or [*] in such [*], then [*]  that the covenants [*] under this Section 6.2 shall not apply to such [*] for the [*] and [*] will receive a [*] to such [*]; provided that [*] that [*] will not [*] such Third Party in [*] under the [*]  against the [*].  Notwithstanding the immediately preceding sentences, [*] may be [*] in any [*] as required by being an [*] to a [*] involving the [*] for [*] purposes, solely as required by law and further [*] may be [*], as required by law, provided that [*] commercially reasonable efforts to limit the amount of [*] and/or [*] requested.  Notwithstanding the foregoing[*] and [*]:  (a) that any covenants granted by [*] regarding the [*] or [*] of [*] pursuant to this Section 6.2 apply only to [*] by [*] and [*] or [*] of by [*] or [*]; and (b) that the covenants do not apply to [*], any [*] to [*], or to any [*] or [*] of this Agreement.  [*] that the foregoing covenant shall not apply to any [*] resulting from the [*] or [*] of [*], or any [*].  Notwithstanding anything above, if [*], then the [*] shall solely in such case mean the period of time terminating [*] from the date of such election.  Further, if [*] or [*] as [*] as provided in Section [*], this covenant [*] shall not apply to [*] listed in Section [*] nor to such [*] not included in [*] as provided in Section [*], as applicable.

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

25

 

6.3           Enforcement.  If [*] any claim against the [*] in violation of Sections 6.1 or 6.2 above, then [*] may seek injunctive relief to stop or enjoin [*] from undertaking such activities in addition to any and all remedies available at law and the [*] shall be fully reimbursed by [*] for their reasonable expenses and direct damages arising from such assertion.  [*] may [*] such expenses and damages [*] to be paid to [*].

 

6.4           Assignment.  Subject to the terms and conditions of this Agreement, the covenant in Section 6.1 shall be binding on any successors-in-interest, assigns, mergers, reorganizations, or any other change of control of [*], but only as to [*] obtained by [*] or knowledge to which [*] exposed, directly or indirectly, from [*] during the duration of or as a result of the CDP.  In addition, subject to the terms and conditions of this Agreement, the covenant in Section [*] shall be binding on any successors-in-interest, assigns, mergers, reorganizations, or any other change of control of [*], but only as applicable to the [*] owned by [*] on the day immediately prior to such change of control and not to any other [*] owned by the successor in interest or assignee.

 

6.5           Patent Sales.  Subject to the terms and conditions of this Agreement, if [*] or otherwise [*] or [*] any [*] or [*] under any of the [*] covered by the covenant [*] in Section [*] above (“[*]” or “[*]” as the case may be), unless such rights are specifically excluded therein, at any time during the period of time that such [*] would have been subject to the covenant set forth in Section [*] above but for such [*], to any Third Party [*] of [*], then [*]:  (i) retroactively [*], as of immediately prior to such [*], a [*] with respect to any [*] of by [*] prior to such [*]; and (ii) shall make such [*] subject to the covenant set forth in Section [*] above.

 

6.6           Application to Affiliates.  For purposes of this Section 6, Intermolecular shall mean Intermolecular and/or its Affiliates as appropriate.  Toshiba shall mean Toshiba Corporation and/or its Affiliates as appropriate.  SanDisk shall mean SanDisk Corporation and/or its Affiliates as appropriate.

 

6.7           Termination of Covenants.  If, at any time before [*] assertion of claims of [*] subject to covenants set forth in this Section 6 against a particular Protected Entity, such particular Protected Entity asserts claims of [*] against [*], or seek to [*] of [*] other than enforcement of or disagreement concerning the [*] provisions set forth in this agreement [*], the covenants set forth in this Section 6 shall immediately terminate with respect to such particular Protected Entity.  In addition, in the event of a change of control, merger, acquisition or sale of all or substantially all of the assets of [*], or of the sale of an Affiliate, subsidiary or product line of [*] the covenants granted in this Section 6 shall apply only to the products, processes, Technologies or services of [*], as of the date of such change of control, and shall not apply to any of the products, processes, Technologies, or services of the acquiring entity.

 

7.             WARRANT

 

7.1           Warrant.

 

7.1.1        Upon execution of the Agreement, Intermolecular will issue to each of Toshiba and SanDisk a warrant (each a “Warrant” and together the “Warrants”) to purchase a number of shares equal to the Warrant Amount (as defined below).  Each Warrant shall have an

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

26

 

exercise price of $3.04144 per share (the “Exercise Price”) and be exercisable only during the Exercise Period (as defined below).  Each of Toshiba and SanDisk must deliver an election notice of its intention to exercise the Warrant and the number of shares of Intermolecular common stock it wishes to purchase pursuant to the Warrant (an “Election Notice”) not later than the expiration of the Exercise Period.  The closing of the issuance of the shares to be issued pursuant to the Warrants shall occur not more than 30 days after the expiration of the Exercise Period.  At the closing Intermolecular shall at its sole expense issue all necessary and appropriate documents evidencing the issuance of the Shares.  Intermolecular represents that the Exercise Price is the lowest price at which shares were purchased by investors in Intermolecular’s Series D financing round in December 2008.  Intermolecular agrees to provide SanDisk and Toshiba upon request at the time of the License Election an investor information packet containing information which is no less than the information provided by Intermolecular or on Intermolecular’s behalf to investors in any investment round preceding the conclusion of the Exercise Period to purchasers of common stock and, in addition, shall also include a written summary of (i) the then-current capitalization table stating shares by class (including shares reserved for issuance under outstanding instruments (e.g., options, other convertible securities)) and (ii) the then-total dollar amount of outstanding liquidation preferences.

 

7.1.2        “Exercise Date” shall mean the date SanDisk and/or Toshiba makes an effective election under Section 4.2.2(A), Section 4.2.2(C) or Section 4.2.2(D) (a “License Election”).

 

7.1.3        The “Exercise Period” shall be a period from and after the Exercise Date and ending upon the date one hundred and twenty (120) days from the end of the CDP.

 

7.1.4        The “Warrant Amount” with respect to each Warrant shall be an amount equal to (1) 1,644,736 less (2) the number of shares of Common Stock elected to be purchased in the Notice of Exercise with respect to the other Warrant being issued on the date hereof; provided, however, that (a) if both Toshiba and SanDisk elect to purchase more than 822,368 shares of Common Stock, then the Warrant Amount shall be an amount equal to 822,368; and (b) if either Toshiba or San Disk elects to purchase less than 822,368 shares then the Warrant Amount, in which case such lesser amount shall be the Warrant Amount for such party and the other party shall have the right but not the obligation to purchase the balance up to an aggregate of 1,644,736 shares.  In no event shall the aggregate Warrant Amount purchasable by SanDisk and Toshiba collectively hereunder exceed 1,644,736.

 

7.1.5        The form of warrant is attached hereto as Exhibit G.

 

8.             CONFIDENTIALITY

 

8.1           Confidentiality.  Except as otherwise expressly provided in this Agreement, the parties agree that each receiving party of another party’s Confidential Information shall not, except as expressly provided in this Section 8, disclose to any Third Party, or use for any purpose, any such Confidential Information furnished to it by a disclosing party pursuant to this Agreement, except in each case to the extent that it can be established by the receiving party by competent proof that such information:

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

27

 

(a)           was already known to the receiving party, other than under an obligation of confidentiality, at the time of disclosure;

 

(b)           was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving party;

 

(c)           became generally available to the public or otherwise part of the public domain after disclosure and other than through any act or omission of the receiving party in breach of this agreement;

 

(d)           was independently developed by the receiving party without use of, or reference to, the other party’s confidential information, as demonstrated by documented evidence prepared contemporaneously with such independent development; or

 

(e)           was disclosed to the receiving party, other than under an obligation of confidentiality, by a Third Party authorized and entitled to disclose such information to others.

 

8.2           Permitted Use and Disclosures.  Notwithstanding the restrictions of Section 8.1, each party hereto may (a) use Confidential Information disclosed to it by another party to the extent necessary for that party to perform its obligations or undertake the activities set forth in the Development Plan and (b) use or disclose Confidential Information disclosed to it by such other party to the extent such use or disclosure is reasonably necessary in (i) exercising the rights and licenses granted hereunder, (ii) prosecuting or defending litigation, (iii) complying with applicable laws, governmental regulations or court orders or submitting information to tax or other governmental authorities (including the Securities and Exchange Commission), or (iv) preparing, filing and prosecuting patent applications; in each case, provided that if a party is required to make any such disclosure, other than pursuant to a confidentiality agreement, it will give reasonable advance notice to the disclosing party of such disclosure and will use reasonable efforts to secure confidential treatment of such information (whether through protective order or otherwise), except to the extent inappropriate with respect to patent applications.  It is understood that any party may also disclose the Confidential Information of a disclosing party upon receipt of the written consent to such disclosure by a duly authorized representative of the disclosing party.  For purposes of this Section 8, SanDisk and Toshiba may (subject to the limitations of use applicable to employees of SanDisk, Toshiba or their Affiliates) use third party contractors retained by SanDisk, Toshiba or their Affiliates as applicable, that have entered into appropriate non-disclosure agreements with SanDisk, Toshiba or their Affiliates, as applicable, and with Intermolecular where such third party contractors have direct access to the CDP or have been provided to the Intermolecular Confidential Information.  SanDisk and Toshiba shall be responsible for their respective breaches of this Section 8 by such third party contractors to the same extent as for SanDisk, Toshiba and their Affiliates respective employees.

 

8.3           Nondisclosure of Terms.  Each of the parties hereto agrees not to disclose the terms of this Agreement to any Third Party without the prior written consent of the other party hereto, except to such party’s attorneys, accountants, advisors, investors and financing sources and their advisors and others on a need to know basis under circumstances that reasonably ensure the confidentiality thereof, to the extent required by law, in connection with the enforcement of

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

28

 

this Agreement or rights under this Agreement or in connection with a merger, acquisition, financing transaction or proposed merger, acquisition or financing transaction.

 

9.             LIMITED REPRESENTATIONS AND WARRANTIES AND INDEMNIFICATION

 

9.1           By Intermolecular.  Intermolecular represents and warrants that:  (a) it has the right and authority to enter into this Agreement, and to fully perform its obligations hereunder; (b) this Agreement is a legal and valid obligation binding upon it and enforceable in accordance with its terms; (c) Intermolecular owns, or possesses a valid and enforceable license to use, and has full power and authority to license or sublicense, as the case may be, all Intermolecular’s Intellectual Property Rights licensed or sublicensed to Toshiba and SanDisk pursuant to this Agreement; (d) Intermolecular’s compliance with its obligations under this Agreement will not violate third party agreements nor give rise to financial obligations on the part of Toshiba, Toshiba Affiliates, SanDisk or SanDisk Affiliates under any Third Party agreements; and (e) it will perform the services contemplated by this Agreement in a professional and workmanlike manner and in accordance with relevant industry standards applicable to the services.

 

9.2           By Toshiba and SanDisk.  Toshiba and SanDisk each individually represent and warrant that:  (a) it has the right and authority to enter into this Agreement, and to fully perform its obligations hereunder; (b) this Agreement is a legal and valid obligation binding upon it and enforceable in accordance with its terms; and (c) each owns, or possesses a valid and enforceable license to use, and has full power and authority to license or sublicense, as the case may be, all Intellectual Property Rights which are or may be licensed to Intermolecular under this Agreement.

 

9.3           Disclaimer.  Toshiba and SanDisk each acknowledge that the CDP is by its nature a technology development project and there is no guarantee that the project will be successful, in whole or in part or will meet Toshiba’s or SanDisk’s anticipated needs.  Each party further acknowledges that the failure of the parties to successfully develop and commercialize [*] Technology, CDP Products or Non-CDP Products as the result of the CDP shall not constitute a breach of any representation or warranty or other obligation under this Agreement.  EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, TOSHIBA, SANDISK, AND INTERMOLECULAR MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OR CONDITIONS OF ANY KIND, AND EXPRESSLY DISCLAIM ALL OTHER REPRESENTATIONS, WARRANTIES AND CONDITIONS, WHETHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO BACKGROUND IP, FOREGROUND IP, HPC TECHNOLOGY OR ANY INFORMATION OR TECHNOLOGY DISCLOSED OR PROVIDED UNDER THIS AGREEMENT, INCLUDING ANY DELIVERABLES PROVIDED HEREUNDER.  WITHOUT LIMITING THE FOREGOING, EACH PARTY HEREBY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF TITLE, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE, OR VALIDITY OF ANY BACKGROUND IP, FOREGROUND IP, OR HPC TECHNOLOGY, PATENTED OR UNPATENTED, OR NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

29

 

9.4           Indemnification.  Intermolecular shall indemnify, defend and hold harmless Toshiba, Toshiba Affiliates, SanDisk and SanDisk Affiliates against any Third Party suits, actions, claims or proceedings alleging that (a) the HPC Technology, HPC Derivatives, or any Licensed IP provided or licensed by Intermolecular under this Agreement infringes or misappropriates such Third Party’s Intellectual Property Rights and/or (b) Intermolecular has caused property damage to a Toshiba or SanDisk facility, and Intermolecular agrees to reimburse Toshiba, Toshiba Affiliates, SanDisk and SanDisk Affiliates for all damages, liabilities, costs and expenses, including reasonable attorneys’ fees, finally awarded against Toshiba, Toshiba Affiliates, SanDisk and SanDisk Affiliates by a court of competent jurisdiction that may result from any such Third Party claim or property damage or any settlement amount, as applicable; provided that (i) SanDisk and/or Toshiba (as applicable) notifies Intermolecular promptly in writing of the claim; and (ii) SanDisk and/or Toshiba (as applicable) assist and cooperates reasonably with Intermolecular, at Intermolecular’s expense, in defending and settling such claim.  Intermolecular shall have sole control of the defense and all related potential settlement negotiations, provided that Intermolecular shall not enter into any settlement which would adversely affect Toshiba, Toshiba Affiliates, SanDisk or SanDisk Affiliates without such party’s prior written consent.  In addition, each of SanDisk and Toshiba shall be entitled to be represented by its own respective counsel at its own respective expense.  Intermolecular shall maintain appropriate insurance to permit Intermolecular to reasonably carry out its indemnity obligations under this Agreement.

 

10.          LIMITATION OF LIABILITY

 

10.1         Intermolecular.

 

TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, EXCEPT FOR INTERMOLECULAR’S OBLIGATIONS UNDER SECTIONS 6 AND 9.4 OF THIS AGREEMENT, A BREACH BY INTERMOLECULAR OF ITS CONFIDENTIALITY OBLIGATIONS UNDER SECTION 8, OR A BREACH OF ANY LICENSE RESTRICTIONS APPLICABLE TO INTERMOLECULAR:  (I) UNDER NO CIRCUMSTANCES WILL INTERMOLECULAR BE LIABLE TO ANY PARTY UNDER ANY LEGAL OR EQUITABLE THEORY, INCLUDING UNDER CONTRACT, STRICT LIABILITY OR OTHERWISE, FOR ANY LOST PROFITS, LOST DATA, LOST BUSINESS OPPORTUNITY, INJURY TO BUSINESS REPUTATION OR EQUIPMENT DOWNTIME, OR FOR ANY CONSEQUENTIAL, PUNITIVE INCIDENTAL, INDIRECT OR SPECIAL DAMAGES OF ANY KIND IN CONNECTION WITH THE SUBJECT MATTER OF THIS AGREEMENT, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, AND (II) IN NO EVENT WILL INTERMOLECULAR’S AGGREGATE LIABILITY TO ANY PARTY EXCEED THE GREATER OF (A) US$[*], AND (B) CUMULATIVE AMOUNTS PAID OR PAYABLE BY TOSHIBA AND SANDISK (OR BY THIRD PARTIES BASED ON LICENSES MADE PURSUANT TO THIS AGREEMENT) TO INTERMOLECULAR IN THE [*] MONTHS PRECEDING THE CLAIM.

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

30

 

10.2         SanDisk and Toshiba.

 

TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, EXCEPT FOR A BREACH BY SANDISK OR TOSHIBA OF THEIR RESPECTIVE CONFIDENTIALITY OBLIGATIONS UNDER SECTION 8, OR A BREACH OF ANY LICENSE RESTRICTIONS:  (I) UNDER NO CIRCUMSTANCES WILL SANDISK AND/OR TOSHIBA BE LIABLE TO ANY PARTY UNDER ANY LEGAL OR EQUITABLE THEORY, INCLUDING UNDER CONTRACT, STRICT LIABILITY OR OTHERWISE, FOR ANY LOST PROFITS, LOST DATA, LOST BUSINESS OPPORTUNITY, INJURY TO BUSINESS REPUTATION OR EQUIPMENT DOWNTIME, OR FOR ANY CONSEQUENTIAL, PUNITIVE, INCIDENTAL, INDIRECT OR SPECIAL DAMAGES OF ANY KIND IN CONNECTION WITH THE SUBJECT MATTER OF THIS AGREEMENT, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, AND (II) IN NO EVENT WILL SANDISK’S OR TOSHIBA’S AGGREGATE LIABILITY TO ANY PARTY EXCEED THE AMOUNTS DUE AND PAYABLE BY SANDISK AND TOSHIBA TO INTERMOLECULAR.

 

10.3         Basis of Agreement.  EACH PARTY ACKNOWLEDGES AND AGREES THAT THE FOREGOING LIMITATIONS OF LIABILITY ARE AN ESSENTIAL ELEMENT OF THE BASIS OF THE BARGAIN AMONG THE PARTIES AND THAT IN THE ABSENCE OF SUCH LIMITATIONS, THE ECONOMIC AND OTHER TERMS OF THIS AGREEMENT WOULD BE SUBSTANTIALLY DIFFERENT.

 

11.          TERM; TERMINATION

 

11.1         Term of Agreement.  The Agreement, unless terminated or canceled as provided in this Section 11, shall remain in full force and effect for the full Initial Term, and may be extended for up to two (2) additional one (1) year periods by Toshiba and SanDisk providing notice to Intermolecular of their intention to renew the Agreement providing thirty (30) days advance written notice to Intermolecular before the expiration of the Initial Term or any extension thereof.  SanDisk and Toshiba shall receive at least as favorable commercial terms from Intermolecular if they elect to extend the Term beyond the Initial Term, as those commercial terms governing the Initial Term.  If SanDisk and/or Toshiba request to extend the Term for less than one (1) year and/or wish to have lower rates in return for extending the Term, the parties shall discuss and work together in good faith to agree to such request (Intermolecular shall not unreasonably withhold agreement to a request to extend the duration of the Term).

 

11.2         Termination for Convenience.  Either Toshiba or SanDisk may terminate this Agreement for convenience without penalties of any kind, in the event of an acquisition, merger, assignment, reorganization or other change of control of Intermolecular, by providing [*] days advance written notice to Intermolecular.  “Change of control” under this Section 11.2 excludes (a) an IPO by Intermolecular, and (b) the acquisition of Intermolecular by either a financial entity, a semiconductor equipment manufacturer or a semiconductor materials manufacturer, provided that any of these entities referred to in this (b) are not affiliated with an entity that designs and/or manufactures semiconductor integrated circuits, and that any party in (b) within [*] days notifies and confirms in writing to SanDisk and Toshiba that such party shall assume all of Intermolecular’s obligations under this Agreement and SanDisk and Toshiba shall have the right to terminate this Agreement unless such party meets requirements in (b).

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

31

 

11.3         Termination for Breach.  Either Toshiba or SanDisk may terminate this Agreement in the event that Intermolecular has materially breached or defaulted in the performance of any of its material obligations hereunder, and such default has continued for [*]days after written notice thereof was provided to Intermolecular by a non-breaching party; or in the event of insolvency or bankruptcy.  Intermolecular may terminate this Agreement in the event that either Toshiba or SanDisk has materially breached or defaulted in the performance of its material obligations hereunder, and such default has continued for [*]days after written notice thereof was provided to the breaching party by Intermolecular.  Any termination shall become effective at the end of such [*]day period unless the breaching party (or any other party on its behalf) has cured any such breach or default prior to the expiration of the [*] day period.

 

11.4         Effect of Termination.

 

11.4.1      Accrued Rights and Obligations.  Termination of this Agreement for any reason shall not release any party hereto from any liability or obligation that, at the time of such termination, has already accrued to the other parties or that is attributable to a period prior to such termination, nor shall it preclude any party from pursuing any rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement.

 

11.4.2      Return of Confidential Information.  Upon any termination of this Agreement, Toshiba, SanDisk and Intermolecular, as applicable, shall promptly destroy or return to the other all Confidential Information received from any other party other than as required to enforce or defend any continuing or surviving rights and pursuant to this Agreement obligations under this Agreement.

 

11.5         Survival.  If this Agreement terminates for any reason or expires, then Sections [*] and [*] of this Agreement shall survive such termination or expiration.

 

12.          MISCELLANEOUS

 

12.1         Governing Laws and Dispute Resolution.  This Agreement shall be governed by and construed in accordance with the laws of the state of California in the United States, without regard to its choice of law rules.  All disputes between the parties in connection with or arising out of this Agreement shall first be discussed in good faith between the parties in order to try to find an amicable solution.  If no solution can be found to settle the dispute, then such dispute shall be finally settled by arbitration in accordance with the default rules and procedures of American Arbitration Association sitting in Hawaii and conducted in English.  Within [*] days of notice that a party wants to submit a dispute to arbitration, the parties will attempt to mutually agree upon an independent arbitrator with expertise in the semiconductor industry.  If the parties are unable to agree on an independent arbitrator within [*] days, AAA will select an arbitrator within [*] days.  The arbitrator shall determine what discovery will be permitted consistent with the goal of limiting the costs and time for such a proceeding.  The parties and arbitrator shall use all reasonable efforts to complete any arbitration subject to this Section 12.1 within [*] from the selection of the arbitrator.  The parties agree that any award of damages shall not include punitive, special, consequential, or indirect damages except as specifically allowed in this Agreement and shall comply with the limitation of liability provisions set forth herein.  The

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

32

 

arbitrator’s decision shall be in a detailed writing setting forth the reasons for their decision and shall be provided concurrently to each party.  The arbitration award shall be final and binding on the parties.  Unless otherwise agreed to by the parties, each party shall pay one-third of the arbitration fees and expenses and shall bear all of its own expenses in connection with the arbitration.  Notwithstanding any of the foregoing, any party shall have the right to seek, at its own cost and expenses, preliminary and temporary injunctive relief pending resolution of the dispute via arbitration.  The parties expressly disclaim the application of the United Nations Convention on the International Sale of Goods to this Agreement.

 

12.2         Assignment.  No party may assign or transfer this Agreement either voluntarily or by operation of law, in whole or in part, without the prior written consent of the other parties, such consent not to be unreasonably conditioned, delayed or withheld, and any attempt to do so will be null and void.  Notwithstanding the foregoing, any party may assign this Agreement without such consent to a parent, subsidiary, or Affiliate, or assign this Agreement without consent to a successor in interest to its business (whether by merger, acquisition, consolidation, change of control, reorganization or sale of substantially all of its assets), provided that if Intermolecular assigns this Agreement to a successor in interest, such successor in interest within [*] days notifies and confirms in writing to SanDisk and Toshiba that such successor in interest shall assume all of Intermolecular’s obligations under this Agreement and SanDisk and Toshiba shall have the right to defer any payment under this Agreement until SanDisk and Toshiba have confirmed, in writing, such purported assignment.  The parties acknowledge and agree that if this Agreement is assigned by Toshiba or SanDisk to a successor in interest as a result of a merger, acquisition, consolidation, change of control, reorganization or sale of substantially all of their assets, then (a) the caps set forth in Section 5.4.2 shall terminate and the Fees payable shall be uncapped thereafter; and (b) the covenants set forth in Section [*] shall not apply to the successor in interest or to any products or services of such successor in interest other than the specific, then-current version of the CDP Products and Non-CDP Products in commercial production at the closing of the transaction resulting in the change of control.  The parties further acknowledge and agree that if this Agreement is assigned by Intermolecular to a successor in interest as a result of a merger, acquisition, consolidation, change of control, reorganization or sale of substantially all of its assets, then the covenants set forth in Section [*]shall not apply to [*]independently owned or controlled by the successor in interest on the date immediately prior to the closing of the transaction resulting in the change of control, nor shall the covenants set forth in Section [*] apply to any [*]created or acquired by such successor in interest after the closing of the transaction resulting in the change of control unless the identity of the former Intermolecular as a functional unit remains identifiable in which case the covenants shall continue to apply but only as to [*]created by the said identifiable functional unit during the [*].  Notwithstanding the foregoing, the covenants set forth in Section [*] still apply to any [*] filed by such successor and claiming priority to any earlier [*]obtained or developed by [*]before or during the [*].  Subject to the foregoing provisions, this Agreement will be binding on and inure to the benefit of the parties and their respective successors and permitted assigns.

 

12.3         Drafting.  In interpreting and applying the terms and provisions of this Agreement, the parties agree that no presumption shall exist or be implied against the party that drafted such terms and provisions.

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

33

 

12.4         Waiver.  It is agreed that no waiver by any party hereto of any breach or default of any of the covenants or agreements herein set forth shall be deemed a waiver or an expectation of non-enforcement as to any subsequent and/or similar breach or default.

 

12.5         Non-Solicitation.  During the Initial Term of this Agreement no party may individually, or in concert with or through any other person, actively recruit or solicit employment of any scientific or technical personnel of any other party.  The foregoing restriction shall not apply to, or be breached by:  (i) advertising open positions, participating in job fairs, and conducting comparable activities to recruit skilled or unskilled help from the general public, or responding to individuals contacted through such methods, (ii) responding to unsolicited inquiries about employment opportunities or possibilities from job placement agencies or other agents acting for unidentified principals, or (iii) responding to unsolicited inquiries about employment opportunities from any individual.

 

12.6         Severability.  In the event that any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect to the fullest extent permitted by law without said provision, and the parties shall amend the Agreement to the extent feasible to lawfully include the substance of the excluded term to as fully as possible realize the intent of the parties and their commercial bargain.

 

12.7         Independent Contractors.  The relationship of the parties hereto is that of independent contractors.  Each party shall not be deemed to be an agent, partner, joint venture or legal representative of the other for any purpose as a result of this Agreement or the transactions contemplated thereby.

 

12.8         Press Releases or Public Statements.  No Party shall issue any press release, publicity statement, communication with stockholders, public notice or other public disclosure relating directly to this Agreement or the transactions contemplated hereby without prior notice to, consultation with and the prior written consent of the other parties.

 

12.9         Compliance with Law.  In exercising their rights and undertaking their obligations under the Agreement, each party shall fully comply in all material respects with the requirements of any and all applicable laws, regulations, rules and orders of any governmental body having jurisdiction over the exercise of rights under this Agreement.  Without limiting the foregoing, each party agrees to comply with all applicable export and re-export control laws and regulations maintained by the United States or Japanese governments.

 

12.10       Notices.  All notices, requests and other communications hereunder shall be in writing and shall be hand delivered, or sent by express delivery service with confirmation of receipt, or sent by registered or certified mail, return receipt requested, postage prepaid, or by electronic transmission (with written confirmation copy by registered first-class mail), in each case to the attention of the chief legal officer at the respective address indicated above.  Any such notice shall be deemed to have been given when received.  Any party may change its address by giving the other party written notice, delivered in accordance with this Section.

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

34

 

12.11       Force Majeure.  No party shall lose any rights hereunder or be liable to any other party for damages or losses (except for payment obligations then owing) on account of failure of performance by the defaulting party if the failure is occasioned by war, strike, fire, earthquake, flood, lockout, embargo, act of terrorism, governmental acts, or any other reason where failure to perform is beyond the reasonable control and not caused by the negligence, intentional conduct or misconduct of the non-performing party and such party has exerted all reasonable efforts to avoid or remedy such force majeure; provided, however, that in no event shall a party be required to settle any labor dispute or disturbance.

 

12.12       Headings; Construction.  The captions to the several Sections hereof are not part of this Agreement, but are included merely for convenience of reference and shall not affect its meaning or interpretation.  As used in this Agreement, the word “including” means “including without limitation.”

 

12.13       Counterparts.  This Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement.

 

12.14       Complete Agreement.  This Agreement, together with its Exhibits and their attachments, constitutes the entire agreement, both written and oral, among the parties with respect to the subject matter hereof, and all prior agreements respecting the subject matter hereof, either written or oral, express or implied, shall be superseded by this Agreement.  Without limitation to the foregoing, except as provided in Section 4.2.2(B), the 2006 Agreement is hereby superseded and replaced by this Agreement, except for Intermolecular’s and SanDisk’s surviving confidentiality obligations set forth in the 2006 Agreement.  If there is any conflict between the confidentiality provisions in this Agreement and in the 2006 Agreement, the confidentiality provisions in this Agreement shall control.  No amendment or change hereof or addition hereto shall be effective or binding on either of the parties hereto unless reduced to writing and executed by the respective duly authorized representatives of Toshiba, SanDisk and Intermolecular.  The parties further agree that any additional or inconsistent terms and conditions of any purchase order, invoice or like document issued in connection with this Agreement shall be superseded in full by the terms and conditions of this Agreement and any Exhibit hereunder, and any such additional or inconsistent terms, unless specifically agreed to in writing by the parties at the time, are hereby rejected.

 

12.15       Third Party Beneficiaries.  Except as expressly provided in this Agreement, there are no Third Party beneficiaries expressly or impliedly intended under this Agreement.

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

35

 

In Witness Whereof, the parties hereto have executed this document as the Effective Date above, or if no date is set forth, the last date set forth below.

 

	
Toshiba   Corporation
    	
 
    	
SanDisk   Corporation
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
By:
    	
/s/   Hiroto Nakai
    	
 
    	
By:
    	
/s/   Ben Tessone
    
	
Name:
    	
Hiroto   Nakai
    	
 
    	
Name:
    	
Ben   Tessone
    
	
Title:
    	
SM,   Flash Business Strategy Development
    	
 
    	
Title:
    	
VP,   Worldwide Procurement
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Intermolecular, Inc.
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
By:
    	
/s/   David Lazovsky
    	
 
    	
 
    
	
Name:
    	
David   Lazovsky
    	
 
    	
 
    
	
Title:
    	
President &   CEO
    	
 
    	
 
    

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

36

 

Exhibit A—[*]IP (Non-Exhaustive List of Patents as of Effective Date)
 Exhibit B—Development Plan
 Exhibit C—IM [*]Developed Technology
 Exhibit D—Original CDP Developed Technology
 Exhibit E—Workflow Infrastructure
 Exhibit F—Exclusions from Section 6.2
 Exhibit G—Form of Warrant
 Exhibit H—Intermolecular Background IP for the CDP

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

37

 

EXHIBIT A

 

CATEGORY ONE IP

 

(Non-Exhaustive List of Patents as of Effective Date)

 

[Intermolecular to provide non-confidential summary to SanDisk and Toshiba prior to
 Effective Date, and final version to be provided immediately after Effective Date]

 

Non-confidential summary:

 

US Applications:

 

	
#
    	
 
    	
Title
    	
 
    	
Short Description
    	
 
    	
App. No.
    	
 
    	
IM Ref. No.
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    

 

PCT Applications:

 

	
#
    	
 
    	
Title
    	
 
    	
Short Description
    	
 
    	
Application
   Number
    	
 
    	
IM Ref. No.
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    

 

Foreign Applications:

 

	
#
    	
 
    	
Title
    	
 
    	
Short Description
    	
 
    	
Country
    	
 
    	
Application
   Number
    	
 
    	
IM Ref. No.
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

 

EXHIBIT B

 

DEVELOPMENT PLAN - PHASE I

 

(Version [*])

 

[*]

 

Common criteria for all [*]:

 

[*]

 

[*]

 

	
Stage
    	
 
    	
Task
    	
 
    	
Goal
    	
 
    	
Timeline
    	
 
    	
Metric/Output
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

 

	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

 

EXHIBIT C

 

IM [*] Developed Technology

 

US Applications:

 

	
#
    	
 
    	
Title
    	
 
    	
Short Description
    	
 
    	
App. No.
    	
 
    	
IM Ref. No.
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

 

EXHIBIT D

 

Original CDP Developed Technology

 

[*] (“[*]”) and

[*] (“[*]”) DOCUMENTATION

 

[*]

 

Exhibit A—[*]

 

Exhibit B—[*] Pivot Table

 

Exhibit C—Invention Disclosures

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

 

EXHIBIT A (1 OF 2)

 

 [*]

 

	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    

 

[*]

[*]

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

 

EXHIBIT A (2 OF 2)

 

BKM Condition

 

	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    

 

[*]

[*]

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

 

[*]

[*]

 

Intermolecular Confidential

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

 

Exhibit B — [*] Pivot Table

 

	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

 

Exhibit B - TFS Pivot Table

 

	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Confidential

 

 

Exhibit B - TFS Pivot Table

 

	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Confidential

 

 

Exhibit B - TFS Pivot Table

 

	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Confidential

 

 

EXHIBIT C—Invention Disclosures

 

	
Docket
   #
    	
 
    	
Title
    	
 
    	
Short Description
    	
 
    	
Exemplary Claim
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    

 

Intermolecular and SanDisk

Confidential Information

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

 

Exhibit C-1

 

	
FILE NO. [*]
    	
 
    	
INTERMOLECULAR, INC. - CONFIDENTIAL
    

 

INTERMOLECULAR, INC.
 INVENTION DOCUMENTATION FORM

 

1. [*]

 

2. [*]

3. [*]

 

4. [*]

 

4(a) [*]

4(b) [*]

 

4(c) [*]

 

5. [*]

 

5(a) [*]

5(b) [*]

 

6.

 

7. [*]

 

7(a) [*]

7(b) [*]

 

8.

 

Contains Intermolecular Confidential and

Attorney Client Privileged Information

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

1

 

	
FILE NO. [*]
    	
 
    	
INTERMOLECULAR, INC.   -CONFIDENTIAL
    

 

	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
																				

 

Contains Intermolecular Confidential and

Attorney Client Privileged Information

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

2

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

 

[*]

 

[*].

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

 

	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

 

	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

 

	
 
    	
 
    	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
[*]
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

 

	
 
    	
 
    	
[*]
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

 

[*]

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

 

[*]

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

 

[*]

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

 

INTERMOLECULAR, INC.
 INVENTION DOCUMENTATION FORM

 

1. [*]

 

2. [*]

3. [*]

 

4. [*]

 

4(a) [*]

4(b) [*]

 

4(c) [*]

 

5. [*]

 

5(a) [*]

5(b) [*]

 

6.

 

7. [*]

 

7(a) [*]

7(b) [*]

 

8.

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

 

[*]

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

 

[*]

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

 

[*]

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

 

[*]

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

 

[*]

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

 

Exhibit C-3

 

	
FILE NO. [*]
    	
 
    	
INTERMOLECULAR, INC. — CONFIDENTIAL
    

 

INTERMOLECULAR, INC.
 INVENTION DOCUMENTATION FORM

 

1. [*]

 

2. [*]

3. [*]

 

4. [*]

 

4(a) [*]

4(b) [*]

 

4(c) [*]

 

5. [*]

 

5(a) [*]

5(b) [*]

 

6.

 

7. [*]

 

7(a) [*]

7(b) [*]

 

8.

 

Contains Intermolecular Confidential and
 Attorney Client Privileged Information

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

1

 

	
FILE NO. [*]
    	
 
    	
INTERMOLECULAR, INC. — CONFIDENTIAL
    

 

[*]

 

[*]

 

Contains Intermolecular Confidential and
 Attorney Client Privileged Information

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

2

 

	
 
    	
 
    	
 
    

 

[*]

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

3

 

	
 
    	
 
    	
 
    

 

[*]

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

4

 

	
 
    	
 
    	
 
    

 

[*]

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

5

 

	
 
    	
 
    	
 
    

 

[*]

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

6

 

	
 
    	
 
    	
 
    

 

[*]

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

7

 

	
 
    	
 
    	
 
    

 

[*]

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

8

 

	
 
    	
 
    	
 
    

 

[*]

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

9

 

	
 
    	
 
    	
 
    

 

Exhibit C-4

 

	
Lead   Inventor:
    	
 
    	
[*]
    	
 
    	
Supervisor:
    	
 
    	
[*]
    
	
Docket   No.:
    	
 
    	
[*]
    	
 
    	
 
    	
 
    	
 
    
	
TITLE   OF INVENTION:
    	
 
    	
[*]
    	
 
    	
 
    	
 
    	
 
    

 

Problem Addressed by Invention:

	
[*]
    

 

Previous Approaches to Solving Problem:

	
[*]
    

 

Brief Description of Invention:  (Attach all relevant drawings, specs, flowcharts, design review or notebook entries)

	
[*]
    

 

Enabling and Best Mode disclosure:

	
[*]
    
	
 
    
	
 
    	
[*]
    	
 
    

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

10

 

	
 
    	
 
    	
 
    

 

	
[*]
    
	
 
    
	
 
    	
[*]
    	
 
    

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

11

 

	
 
    	
 
    	
 
    

 

Alternative structures/steps:

	
 
    

 

Key Words:

	
[*]
    

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

12

	
 
    	
 
    	
 
    

EXHIBIT E

 

Workflow Infrastructure

 

	
Dedicated
   Equipment
    	
 
    	
Description
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    

 

	
Other
   Equipment
    	
 
    	
Description
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    

 

Physical Metrology & E-Test Tools

 

	
[*]
    	
 
    
	
[*]
    	
 
    
	
[*]   
    	
 
    
	
[*]
    	
 
    
	
[*]
    	
 
    
	
[*]
    	
 
    
	
[*]
    	
 
    
	
[*]
    	
 
    
	
[*]
    	
 
    
	
[*]
    	
 
    
	
[*]
    	
 
    
	
[*]
    	
 
    
	
[*]
    	
 
    
	
[*]
    	
 
    
	
[*]
    	
 
    

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

13

	
 
    	
 
    	
 
    

EXHIBIT F

 

Exclusions from Section 6.2

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

14

	
 
    	
 
    	
 
    

EXHIBIT G

 

Form of Warrant

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

15

	
 
    	
 
    	
 
    

EXHIBIT H

 

Exhibit H as of May 10, 2010

 

	
Items
   #
    	
 
    	
Docket
   #
    	
 
    	
Title
    	
 
    	
Serial No.
    	
 
    	
Filing Date
    	
 
    
	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    	
[*]
    	
 
    

 

[*]

[*]

 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}]]